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The ethical and practical issues of obtaining a blood sample pose a significant challenge to 
performing pharmacokinetic studies in children, infants and neonates. Dried blood spot 
analysis, based on the collection of a micro blood sample has potential to overcome these 
difficulties. There are at present a limited number of reports on the utility of dried blood 
spot analysis in clinical pharmacokinetic studies. The studies described in this thesis were 
undertaken to investigate the accuracy and precision of dried blood spot sampling coupled 
with mass spectrometry detection for drug quantification, and clinically validate the 
robustness and feasibility of this technique for pharmacokinetic studies in preterm 
neonates. Dried blood spot methods were developed for application to pharmacokinetic 
studies of test drugs dexamethasone and caffeine. 
Investigations were focused on the blood collection system, analyte recovery and 
optimisation of the detection system. In-vitro validation results indicated developed 
methods were precise, accurate and selective in accordance with the Food and Drug 
Administration regulatory guidelines on the assessment of bioanalytical methods. Results 
were not significantly affected by small variations in the blood volume spotted or the 
presence of petroleum jelly, which is often used on the sampling site during capillary blood 
collection in neonates. Variability in haematocrit was determined to be the single most 
important factor affecting assay accuracy. Stability assessments by comparison with 
freshly prepared samples verified the suitability of sample drying, storage and post sample 
extraction conditions. An investigation of method transferability between different 
analytical instruments was undertaken with caffeine to provide an assessment of the 
robustness of dried blood spot analysis. Results generated from a single and triple 
quadrupole mass spectrometer were comparable with an expected lower limit of 
quantification with the latter technique most likely due to a greater ionisation and detection 
efficiency.   
Intravenous dexamethasone pharmacokinetics was determined in 5 preterm neonates 
receiving treatment for chronic lung disease. Individual pharmacokinetic analyses were 
performed using a one compartment model to estimate primary pharmacokinetic 
parameters, clearance (mean, 0.18 l/h/kg) and volume of distribution (mean, 1.33 l/kg). 
The whole blood derived mean estimates were similar to previous plasma clearance and 
volume estimates of 0.14 l/h/kg and 1.91 l/kg, respectively reported in neonates (n=7). This 
highlights the potential for dried blood spot analysis as an alternative to conventional 
plasma based methods for dexamethasone dose optimisation studies in neonates. The 
population pharmacokinetics of oral / intravenous caffeine was determined in 67 preterm 
neonates. A one compartment model was used to describe the blood concentration-time 
data. Model evaluation using a bootstrapping technique confirmed the robustness and 
stability of the developed model. Pharmacokinetic parameters derived from dried blood 
spot drug measurements were estimated with precision (relative standard error < 10%) and 
were comparable to estimates of plasma clearance (mean, 7.3 vs. 7.0 ml/h/kg) and volume 
of distribution (mean, 593 vs. 851 ml/kg) from a previous population study in neonates 
(n=110). Weight and postnatal age were the most influential covariates in the clearance 
model which is in agreement with previous population studies. 
These results demonstrate that dried blood spot analysis is a practical technique, with 
significant potential as a robust method for use in clinical pharmacokinetic studies in 
vulnerable populations such as preterms. Haematocrit related effects on paper will need to 
be accounted for if this potential is to be realised. Further investigations to determine the 
reproducibility of capillary blood sampling in neonates and the impact of using blood drug 
measurements on pharmacokinetic parameter estimation will be necessary before 
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Chapter 1  





A significant limitation in performing neonatal and paediatric pharmacokinetic (PK) 
studies is the need for blood sampling. Traditional plasma based drug quantification 
methods most often require a relatively large blood volume (0.5 - 10 ml) at each time 
point to generate sufficient plasma for analysis. This poses ethical and practical 
challenges around obtaining PK data in these age groups. Dried blood spots (DBS) 
represent an alternative matrix for measurement of circulating drug concentrations. The 
DBS technique typically involves the collection of a few drops of blood onto filter 
paper. This sample format provides a method of handling liquid blood and is amenable 
to a range of quantitative and qualitative analyses. There is now an increased awareness 
of the potential advantages of DBS over conventional plasma drug measurements used 
in PK studies. Requiring only a micro blood volume (usually less than 50 μl), DBS 
analysis has the potential to overcome difficulties associated with blood collection in 
neonates and children and thereby facilitate much needed PK studies. The use of DBS 
was first widely introduced in the 1960’s  by Dr Guthrie, a neonatologist, to measure 
levels of phenylalanine in newborns for the diagnosis of phenylketonuria (Guthrie and 
Susi, 1963). DBS has subsequently been used as a sampling technique in the therapeutic 
drug monitoring (TDM) of some drugs in clinical practice (Coombesa et al., 1984, 
AbuRuz et al., 2006, la Marca et al., 2008).  
Plasma has been the preferred matrix for drug quantification studies largely due its 
relative ease of handling compared with liquid whole blood. As such it has become the 
gold standard for performing pre-clinical and clinical PK studies. Although there is 
some experience of DBS in drug quantification through TDM, its application to 
generate PK data is limited (Beaudette and Bateman, 2004, Filippi et al., 2009, 
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Mohammed et al., 2010, Spooner et al., 2010, Kole et al., 2011, Suyagh et al., 2011). 
In-vitro validation reports clearly demonstrate the potential to accurately and precisely 
quantify pharmaceutical compounds using DBS (Liang et al., 2009, Spooner et al., 
2009). There are however, relatively fewer reports on the clinical evaluation of DBS 
techniques applied to PK studies. All drug quantification methods must be 
demonstrably accurate and reliable so that the results from subsequent PK analysis of 
the data can be applied to optimise drug treatment schedules for patients. More 
extensive clinical validations of DBS analysis will therefore be essential before 
widespread use of the technique in PK studies is possible.  
The in-vitro and clinical studies described in this thesis were designed to investigate the 
robustness and reliability of DBS quantification as an alternative to traditional plasma 
based methods in PK studies. Investigations were carried out in neonates and adults 
using the target drugs dexamethasone and caffeine.  
1.2 Pharmacokinetic studies  
Understanding the PK of a given compound in humans forms an essential part of the 
drug development process. PK studies typically involve the collection of repeat blood 
samples in order to determine the drug concentration-time profile. They are often 
combined with efficacy (pharmacodynamic, PD) studies to generate critical information 
for the safe and effective prescribing of medicines which include the dosage 
requirement, administration frequency and treatment length. The information gathered 
from these studies serve as the scientific foundation for dosing regimens used in clinical 
efficacy (and safety) trials of medicines (Howland, 2008). In turn, clinical efficacy trials 
form the basis for prescribing a medicine to the general population. Most medicines 
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used in adults have been formally tested in this manner and thus doses are prescribed on 
the basis of scientific evidence. In contrast, a significant proportion of medicines 
administered to children and neonates have not been subjected to such rigorous testing. 
In the absence of regulatory valid studies by pharmaceutical companies these drug 
treatments when clinically necessary are prescribed on an unlicensed and (or) off-label 
basis (Conroy et al., 1999, Conroy and McIntyre, 2005, Lindell-Osuagwu et al., 2009). 
Studies suggest the deficit in evidence based medicine is greatest in neonates with 
approximately 90% of neonates on the neonatal intensive care unit (NICU) and 70% of 
hospitalised children receiving at least one unlicensed or off-label drug treatment during 
their care (Conroy et al., 1999, Conroy et al., 2000). This raises serious concerns around 
short and long term safety for medicines currently used in children and neonates 
(Cuzzolin et al., 2006). 
1.3 Barriers to performing neonatal and paediatric PK studies 
1.3.1 Ethics, economics and logistics 
A reluctance to perform PK and PD studies in children has been in part due to the 
perceived risks of involving vulnerable age groups in clinical studies (Saint Raymond 
and Brasseur, 2005). Economic reasons have also contributed to the inequality in drug 
data between different age groups. As children represent a small percentage of the 
market for medicines there is less financial incentive for the pharmaceutical industry to 
develop medicines specifically for children (Matsui et al., 2003). Furthermore, the 
conduct of large clinical studies can be logistically problematic due to limited sampling 
pools and poor recruitment.  
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1.3.2 Blood sampling 
A major barrier to conducting pharmacokinetic trials in children is the relatively large 
volumes of blood (~ 0.5 - 10 ml) at a time required for analysis by most plasma based 
assays. The problem of blood sampling is most apparent in neonates due to their 
comparatively lower circulatory volume. Often numerous blood samples are collected 
from neonates during routine care on the NICU which already makes them at risk of 
iatrogenic blood loss (Weiss et al., 2002). Therefore any drug quantification method 
must enable the measurement of circulating drug concentrations from a micro volume of 
blood. The European Medicines Agency (EMA) guidelines on blood sampling in 
newborns state ‘the trial-related blood loss (including any losses in manoeuvre) should 
not exceed 3% of the total blood volume during a period of four weeks and should not 
exceed 1% at any single time’ (Guidelines on the Investigation of Medicinal Products in 
the Term and Preterm Neonate, 2007). Considering the total blood volume of a neonate 
is estimated at 80 ml/kg body weight, the maximum volume of blood that can be safely 
removed from a 500 g preterm for trial purposes is 1.2 ml over four weeks (Koren, 
1997). PK studies should be designed and performed within these blood sampling 
limitations.  
The problem of repeated blood sampling has been partly resolved by the use of 
population PK study designs that incorporate sparse sampling methodology. This means 
that 2 - 3 blood samples are required from each patient rather than in excess of 12 
samples required by traditional PK modeling methods. The population PK approach is 
able to reliably estimate the values of PK parameters such as clearance (CL), volume of 
distribution (V) and half life (t1/2) and their associated variability within the population. 
Indeed, population PK has been recommended by the regulatory agencies as the 
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preferred approach to studying pharmacokinetics in children (The Role of 
Pharmacokinetics in the Development of Medicinal Products in the Paediatric 
Population, 2007). This approach however, does not overcome the requirement for large 
blood volume samples. 
In circumstances where the volume of blood does not prevent a PK study from taking 
place, blood sampling itself can make children, parents and ethics committees baulk at 
agreeing to a PK study. The degree of pain or discomfort associated with a blood 
sampling method is an important factor for parents when deciding whether to consent to 
their infant’s participation in a study (Anderson et al, 2007). These ethical concerns can 
be reduced by coordinating blood sampling for research purposes with routine clinical 
sampling. Moreover, all blood sampling methods have a failure rate depending on the 
volume of blood needed and the skill of the phlebotomist. The collection of capillary 
blood following a heel-stick prick is a common method for obtaining blood samples on 
the NICU. It is technically less demanding to perform than venepuncture, but it is often 
not possible to collect large volumes of blood with this method. For these reasons, it is 
clear that PK data on drugs used in all age groups will only become readily available 
through the development of assays and methods that are compatible with micro volume 
blood samples. 
1.4 Neonatal and paediatric medicines 
1.4.1 Drug dose estimation in the absence of pharmacokinetic data 
In the absence of age specific PK data, drug doses for administration to children and 
neonates have historically been derived from adult data adjusted according to body 
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weight or body surface area (Anderson et al., 2007). However, these approaches have a 
tendency to either over predict or under predict drug CL and are therefore often 
inappropriate for scaling neonates and children to adults (Holford, 1996). An additional 
problem of using adult PK data for dose selection is that it may have been derived for a 
different disease state to that which it is being intended for. On-going developmental 
changes in drug disposition are prevalent from birth to adolescence which adds to the 
complexity of studying medicines in children and neonates. Drug metabolic pathways 
are immature in the newborn which mean often a smaller dose per kilogram is required 
to produce an equivalent therapeutic drug level (Stevens et al., 2003, Hines, 2007). The 
maturation of specific hepatic enzymes are severely delayed and can extend over several 
years before reaching adult metabolic capacity. Renal function is also reduced in term 
and preterm neonates with adult glomerular filtration rates (GFR) not being reached 
until around one year of age (Rhodin et al., 2009). The International Conference on 
Harmonisation guidelines distinguishes at least four subgroups; newborns (birth to 28 
days of life), infants (1 to 23 months of life), children (2 to 11 years of age) and young 
people (12 to 18 years of age) (Clinical Investigation of Medicinal Products in the 
Paediatric Population, 2001). Each subgroup warrants special consideration in relation 
to their developmental stage to ensure safe and effective prescribing practices and 
therefore the conduct of several clinical studies may be necessary. 
Overdosing and toxicity are recognised risks associated with dosing on the basis of data 
generated in adults. Chloramphenicol and propofol are important examples where 
children and neonates have been prescribed inappropriately high and toxic doses of 
medicines because of unrecognised, age-specific differences in PK (Weiss, 1960, 
Knibbe et al., 2002). There are few instances of drugs prescribed at sub-therapeutic 
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doses based on adult PK data which could reflect the difficulty in detecting treatment 
failure due to age related differences in PK. Overall, potentially useful drugs may be 
perceived as either harmful or ineffective when the real issue may be one of a lack of 
PK data in the relevant age group to support effective treatment. 
1.4.2 Better medicines 
Recognition of the inequality in data between adults and children has led to the 
establishment of the paediatric EU legislation, the ‘Best Pharmaceuticals for Children 
Act’ and the ‘Paediatric Research Equity Act’ in the US and the foundation of the 
Medicines for Children Research Network (MCRN) in the UK (US Congress: Best 
Pharmaceuticals for Children Act, 2002, US Congress: Pediatric Research Equity Act of 
2003, US Congress: Food and Drug Administration Amendments Act of 2007, 
Regulation (EC) No 1902/2006 of the European Parliament and of the Council on 
medicinal products for paediatric use, 2006, Medicines for Children Research Network, 
2005). The aim of EU and US legislation is to improve the evidence base for drugs 
prescribed to children and neonates, whereas networks such as the MCRN aim to 
facilitate appropriate clinical studies of these drugs. According to legislative changes 
which came into force in Europe in 2007, marketing authorisation applications for new 
medicines must include data from paediatric and neonatal studies where there is 
potential for use. In return, pharmaceutical companies are given extended exclusivity on 
patent. The legislative changes also provide incentives to address existing problems 
with older medicines already on the market used on an unlicensed or off-label basis. 
This is a significant step forward to understanding drug pharmacology and improving 
the use of medicines in these age groups. Clinicians, academics and the pharmaceutical 
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industry are faced with the challenge of now performing PK and PK-PD studies to 
enable the licensing of age appropriate medicines. 
1.5 Dried blood spots 
1.5.1 Utility of the dried blood spot 
DBS is a well established technique for collecting and storing blood (Guthrie and Susi, 
1963). Since its use for the detection of phenylketonuria in newborns, advances in 
analytical capability, particularly with mass spectrometry (MS) based techniques have 
enabled the utilization of DBS in prospective newborn screening programmes for a 
range of compounds including acyl carnitines, amino acids, organic acids, thyroxine and 
steroids (Carpenter and Wiley, 2002, Keevil, 2011). With greater than 95% of newborns 
in the US included within the newborn screening programme DBS has become an 
important blood sampling method in the detection of treatable genetic and metabolic 
disorders (Mei et al., 2001). DBS has been used for the detection of a variety of 
biomarkers in clinical and epidemiological studies including amino acids, hormones, 
cytokines, trace elements and vitamins (Nelson et al., 1998, Butter et al., 2001, 
Skogstrand et al., 2005, Holub et al., 2006, Chaudhuri et al., 2009). It has also been 
used as a matrix for the measurement of human immunodeficiency virus, human 
immunodeficiency virus drug resistance genotyping, genotyping and metabolite 
profiling (Mwaba et al., 2003, Ziemniak et al., 2006, Wijnen et al., 2008, Hollegaard et 
al., 2009, Wang et al., 2010, Yang et al., 2010, Kong et al., 2011). These applications 
highlight the breadth of DBS usage and the potential to study a range of compounds 
spanning a spectrum of low to high molecular weight. 
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1.5.2 Dried blood spots in drug quantification 
Plasma or serum from venous blood sampling is the gold standard biological fluid for 
drug quantification and is reflected by the large volume of reported assays for these 
matrices in the literature. In comparison, there are fewer reports of the measurement of 
drug levels within DBS samples, although a significant increase in the use of the 
technique has been documented over the last few years (Li and Tse, 2010). Many of 
these reports stem from application to TDM through which a range of drugs including 
methylxanthines, anticonvulsants, antimalarials, antidiabetics, antivirals and 
immunosuppressants have been quantified (Coombesa et al., 1984, AbuRuz et al., 2006, 
la Marca et al., 2008, Wilhelm et al., 2009b, Blessborn et al., 2010, Van Schooneveld et 
al., 2010). These methods have been shown to perform to the accuracy and precision 
requirements of drug regulatory analytical guidelines on which plasma based assays are 
validated. 
Understanding the application of DBS in PK studies is still in its infancy. As an 
emerging alternative method for performing drug quantification in PK studies, it is of 
particular interest to bioanalysts in the pharmaceutical industry because pre-clinical PK 
studies of drugs in small mammals face the same ethical and technical challenges as PK 
studies in neonates (Barfield et al., 2008). The need for large blood volumes per time 
point means that blood sampling must be performed using several animals. Composite 
sampling reduces blood loss per animal but introduces animal-to-animal variability and 
results in an increase in numbers of euthanized animals. A smaller sampling volume 
enables serial sampling from a single small animal whilst complying with the 3R’s 
initiative which aims to reduce, refine and replace animal use in drug development 
research. This method also enables better quality PK data as all concentration 
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measurements are taken from a single animal. Development and application of DBS 
based methods for pre-clinical PK studies and toxicokinetic (TK) studies have been 
reported (Beaudette and Bateman, 2004, Barfield et al., 2008, Liang et al., 2009, 
González et al., 2011, Kole et al., 2011, Smith et al., 2011). There are fewer 
applications to determine drug concentrations in clinical PK studies. Spooner et al 
reported on the development of an analytical method specifically for the measurement 
of paracetamol concentrations in 15 μl DBS samples (Spooner et al., 2009). The 
developed method validated to regulatory standards was subsequently used in a PK 
study involving 11 healthy adult volunteers in a single dosing study with paracetamol 
(Spooner et al., 2010). This same test compound has been used to evaluate the potential 
of DBS in PK studies by other investigators (Mohammed et al., 2010). Youhnovski et al 
reported on the application of a naproxen DBS method in adult bioequivalence and PK 
studies (Youhnovski et al., 2010).  
There are reports of the application of DBS methods for PK determination in paediatric 
and neonatal populations. The PK of topiramate has been investigated in 13 term 
newborns using a DBS assay requiring approximately 20 μl of blood (la Marca et al., 
2008, Filippi et al., 2009). Suyagh et al developed a DBS based method for the 
investigation of metronidazole and reported on the subsequent application to determine 
the population PK of metronidazole in 32 preterm neonates (Suyagh et al., 2010a, 
Suyagh et al., 2011). The same investigators have also described the development and 
application of a DBS method for the estimation of canrenone levels in paediatric 
patients (Suyagh et al., 2010b). 
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1.5.3 Dried blood spot technique 
1.5.3.1 Blood sample collection, spotting and storage 
In DBS sampling capillary blood is usually obtained from the heel or finger using a 
sterile disposable lancet. Due to the method of obtaining blood, the sample collected is a 
mixture of venuole, arteriole and capillary blood as well as intracellular and interstitial 
fluids (Blumenfeld et al., 1977). It has been recommended that the first blood drop 
containing a higher proportion of tissue fluid should be wiped away however, this 
practice is not standardised (Mei et al., 2001). Droplets formed on the skin surface are 
allowed to saturate a specialised high quality cellulose based filter paper. This direct 
approach of blood collection has been widely adopted throughout newborn screening 
programmes. An alternative approach involves the collection of blood into a capillary 
tube containing anticoagulant. Blood is drawn up into the capillary via capillary action 
and then dispensed onto filter paper using a suction bulb (Spooner et al., 2009). Blood 
may also be initially collected into a blood tube containing anticoagulant and then 
spotted using a pipette, but this method is associated with wastage of matrix. Whichever 
spotting method is selected it is important that it results in an even spreading of blood 
across the sample collection area. Samples must be spotted within the designated area 
and an even colour should be visible on both sides of the filter paper (which indicates 
complete saturation). Blood collected from venous and arterial sampling sites where 
available are equally suitable for producing DBS samples.  
Collected samples must be thoroughly dried prior to storage as moisture may harm the 
sample by encouraging bacterial growth or altering its elution time (Mei et al., 2001). A 
minimum drying time of 3 hours at 22°C over an open non-absorbent surface is 
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generally recommended, but this will vary according to the filter paper type used, 
temperature and humidity (Denniff and Spooner, 2010b). If necessary, DBS samples 
can be protected from the effects of moisture and humidity by storage in plastic sealable 
bags containing sachets of desiccant and humidity indicator cards.  
Importantly, the DBS technique is compatible with blood collection procedures on the 
NICU. The simplicity of the DBS method also makes it a good candidate for collecting 
and storing blood for PK studies in other age groups.   
1.5.3.2 Dried blood spot processing 
In the first step of the analytical process a circular disc of blood of fixed diameter is 
punched from the centre of the DBS sample and transferred to a clean glass vial (Figure 
1.1). A disc punched from a DBS sample this way provides a volumetric measurement, 
similar to the use of a pipette for liquid measurements. For this reason homogenous and 
reproducible distribution of analyte on the filter paper is of importance. It is therefore 
also important that a device which produces a reproducible disc diameter is used. 
Sample homogeneity may be affected by the type of filter paper, volume of blood 
spotted and analyte properties (Mei et al., 2001, Clark et al., 2010). The sub-sampled 
disc of blood is extracted with an organic solvent, most commonly acetonitrile or 
methanol or a mixture of organic and aqueous solvent containing an internal standard 
(IS) (Barfield et al., 2008, la Marca et al., 2008, Spooner et al., 2009, Suyagh et al., 
2010b). Agitation, mixing or sonication may be necessary to aid analyte extraction. 
Sample clean-up procedures such as solid phase and liquid-liquid extraction have been 
used by some analysts (Liu et al., 2010, Suyagh et al., 2010b). Any residues arising 
from the filter paper can be removed via centrifugation and an aliquot of the resultant 
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extract is subsequently analysed using a selected detection method. A comparison of 
selected DBS based methods reported in the literature which have been specifically 
developed for application to PK or TK studies are presented in Table 1.1. A variety of 
filter papers and punch sizes have been employed, but the volume has been kept 
relatively low (15 to 50 μl) compared with earlier DBS methods used in TDM (20 to 
200 μl) (Edelbroek et al., 2009). Extraction procedures have commonly involved liquid 








Figure 1.1 A schematic diagram of the typical DBS analytical process 
 
The micro blood volume associated with DBS analysis is a clear advantage to PK 
studies in patient populations where blood sampling limitations apply. Another 
advantage is that many analytes are stable within DBS samples at room temperature for 
several weeks to months. Therefore storage is simplified and shipment of samples from 
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transport conditions (Ntale et al., 2008, Liang et al., 2009). This should make DBS a 
more economical sampling method. Samples in a DBS format also present less of a 
biohazard risk compared with liquid plasma or blood and can enhance the stability of 
some compounds (Bowen et al., 2010, D’Arienzo et al., 2010). Additionally, there is no 
need to centrifuge samples that is a requirement with plasma analysis thereby reducing 
the complexity of the blood collection process. DBS also provides a convenient way of 
handling small sample volumes that can be difficult with low plasma volume analysis. 
These factors make DBS quantification a potentially very useful method for performing 
multi-centre national and international PK studies as well as studies in resource limited 
settings (Johannessen et al., 2009, Amsterdam and Waldrop, 2010). The ability to 
measure drug concentrations within alternative dried matrix spots such as plasma has 
been demonstrated (Barfield and Wheller, 2011). This enables the benefit of some of the 
advantages of DBS analysis and maybe useful in situations where plasma is preferred in 
PK studies.   
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Table 1.1 A comparison of selected DBS methods developed for application to pharmacokinetic and toxicokinetic studies 
Author  Compound and application Filter paper, DBS 
volume & punch 
diameter 
Extraction procedure Detection 
system 







50 μl, 3 mm 
Solvent: 50 μl IS in acetonitrile:water (50:50, v/v)  + 100 
μl 2% ammonium hydroxide + 700 μl methyl tert-butyl 
ether. 
Samples vortexed (3 minutes) and centrifuged (5 
minutes). 500 μl of organic layer concentrated. Residue 









40 μl, 3.2 mm 
Solvent: 150 μl IS in acetonitrile:aqueous formic acid 
0.1% (80:20, v/v). 
Samples placed in an ultra-sonic bath at 37°C for 15 
minutes. Centrifugation at 12,000 x g for 5 minutes. 
UPLC-
MS/MS 
Barfield et al., 
2008; Spooner 









15 μl, 3 mm 
Solvent: 100 μl IS in methanol. 
Sample vortexed for 30 seconds and centrifuged at 3000 




Table 1.1 Continued 
 
UPLC = ultra performance liquid chromatography; LC-UV = liquid chromatography ultraviolet; LC-MS = liquid chromatography mass spectrometry; 
LC-MS/MS = liquid chromatography tandem mass spectrometry.
Author  Compound and application 
 
Filter paper, DBS 
volume & punch 
diameter 
Extraction procedure Detection 
system 







30 μl, 6 mm 
Solvent: 25 μl IS in water + 975 μl water. 
Samples vortexed for 10 seconds at 10 minute interval 
over 30 minutes. 
LC-UV 







30 μl, 6 mm 
Solvent: 2 ml IS in methanol. 
Sample shaken every 20 minutes over 60 minutes. 
Extract dried to a residue and reconstituted with 1 ml 
acetonitrile:water (10:90, v/v). Sample clean up using 
solid phase extraction, eluate dried to residue and 
reconstituted with 100 μl of mobile phase. 
LC-MS 







20 μl, two 3.2 mm 
discs 
Solvent: 200 μl IS in acetonitrile: aqueous formic acid 
0.05% (70:30, v/v). 




1.5.3.3 Dried blood spot sampling paper  
The sampling paper type Schleicher & Scheull 903 (S&S 903 or Whatman 903) is 
extensively used in newborn screening programmes and is classified by the US Food 
and Drug Administration (FDA) agency as a class II medical device. The paper is 
manufactured from high purity cotton linters to give an accurate and reproducible 
absorption of blood in accordance with the US National Committee on Clinical 
Laboratory Standards (Mei et al., 2001). The quality of the filter paper is also tested 
independently by the Newborn Screening Quality Assurance Programme (NSQAP) at 
the Centre for Disease Control and Prevention. This provides an independent evaluation 
of the filter paper and importantly gives assurance that new filter paper batches perform 
to the standards of previous batches. The Ahlstrom grade 226 paper is an alternative 
FDA approved blood collection paper for newborn screening and also undergoes an 
independent assessment by the NSQAP. The two FDA approved filter papers have 
shown a comparable performance in analyte quantification (Mei et al., 2010).  
Investigations conducted by the NSQAP to evaluate the uniformity and absorption 
characteristics of the filter paper involve the use of an isotopic method. Briefly, whole 
blood adjusted to 55% haematocrit is enriched with 
125
I-L-thyroxine and spotted in 100 
µl aliquots to the test filter paper. Once dried, a 3.2 mm disc is taken from the centre 
and four peripheral locations. The blood volume contained within the 3.2 mm disks is 
determined by measuring the total number of gamma counts in each disc and comparing 
them to the total number of gamma counts per unit volume of blood. The absorption 
time and spot size produced are also used to assess the absorption characteristics of the 
filter paper.  
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Whereas filter papers S&S 903 and Ahlstrom 226 are untreated, chemically treated 
cellulose papers (FTA & FTA Elute, Whatman, GE Healthcare) are also available. 
These papers upon contact lyse cells, deactivate enzymes and provide antimicrobial 
protection (Whatman FTA Elute). This paper was designed for nucleic acid and protein 
analysis but has also been utilised in drug quantification (Barfield et al., 2008, Spooner 
et al., 2009, Lad, 2010). Several other filter papers are available for analyte 
quantification of which S&S 903 is the most extensively investigated and used.  
1.5.4 Analytical challenges in dried blood spot analysis 
The advantages of DBS analysis over conventional plasma drug quantification methods 
are clear. There are however, many factors inherent to DBS analysis with potential to 
adversely affect drug quantification. The FDA guidelines on bioanalytical validation 
provide guidance on the range of tests to be carried out and the criteria which developed 
methods must meet to be considered suitable for drug bioanalysis. The outlined 
validation criteria apply equally to measurements in whole blood and plasma, but do not 
cover the additional factors such blood spot size and haematocrit that may need to be 
considered when validating the performance of DBS methods (O'Broin, 1993, Mei et 
al., 2001). The blood collection and spotting procedure implemented are also potential 
sources of error. Although relatively simple to perform, experience from newborn 
screening programmes have highlighted that bed side errors can occur resulting in DBS 
samples that do not meet the minimum quality requirements for analysis. Reasons for 
sample rejection include multiple spotting, blood layering and insufficient sample for 
analysis (Guidelines for Newborn Blood Spot Sampling, UK Newborn Screening 
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Programme, 2008). Repeat sampling is not a viable option in PK studies where an 
inadequate sample would result in missing data.  
The increased potential for problems in drug quantification with DBS mean that many 
more validation tests in addition to those already carried out for plasma are required. 
This significantly increases the amount of time that must be spent during the validation 
procedure. The time consuming process involved in DBS analysis has also been cited as 
a major disadvantage by some analysts. Many of these practical aspects are being 
overcome with better automation involving robotic punching of DBS samples and 
solvent addition (Wong et al., 2010). Investigations into the direct analysis of DBS 
samples with various techniques such as paper spray analysis, direct elution and direct 
desorption by desorption electrospray ionisation and direct analysis in real time have 
been reported (Abu-Rabie and Spooner, 2009, Kertesz and Van Berkel, 2010, Crawford 
et al., 2011, Manicke et al., 2011). These methods have the potential for high-
throughput analysis with minimal sample handling. 
The micro blood volume used in DBS analysis and the consequent need for higher 
detection sensitivities is likely to have contributed to its limited use outside the context 
of newborn screening programmes. Improvements in analytical instruments particularly 
with MS have increased the feasibility of drug analysis from low volume sampling 
(Zhang et al., 2008). Despite these advances, the sensitivity requirements with DBS 
sampling may mean that such an approach is less viable for some drugs at present.  
1.5.5 Blood concentration measurements for pharmacokinetic evaluations 
Conventionally, plasma measurements have been used to define the concentration-time 
profile of a compound, estimate PK parameters and provide an assessment of drug 
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exposure and safety. It is usually the unbound fraction of drug in plasma that is 
available to exert a pharmacological effect and this forms the basis for another 
important reason for its preference to whole blood drug concentration measurements 
(Rowland and Emmons, 2010). Regulatory guidelines stipulate drug exposure may be 
represented by concentration measurements in plasma, serum or whole blood matrices 
(ICH Harmonised Tripartite Guideline, 1994). Therefore the use of DBS is a valid 
matrix for determining drug PK. However, before it is possible for DBS to become a 
routine method in PK studies it will be necessary to ascertain the robustness of the 
technique through clinical validations. The problems which can occur in PK 
interpretation when using blood concentration measurements over plasma 
measurements have been highlighted (Rowland and Emmons, 2010). These are most 
likely to occur for drugs which show preferential distribution (into plasma or red blood 
cells) and where a large variability in factors which govern the partitioning process e.g. 
protein binding and haematocrit are expected in the study population. Therefore it will 
be important to consider the implications and appropriateness of DBS sampling within 
the context of planned use.  
1.6 Bioanalysis of dried blood spots 
The micro volume blood sample available for analyte quantification and complexity of 
the sample matrix pose several challenges for DBS analysis. For these reasons liquid 
chromatography with single quadrupole mass spectrometry (LC-MS) and more often 
tandem mass spectrometry (LC-MS/MS) quantification techniques have been preferred 
due to their inherent sensitivity and specificity. High resolution MS has the advantage 
of increased compound selectivity and has been applied to the quantification of drugs in 
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DBS samples (Tanna et al., 2011). Other analytical techniques including LC with 
ultraviolet (UV) or fluorescence detection and radioimmunoassay (RIA) have also been 
used in DBS analysis with success (Neese and Sovka, 1977, Croes et al., 1994, Mei et 
al., 1998, AbuRuz et al., 2006). The final choice of detection system will depend on the 
properties of the compound under study as well as the required level of detection 
sensitivity.  
Detection methods used in the UK newborn screening programme have included 
immunoassay, LC-MS/MS and LC-UV depending on the condition screened (Pollitt et 
al., 1997, Venditti et al., 2003).  
1.6.1 Liquid chromatography single quadrupole mass spectrometry 
Mass spectrometry based techniques have been used in various fields including 
quantitative bioanalysis for PK studies, drug metabolite analysis, proteomics, and 
pharmaceutical degradation and stability testing (Lim and Lord, 2002). A variety of 
instruments are available with capabilities of performing qualitative and quantitative 
analyses to various levels. The simplest instrument is the LC-MS consisting of a liquid 
chromatography unit attached to a mass spectrometer via an interface which provides 
compatibility between the two techniques. In the first stage of analysis an aliquot of 
sample mixture is injected into a continuous flow of liquid mobile phase which is 
carried to a reversed phase column packed with bonded silica particles. The rate at 
which a given compound travels through the column is governed by its polarity and 
experimental conditions which include mobile phase composition and column 
properties (Snyder et al., 1997). Compounds with little affinity for the stationary phase 
will travel at essentially the same rate as the mobile phase. Using these principles, LC is 
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used to achieve separation of a mixture of components. Compounds eluting from the 
column are carried by the mobile phase to the ionisation interface for analysis by MS. 
1.6.1.1 Ionisation interfaces for mass spectrometry 
Atmospheric pressure chemical ionisation (APCI) and electrospray ionisation (ESI) are 
two of the most popular interfaces used in LC-MS and can be used to study a broad 
range of compounds (Kostiainen et al., 2003). ESI techniques are useful for studying 
small to large molecules that become multiply charged [M+nH]
n+
 including proteins to 
100,000 daltons and above (Polettini, 2006). During ESI a strong electrical field is 
applied to the eluant from the LC column as it passes through a nebulizer needle. This 
creates an accumulation of charged liquid at the end of the needle which leads to the 
formation of highly charged droplets. The charged droplets are attracted toward the 
capillary sampling orifice through a counter flow of heated nitrogen gas, which shrinks 
the droplets and carries away uncharged material. The droplet size decreases until the 
surface tension cannot stabilize the charge at which point an explosion occurs resulting 
in the formation of charged molecular ions [M+H]
+
 with little or no fragmentation 
(Agilent Technologies LC-MSD software operation, 2000).  
In APCI a gas phase chemical ionisation process is used to ionise the sample. The 
process begins with gas mediated nebulisation into a hot (250 to 400°C) vaporizer 
chamber resulting in rapid evaporation of spray droplets (Agilent Technologies LC-
MSD software operation, 2000). The gas phase (vaporized) solvent and analyte 
molecules produced are ionised by the discharge from a corona needle which serves to 
initiate the ionisation process. Here the solvent plays an important role in the ionisation 
process by transferring a proton to the analyte provided the proton affinity of the analyte 
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is greater than that of the solvent. This ionisation process usually produces a singly 
charged molecular ion [M+H]
+
. Like electrospray, APCI is a soft ionisation technique 
but may result in a greater degree of fragmentation. APCI is only used for samples that 
can be vaporized and is particularly useful in the study of intermediate molecular weight 
and polarity compounds (Agilent Technologies LC-MSD software operation, 2000). 
1.6.1.2 Ion transmission 
All charged ions produced at the interface enter the mass spectrometer through the 
capillary sampling orifice (Figure 1.2) and are transmitted through a narrow glass 
capillary. An octopole is used to guide ions towards a quadrupole mass filter consisting 
of four parallel rods. Specific voltages are applied to these rods to filter out the ion of 
interest. The selected ions follow a trajectory towards the detector which creates a signal 
that is represented by a LC-MS chromatogram. The integrated peak area or height is 
proportional to the amount of analyte present and is used to quantify its concentration 
within a given sample. This mode of data acquisition is referred to as single ion 
monitoring (SIM). By varying the voltage applied it is also possible to monitor multiple 
ions from a sample and perform scans across a mass range for qualitative purposes.  
1.6.2 Liquid chromatography triple quadrupole mass spectrometry 
A triple quadrupole mass spectrometer consists of two quadrupole mass filters (Q1 and 
Q3) separated by a collision cell (Figure 1.3). Like LC-MS, an ESI or APCI interface is 
commonly used for sample ionisation. Here the first quadrupole is used to direct the 
molecular ion (precursor) of interest to the collision cell. Within this cell ions collide 
with an inert gas such as nitrogen or helium to induce fragmentation of the precursor ion 
(Barker, 1999). The degree of fragmentation which occurs is dependent on the 
25 
 
compound type and the fragmentor voltage applied (Takino et al., 2003). A second 
quadrupole is used to separate and direct selected product (fragmentation) ions to the 
detector. This mode of operation is termed selected reaction monitoring, SRM. The 
product ions are pieces of the precursor and are therefore representative of the overall 
structure of the precursor ion. There are various types of instruments which perform 
MS/MS analysis, all however encompass an isolation and fragmentation process within 
the instrument. For drug quantification purposes, monitoring a product ion (SRM) 
compared to SIM in LC-MS confers additional assurance that the selected ion for 
monitoring represents the compound of interest. Additional specificity is gained through 
the ability to monitor a fragmentation pathway which is dependent on compound 
structure. This can lead to improved detection sensitivity for some compounds. The 
ability to fragment ions has also played a very important role in drug metabolic studies, 
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1.7 Dexamethasone in the treatment of chronic lung disease of the newborn 
Dexamethasone is amongst the most potent glucocorticosteroids used in clinical 
practice (British National Formulary, 2009). It is mainly used for the treatment of 
inflammatory conditions, allergic disorders, cerebral oedema and as an antiemetic with 
chemotherapy. The drug is also used to induce foetal lung maturation in women at risk 
of preterm labour and in the treatment of chronic lung disease in neonates (Brownfoot et 
al., 2008, Halliday et al., 2010).  
1.7.1 Chronic lung disease of the newborn 
Chronic lung disease (CLD) of the newborn predominantly affects premature neonates 
and is a significant and perenial contributor to the morbidity and mortality observed in 
this population (Jobe and Bancalari, 2001, Kinsella et al., 2006). Though there are 
modern variations in the specific time frame, it has customarily been defined by the 
need for supplementational oxygen at 36 weeks postconceptual age, with persistant 
respiratory symptoms accompanied by an abnormal chest radiograph. The incidence of 
CLD amongst ventilated newborns is approximately 25% and the risk of developing 
CLD is strongly associated with the degree of prematurity with 75% of all cases 
occuring in newborns weighing less than 500 g compared with 5% in those above 1500 
g (Kinsella et al., 2006). The development of CLD has also been linked to mechanical 
ventilation and oxygen therapy for the treatment of respiratory distress syndrome and 
infection, which may have additive or synergistic roles in disease progression (Kinsella 
et al., 2006). There is substantial evidence to suggest that an inflammatory response is 
central to the development of CLD (Kotecha et al., 1996, Ramsay et al., 1998, Kazzi et 
al., 2001, Beresford and Shaw, 2002). Elevated levels of acute pro-inflammatory 
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cytokines IL-1β, IL-1α, IL-6 and IL-8 have been detected in lung lavage fluid during the 
first few postnatal days in infants who go on to develop CLD. These acute phase pro-
inflammatory mediators are markedly increased during the first 2 to 3 postnatal weeks 
and remain elevated for several weeks thereafter. A combination of underdeveloped 
lungs, continuous injury and a reduced defence capacity is thought to explain the 
observed persistant inflammatory state (Jobe and Bancalari, 2001). Following the initial 
acute inflammtory response pro-inflammatory cytokines trigger a cascade of 
inflammatory events which lead to the release of enzymes responsible for lung 
remodeling (Sweet and Halliday, 2005). Profound structural lung changes have been 
observed in infants with CLD resulting in reduced respiratory function. Respiratory 
symptoms persist for two years after birth and may continue into adolescence (Kinsella 
et al., 2006). Treament most often necessitates regular medication and frequent re-
admissions to the hospital, which can be distressing for the young patient, parents and 
carers.   
1.7.2 Treatment with dexamethasone 
Dexamethasone has been widely used to oppose the pro-inflammatory state observed in 
premature neonates either developing or with CLD (Lemons et al., 2001). Despite 
extensive usage it remains to be prescribed on an off-label basis on the NICU. Several 
studies have shown that dexamethasone treatment acutely improves lung mechanics and 
reduces the incidence of CLD, but is associated with short term complications (Halliday 
et al., 2009a, Halliday et al., 2009b, Halliday et al., 2010). These include growth 
retardation, intestinal perforation, hypertension and hyperglycaemia requiring insulin 
therapy (Anderson et al., 2001, Halliday et al., 2010). Concerns over long term 
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neurodevelopmental impairment namely cerebral palsy led to joint guidelines from the 
European Association of Perinatal Medicine in 2001 and the American Academy of 
Pediatrics and the Canadian Paediatric Society in 2002 on the use of postnatal steroids 
for the treatment of CLD (Barrington, 2001, Halliday, 2001). The guidelines concluded 
that the routine use of systemic corticosteroids for the prevention or treatment of CLD 
in infants with very low birth weight is not recommended outside clinical trials ‘except 
in exceptional circumstances’. Although use of dexamethasone has declined over the 
years, a substantial proportion of very low birth weight infants continue to be treated 
with postnatal steroids (Walsh et al., 2006). 
The doses used in the treatment of CLD have been empirically based. Initial 
investigative trials used high dexamethasone doses for prolonged periods with 
subsequent trials gradually using smaller doses for shorter periods. The dose in trials to 
date has ranged from 0.05 - 0.5 mg/kg per day (Cummings et al., 1989, Yates and 
Newell, 2010). There is some evidence of a dose-response relationship of 
dexamethasone in CLD with higher doses more effectively reducing the incidence of 
CLD (Onland et al., 2008). However, studies within which high versus low dosing 
regimens have been investigated are generally too small to draw any firm conclusions. 
Despite several trials, incorporating various dosing schedules, the optimum 
dexamethasone dosing regimen remains unknown. There is no consensus on the dose 
that should be used in clinical practice and at present dosing regimens vary significantly 
between NICUs. At the local Leicester NICU dexamethasone is initiated at 250 μg/kg 
12 hourly and gradually reduced to 25 μg/kg 12 hourly over 10 days.  
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A major problem with the dose finding approach that has been used is that it does not 
take into account the disposition of dexamethasone in neonates. An initial study 
exploring the PK-PD relationship of dexamethasone would provide an efficacious dose 
range around which to design a much more efficient and possibly more conclusive trial. 
However, there are only two studies involving 16 patients reported on the PK of 
dexamethasone (Charles et al., 1993, Lugo et al., 1996). With limited PK data it is not 
possible to derive dosing information which take into account the variability which exist 
in infants between 24 and 36 weeks gestation.  
The issue of postnatal steroid use is further complicated by a meta-analysis suggesting 
the beneficial effects of dexamethasone in premature infants at high risk of developing 
CLD (> 50%) may actually outweigh the risks of therapy (Doyle et al., 2005). Therefore 
a proportion of premature neonates may be unfairly denied the beneficial effects of 
steroidal anti-inflammatory drugs based on disproportionate fears over adverse long 
term neurodevelopmental outcomes. This poses a dilemma for neonatologists whose 
primary objective is to arrest disease progression. The decision to treat CLD with 
dexamethasone may result in the development of neurodevelopment complications, 
whereas the decision to withdraw steroid treatment will lead to the progression of CLD 
and possibly death. Finding the optimum dose whilst minimising adverse events is now 
considered to be of great clinical importance.  
1.7.3 Dexamethasone pharmacokinetics 
The oral bioavailability of dexamethasone has not been studied in neonates, but the 
results from a healthy adult study suggest extensive absorption (~ 90%) with peak blood 
levels reached 1 hour after dose ingestion (English et al., 1975). In both previous PK 
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studies reported in neonates a non compartment analysis was used to calculate estimates 
of PK parameters following intravenous (IV) dosing. The first study investigated the PK 
of dexamethasone after the administration of a single 400 μg/kg IV dose to 7 premature 
neonates with an average gestational age (GA) of 25.6 weeks (Charles et al., 1993). 
Serial blood samples of 100 to 200 µl were collected at 0.5, 1, 2, 6, 12 and 24 hours 
after dosing and plasma concentrations were determined using LC-UV detection. The 
mean V and CL reported were 1.9 l/kg and 0.14 l/h/kg, respectively, and the half life 
was 9.3 h (range, 5.9 to 16.1 h). In the second study dexamethasone PK was 
investigated  in 9 premature neonates with an average GA age of 27.3 weeks (Lugo et 
al., 1996). Patients were recruited within 4 days of initiating treatment and received 
between 213 to 503 µg/kg of dexamethasone 12 hourly. Blood samples were collected 
at 0.5, 1, 2, 6, and 12 hour intervals after dosing and plasma concentrations were 
measured using a RIA method. Dexamethasone concentration measurements in plasma 
following a 250 μg/kg dose varied between 3.4 and 406.9 ng/ml and therefore 
significantly lower therapeutic levels would be expected in neonates during the course 
of treatment at the Leicester NICU. The mean estimates for V and CL were 1.7 l/kg and 
0.30 l/h/kg, respectively. Similar to the findings of Charles et al the half life varied 
considerably between neonates (mean 6.8, range; 2.2 to 15.8 h). In comparison, mean 
half lives of 4.3 and 2.9 hours have been reported in children and adults, respectively 
(Tsuei et al., 1979, Richter et al., 1983). There is a limited understanding of the 
elimination pathway of dexamethasone in neonates, but a prolonged half life due to 
immature drug clearance pathways are likely to have contributed to the differences in 
half life reported. Further PK studies are urgently required to explore and characterise 
the variability in dexamethasone PK amongst the neonatal population.  
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1.8 Caffeine in the treatment of apnoea of prematurity 
Caffeine is a methylxanthine drug primarily used as a respiratory stimulant in preterm 
neonates with idiopathic apnoea. It is also used to facilitate extubation in ventilated 
infants (British National Formulary for Children, 2009). Caffeine is associated with 
fewer adverse effects and has a wider therapeutic index compared with theophylline 
which belongs to the same class of drug. This has underpinned the preference of 
caffeine in the treatment of apnoea on many NICUs (Henderson-Smart and Steer, 2010). 
1.8.1 Apnoea of prematurity  
Apnoea of prematurity (AOP) is defined by the cessation of breathing for greater than 
15 seconds with bradycardia and hypoxaemia (Schmidt et al., 2006). The episodes of 
apnoea manifest due to immaturity of the centres of the brain which regulate breathing. 
It is a significant problem affecting approximately 85% of preterm neonates born at less 
than 34 weeks GA.  
1.8.2 Treatment with caffeine  
Caffeine is used as a first line treatment in AOP and has been shown to reduce the 
number of apnoaeic episodes and the need for mechanical ventilation during the first 7 
days of treatment (Henderson-Smart and De Paoli, 2010). In infants with apnoea 
caffeine is believed to work through a combination of effects including stimulating the 
central respiratory centre, promoting fluid loss, decreasing the carbon dioxide threshold, 
increasing cardiac output and increasing the response to hypercapnia (Hascoet et al., 
2000, Mathew, 2011). AOP resolves as the breathing centres which control respirations 
mature, enabling discontinuation of caffeine treatment. Most neonates will receive 
33 
 
caffeine treatment until 34 to 35 weeks postmenstrual age (PMA) when the risk of 
apnoea is low.  
Several investigations have been performed in neonates to evaluate caffeine safety and 
PK (Walther et al., 1990, Thomson et al., 1996, Ergenekon et al., 2001). This has led to 
the development of a licensed caffeine citrate formulation (Peyona, Chiesi Farmaceutici 
SpA) approved by the Committee for Medicinal Products for Human Use (CHMP) in 
the treatment of AOP. The dosing regimen currently used in the UK consists of an 
initial loading dose of 10 to 20 mg/kg (caffeine base), followed by a once daily dose of 
2.5 to 4 mg/kg (Natarajan et al., 2007). Caffeine plasma concentrations between 5 and 
20 mg/l are considered to achieve therapeutic effectiveness. However, in infants who 
continue to have apnoeas, it may be reasonable to target a much higher therapeutic 
range of around 30 to 40 mg/l (Lee et al., 1997).  
1.8.3 Caffeine pharmacokinetics 
In neonates, caffeine is extensively and rapidly absorbed with bioavailability 
approaching 100% (Charles et al., 2008). A significantly reduced CL capacity has been 
observed in this population (7.0 ml/h/kg) compared with non-smoking adults (124 
ml/h/kg) resulting in a markedly prolonged half life (101 vs. 3.9 h) (Kaplan et al., 1997, 
Lee et al., 1997, Charles et al., 2008). This is thought to be due to a maturational delay 
in the expression of cytochrome P450 enzymes responsible for the metabolism of 
caffeine (Aldridge et al., 1979). The rate of caffeine CL increases progressively with 
postnatal age (PNA), with a transition to adult levels of elimination occurring at 3 to 5 
months of age (Aranda et al., 1979a). In contrast to dexamethasone, the PK of caffeine 
in neonates has been well characterised and several published population studies are 
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reported in the literature (Thomson et al., 1996, Falcão et al., 1997, Lee et al., 1997, 
Lee et al., 2002, Charles et al., 2008).  
1.9 Population pharmacokinetics 
In traditional PK study designs healthy volunteers or specially selected patients are 
chosen for study to ensure a homogenous treatment group. This enables the study of 
drug disposition under controlled conditions and calculation of precise parameter 
estimates but ignores the biological variability that may exist in the treatment 
population for which the drug is intended (Ludden, 1988, Ette and Williams, 2004a). 
Population PK seeks to characterise and explain the variability in PK parameters within 
a group of individuals which are being clinically treated with the drug of interest. A 
range of factors can alter the dose-concentration relationship including body weight, 
renal and metabolic function and concomitant medication. Through population PK 
studies it is possible to quantify the extent of the influence of factors which alter the 
dose-concentration relationship. This information can then be used to develop a 
population model which predicts the dosage requirement or optimum dose for an 
individual. Such information provides guidance to the clinician for selecting an 
appropriate dosing regimen particularly where clinically significant changes in 
therapeutic outcome are observed (Guidance for Industry: Population Pharmacokinetics, 
1999). PK models are an oversimplification of complex biological processes. Therefore 
although a population model may be useful, none are perfect and the estimated dosage 
requirement in an individual will vary from optimal by some extent. The study of the 
differences between model predicted and observed concentrations is thus a crucial 
component of the population PK model. The magnitude of the unexplained (random) 
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variability between model predicted and observed concentrations is important because 
the safety and efficacy of a drug may decrease as unexplainable variability increases. 
Sources of variability contributing to the goodness of fit between a PK model and the 
observed data can be categorised as interindividual and intraindividual. A PK parameter 
derived for an individual may vary from the population mean estimate and this 
difference is considered the interindividual variability (or between subject variability). 
Intraindividual variability (also known as residual unexplained variability or residual 
error) is the difference between the individual model predicted and observed (or 
measured) concentration values over a given time. Factors contributing to residual error 
include inexplicable changes in individual pharmacokinetics between dosing intervals 
(interoccasion or between occasion variability), errors in drug measurement, 
documentation errors and model misspecification. Population PK modeling aims to 
explain as much of the interindividual variability as possible in order to (i) differentiate 
information from the noise or random components in the system and (ii) improve the 
predictive properties of the model through a reduction in the residual unexplained 
variability (Guidance for Industry: Population Pharmacokinetics, 1999). 
The major advantage of the population PK approach is that unlike traditional PK studies 
it is compatible with sparse sampling, unbalanced numbers of samples from patients and 
random sample collection. This approach therefore lends itself well to special 
populations such as neonates, the elderly and critically ill, where sample collection can 
be challenging and often opportunistic. 
36 
 
1.10 Approaches in population pharmacokinetic parameter estimation 
There are a number of population PK methods that can be used to characterise the 
kinetics of a drug (Ette and Williams, 2004b). The approach selected will depend on the 
objectives of the PK analysis and the study design.  
1.10.1 Naive average data approach 
In this approach the dosing regimen and sample collection are identical for all subjects. 
The number of data points for each sampling interval is therefore equal to the number of 
subjects. The first step involves averaging the value of the data at each sampling time, 
which is possible since samples were collected under identical conditions. A model is 
then fitted to the averaged concentration data to determine the best-fit PK estimates 
which may be interpreted as mean parameter values. Using this approach it is not 
possible to measure the random intraindividual variability component and the observed 
interindividual variability is a result of all sources of error. Therefore it is not possible 
to determine the true interindividual variability and limits application of this method in 
PK data analysis.  
1.10.2 Naive pooled data approach 
All concentration data measured from all patients are treated as though they were 
collected from the same individual. A model is fit to the pooled data and population PK 
estimates are obtained. An imbalanced number of concentration data points from 
individual subjects can lead to the derivation of biased PK parameter estimates. This 
approach may be useful when the expected variations between subjects are small. 
However, as with the naive average data approach interindividual variability is 
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confounded and as a result the variance between individuals cannot be reliably 
estimated.  
1.10.3 Standard two-stage approach 
With this approach, dense concentration-time data from each subject is separately fitted 
using least squares to give individual estimates in the first stage. The individual 
estimates are combined in the second stage and standard statistical calculations are 
performed to determine population mean parameters and their variances. This approach 
offers a simple method of pooling individual parameter estimates but requires a large 
number of concentration data points for analysis and an equal contribution of data from 
each individual. A standard two-stage approach therefore does not lend itself to areas 
such as paediatrics where the collection of data is often limited by sparse sampling 
design. Although all individuals are allowed to contribute equally with this approach it 
is not possible to differentiate between interindividual and intraindividual variability. 
The random effects (variance) calculated for each parameter estimate represents all 
sources of error (between occasion variability, measurement error, and interindividual). 
Hence this method tends to overestimate the true variability of a given parameter in a 
population.  
1.10.4 Non-linear mixed effects model approach 
This is the standard population approach and can be used for the analysis of sparse, 
imbalanced, unstructured, and fragmented observational PK data (Sheiner et al., 1977). 
It may also be used to analyse data following extensive sampling, alone or in 
combination with sparse data. Similar to the naive pooled method, concentration-time 
data from all patients is analysed in a single stage, but takes into account that different 
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data points came from different subjects. Therefore with this approach individuality of 
each subject is maintained and accounted for, even if the data are sparse.  
A mixed effects population PK model provides estimates of population mean values 
(fixed effects) from the full set of individual concentration values and their variability 
within the population (random effects). The random effects encompass interindividual 
variability and intraindividual variability. Importantly, with this approach it is possible 
to model and estimate the magnitude of different sources of variability. In the final stage 
of the analysis, the individual parameters are regarded as random variables and the 
probability distribution of these (often the mean and variance, i.e., intersubject variance) 
is modelled as a function of individual-specific covariates (Guidance for Industry: 
Population Pharmacokinetics, 1999). The timing of sample collection is an important 
consideration in population PK study design, particularly when there are limitations in 
patients available for recruitment as well as the number of samples that can be collected 
from each individual. In this situation there are sampling strategies that can be 
implemented to ensure an informative study design. The collection of trough samples, 
obtained shortly before the next dose is useful for estimating CL. Peak concentration 
times may be targeted in situations where it is important to determine V. A full 
population sampling approach involves the collection of multiple blood samples (1-6) 
from each individual at various times following a dose (Sheiner and Beal, 1983). 
Provided samples are collected at a range of time points from a sufficient number of 
patients it is possible to accurately and precisely estimate a range of PK parameters 
including CL, V and half life and study there variability in the population. A sample 
size of 30 to 50 patients (approximately 180 samples) has been recommended for the 
precise estimation of primary PK parameters (Ette et al., 1998, Anderson et al., 2007). 
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The appropriate number of patients for a population study will vary depending on the 
objectives of the study, the age range of the study population and the number of 
covariates under investigation.   
1.10.5 Computer software programme for analysis     
A number of software programmes are available for performing population PK analyses 
but for the purposes of this thesis NONMEM (non-linear mixed effects modeling) 
version 7.0 was used to analyse all drug concentration-time data. Like most non-linear 
mixed effects modeling approaches, population PK parameter estimation in NONMEM 
is based on the maximum likelihood approach. NONMEM uses a maximum likelihood 
criterion to provide the ‘best fit’ of the data inputted. Estimates for population mean 
values of fixed effects parameters (CL, V and coefficients for covariates which 
influence either of these PK parameters) and the variances of random effects parameters 
(interindividual, intraindividual and interoccasion) are available in the NONMEM 
output. The correctness of the model cannot be determined from the NONMEM output. 
NONMEM however, does give the weighted residuals for each data point and generates 
standards errors associated with estimates which gives the modeller an indication of the 
precision with which population values were estimated (NONMEM Users Guide - Part 
I, 1989, Beal and Sheiner). It also calculates the objective function value (-2 log 
likelihood, -2LL) which is a metric of the goodness of fit of a model (Fisher/Shafer 
NONMEM Workshop, 2007). For two models based on the same data set the one that 
gives the lowest objective function value is the most statistically preferred. Constructing 
scatter plots of the data set prior to NONMEM analysis is an essential component of the 
PK analysis. The process enables the visual detection of imputation errors or outliers 
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with potential to bias parameter estimation at an early stage. They are also useful for 
identifying important covariate-parameter relationships. 
1.10.6 Assessment of goodness of model fit 
The difference in objective function value (OFV) is an important statistical test when 
choosing between two nested models, but it should be accompanied by other selection 
criteria during the model building process as the best model is not necessarily the one 
with the lowest OFV. The standard error and covariance matrix associated with the 
estimation of parameters gives an indication of the estimation process itself. Therefore a 
model with a higher OFV that more precisely estimates parameters may be preferred to 
a model which provides a statistically better fit with less precision. Precision of 
coefficients and exponents used to quantify covariate effects on PK parameters are also 
important to consider when deciding between models. The examination of weighted 
residuals forms an essential part of the model evaluation process. Residuals should be 
randomly distributed with no systematic deviations from predicted model 
concentrations. Graphical plots of residual values versus model predicted and time are a 
useful diagnostic for the detection of underlying problems within the structural model. 
This type of residual analysis also provides important information on the suitability of 
the chosen residual error variance model.  
1.11 Study aims 
The investigations described in this thesis were undertaken to clinically validate the 
robustness of DBS quantification methods for application to PK studies, with specific 
focus in neonates. Aims of the first stage were to develop and validate DBS methods for 
the test drugs dexamethasone and caffeine. In the proceeding stage in-vitro validated 
41 
 
methods were used to determine circulating drug concentrations in patients. Individual 
and population based PK studies were performed in preterm neonates for 
dexamethasone and caffeine, respectively to assess the reliability of the DBS technique 
for the estimation of PK parameters. The PK of caffeine was also determined in healthy 
adults. Clinical validations were facilitated through a comparison of DBS derived PK 
parameter estimates (CL, V and half life) with literature reported plasma estimates for 
agreement. The special ethical considerations around blood collection that apply to 
neonates underpinned the chosen method for performing the DBS and plasma matrix 
comparisons. Clinical investigations were also considered important for allowing an 
assessment of the feasibility of DBS sampling applied to PK studies in a clinical 
environment such as the NICU.    
The decision to investigate dexamethasone was made following extensive discussions 
with study clinicians and on the assumption of sufficient patient numbers to perform a 
clinical validation. Investigations with dexamethasone were considered particularly 
important due to the current clinical need for PK data in neonates. A second test drug, 












Chapter 2  






2.1.1 Dexamethasone quantification in biological fluids 
A variety of analytical techniques have previously been used for the quantification of 
dexamethasone in biological fluids including LC with UV, fluorescence, 
chemiluminescence or MS detection, gas chromatography with mass spectrometry (GC-
MS) and RIA (Ishida et al., 1993, Katayama et al., 1993, Schild and Charles, 1994, 
Lugo et al., 1996, Hidalgo et al., 2003, Qu et al., 2007). A comparison of selected 
techniques reported in the literature is presented in Table 2.1. An LC-UV assay 
requiring a micro volume blood sample whilst maintaining a comparatively good 
detection sensitivity (15 ng/ml) has been reported (Schild and Charles, 1994). Most 
previously reported LC-UV assays have however, required a large blood volume sample 
( 1 ml) to attain a higher degree of sensitivity or have relatively high quantification 
limits rendering the respective methodologies inappropriate for application to neonatal 
PK studies. Detection of levels as low as 0.6 pg/ml from a 100 µl plasma sample has 
been achieved by Katayama and co-workers using LC with fluorescence detection 
however, this method necessitates pre-column derivatisation of dexamethasone with a 
fluorescent compound that is not commercially available (Katayama et al., 1993). The 
need to synthesise a fluorescent tag via a complex series of reactions along with a 
resulting long column retention time makes the method practically less viable. Although 
GC-MS confers high sensitivity it is also associated with a lengthy pre-column 
derivatisation step (approximately 3 hours) and involves handling toxic reagents. LC-
MS and LC-MS/MS have been used to quantify dexamethasone with the outcome of 
low detection limits without the need for time consuming derivatisation steps, however, 
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the majority of MS based methods have required a large blood volume sample (1 - 10 
ml) for analysis. Both ESI and APCI techniques have been used to quantify 
dexamethasone in a variety of biological fluids. Recently an LC-MS/MS dried matrix 
spot method for the quantification of dexamethasone in bovine synovial fluid was 
described in the literature (Christianson et al., 2010). Requiring only a 15 µl sample a 
lower limit of quantification (LLOQ) of 5 ng/ml was achieved. RIA techniques have 
conferred good sensitivity from relatively small blood samples, but a significant degree 
of cross-sensitivity is observed with other corticosteroids and metabolites of 
dexamethasone which compromises its specificity, and thus accuracy (Hochhaus et al., 
1992, Lugo et al., 1996).  
The practice of removing serial large blood volumes for research purposes in neonatal 
and paediatric populations is now generally unacceptable. The EMA have provided 
guidance on the blood sampling volumes appropriate in research studies involving term 
and preterm neonates (Guidelines on the investigation of medicinal products in the term 
and preterm neonate, 2007). However, these guidelines are not evidenced based and 
therefore extra caution is necessary in blood sampling from vulnerable populations such 
as preterms where there is a recognised risk of sampling induced anaemia (Weiss et al., 
2002). The blood volume requirement should be kept to a minimum during the 
development of drug assays. This will also increase the feasibility of opportunistic 
sample collection i.e. immediately after blood has been collected for clinical tests. 
Reported dexamethasone assays have either required large blood volumes or are 
associated with time consuming and complex work-up procedures. A simple micro 
analytical method tailored to the measurement of dexamethasone concentrations in 
neonates is therefore required in order to investigate its PK in this population.  
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Table 2.1 A comparison of selected analytical techniques reported for the 
quantification of dexamethasone in biological fluids with sensitivity expressed as 
either the lower limit of quantification (LLOQ) or limit of detection (LOD) 
 
Reference  Analytical technique 




Volume & type of 
biological fluid  
 






0.1 ml plasma 
 
(Girault et al., 1990) GC-MS  0.1 ng/ml 1 ml plasma 
 
(Hidalgo et al., 2003) 
 
GC-MS  0.2 ng/ml Not specified urine  
 
(Plezia and Berens, 1985) 
 
LC-UV  5 ng/ml 2 ml plasma 
(Schild and Charles, 1994) LC-UV 
 
15 ng/ml  0.1 ml plasma 
(Grippa et al., 2000) 
 
LC-UV 250 ng/ml  1 ml plasma 




10 ng/ml  1.5 ml plasma 
(Kumar et al., 2006) LC-UV 
 
250 ng/ml  0.15 ml plasma 
(Katayama et al., 1993) LC-Fluorescence  0.6 pg/ml 0.1 ml plasma 
(Wu et al., 1995) LC-Fluorescence 1.57 ng/ml  0.2 ml plasma 
(Ishida et al., 1993) Chemiluminescence 
 
15 ng/ml  0.2 ml plasma 
(Chen et al., 2002) LC-MS/MS 0.25 ng/ml  0.5 ml plasma 
(Taylor et al., 2004) LC-MS/MS 0.3 ng/ml  0.5 ml plasma 
(Luo et al., 2005) LC-MS/MS 0.1 ng/ml  1 ml plasma  
(equine) 
(Qu et al., 2007) LC-MS/MS 5 pg/ml  1 ml plasma 
(Christianson et al., 2010) LC-MS/MS 5 ng/ml  15 µl synovial fluid 
(dried matrix spot) 
(Zhang et al., 2011) LC-MS/MS 0.5 ng/ml  50 µl plasma 
(Damonte et al., 2007) LC-MS 5.9 ng/ml  10 ml blood 
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2.1.2 Steroid quantification using dried blood spots  
Several endogenous steroids have been successfully studied using DBS which supports 
the investigation of the technique for the measurement of synthetic steroidal compounds 
such as dexamethasone. The use of DBS analysis for the quantification of 17α-
hydroxyprogesterone (17-OHP) was proposed in 1977 for the diagnosis of congenital 
adrenal hyperplasia (CAH) in neonates (Pang et al., 1977). The test has now become an 
essential component in newborn screening programmes. Early 17-OHP quantification 
methods were based on immunological assays which resulted in cross-reactions of 
specific antigens with other steroids thereby producing a large number of false positive 
results (Wong et al., 1992). To improve the selectivity of the DBS screening method 
and reduce the number of false positive results LC-MS/MS techniques were 
subsequently evaluated for the quantification of 17-OHP (Lai et al., 2002). Preterm 
neonates may exhibit elevated levels of 17-OHP because of stress or delayed maturation 
of 11-hydroxylase which represents an additional contributory factor to the rate of false 
positive results. In order to improve the specificity of the screening process for CAH, 
second tier DBS techniques based on MS/MS detection were developed which enable 
the simultaneous measurement of multiple endogenous steroids important in the 
diagnosis of CAH including 17-OHP, cortisol, corticosterone, deoxycorticosterone, 
progesterone, 11-deoxycortisol, 21-deoxycortisol, androstenedione, testosterone and 
dihydrotestosterone (Janzen et al., 2008). Outside newborn screening programmes, DBS 
has been used for the measurement of testosterone and estradiol in steroid 
pharmacology and biobehavioural studies (Howe and Handelsman, 1997, Shirtcliff et 
al., 2000). DBS coupled with LC-MS/MS has also been used to determine vitamin D 
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status during the perinatal period and study inter-seasonal fluctuations in concentration 
(Eyles et al., 2010). 
As with the majority of compounds measured using DBS, the blood collection method 
in steroid analysis has involved the use of the filter paper S&S 903. Relatively high 
steroid extraction efficiencies have been achieved with the use of either aqueous or 
organic solvents or a combination of both with the result of good assay accuracy and 
precision.  
2.1.3 Aim  
The aim of this part of the thesis was to develop a sensitive and robust DBS based 
method for the quantification of circulating dexamethasone concentrations in neonates, 
and to perform an in-vitro validation of the developed methodology.  
2.2 Preliminary investigations for the selection of a detection system 
2.2.1 Sensitivity  
The detection sensitivity required to measure therapeutic dexamethasone concentrations 
in neonates was assessed by performing a simulation of the PK profile under the 10-day 
dose tapering regimen used on the Leicester NICU. This was done within NONMEM 
(version 7.0) using the First Order estimation method with a GNU Fortran Compiler 95. 
Simulations were based on the mean PK estimates (CL, 143 ml/h; V, 1845 ml) from two 
published reports for dexamethasone in neonates and the assumption of an underlying 
one compartment model (Charles et al., 1993, Lugo et al., 1996). Figure 2.1 shows the 
range of concentrations predicted in plasma during the treatment period for a neonate 
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weighing 1 kg. Based on the mean predicted concentration-time profile a LLOQ of at 
least 1 ng/ml was considered desirable for the measurement of therapeutic 
concentrations during the course of treatment.  
 
 
Figure 2.1 One compartment model used to predict plasma dexamethasone 
concentrations in a 1 kg neonate prescribed a 10-day tapering IV dosing regimen of 
250 µg/kg 12 hourly for 72 hours, then 100 µg/kg 12 hourly for 72 hours, then 50 
µg/kg 12 hourly for 48 hours followed by 25 µg/kg 12 hourly for 48 hours.  
2.2.2 Selection of a detection system 
Initial investigations into potential analytical techniques for the quantification of 
dexamethasone were carried out using LC with UV detection. The detection system was 
selected on the basis of the relatively good LLOQ (15 ng/ml) from a micro volume 
plasma sample (100 μl) previously reported (Schild and Charles, 1994). Analysis was 
performed on an Agilent 1100 LC system consisting of a quaternary solvent delivery 








































wavelength UV detector. The development of a working LC-UV method was 
undertaken using standard solutions of dexamethasone in acetonitrile:water (50:50, v/v). 
An initial UV scan was perfomed to determine the maximum absorption wavelength for 
dexamethasone. UV detection settings (band width, slit width and response time) and 
chromatographic parameters were considered during the method development stage in 
order to optimise the chromatographic peak shape and intensity, whilst achieving 
reasonably short run times. A substantial amount of work was undertaken to investigate 
the effects of mobile phase composition, buffers, pH, column temperature, injection 
volume and composition and flow rate on the resulting chromatographic signal. 
Validation of the final method was performed by analysing calibration standards 
prepared in solvent in replicate (n=3) over a dexamethasone concentration range of 1 to 
1000 ng/ml. The developed analytical technique provided good reproducibility and 
accuracy within a relatively short analysis time (< 5 minutes). With an accuracy 
(relative error %, RE%) and precison (coefficient of variation %, CV%) of ≤ 15% and a 
signal-to-noise ratio of 10, the LLOQ achieved was 2.5 ng/ml from a 90 μl injection 
volume. This was considered too high with respect to the micro blood volume available 
for quantification with DBS sampling and the expected dilution during the extraction 
process.    
Due to a requirement for better analytical sensitvity to measure expected therapeutic 
concentrations, an alternative approach using LC with fluorescence detection was 
considered. Dexamethasone is not a naturally fluorescent compound and therefore a 
derivatisation step must be performed using a fluorescent tag such as EDTN (1-ethoxy-
4-(dichloro-s-triazinyl) naphthalene). EDTN reacts with phenolic hydroxyl groups to 
produce the respective derivatised compound and has previously been used to improve 
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the detection capability of dexamethasone in plasma. On the basis of the relatively low 
detection limit achieved and commercial availability, EDTN was selected for study (Wu 
et al., 1995). The derivatisation procedure as described in the literature was carried out 
using a solution of 1 mM EDTN in acetontitrile and potassium carbonate. Analysis pre 
and post derivatisation was performed using an Agilent 1100 LC system with a 
fluorescence detector and the maximum wavelength of excitation and emission of 
labelled dexamethasone was determined using a PerkinElmer LS45 luminescence 
spectrometer. The chromatograms generated from the analysis of dexamethasone 
following the derivatisation procedure revealed a peak at a retention time of 
approximately 20 minutes which was assigned to the dexamethasone-EDTN derivative. 
However, due to the impurity of the purchased EDTN unknown reagent peaks severely 
interfered with the integration of the dexamethasone-EDTN peak. Attempts to improve 
the purity of EDTN via recrystallization with acetonitrile and methanol were not 
successful and hampered further progress with the fluorescent tag.  
Given the difficulties encountered with fluorescence derivatisation and the need for 
better detection sensitivity LC-MS with ESI was subsequently investigated. Initial 
results with LC-MS indicated at least a 10 fold improvement in detection sensitivity 
compared with the LC-UV method. Therefore LC-MS was selected as the analytical 




2.3.1 Chemicals and materials 
Dexamethasone (9-fluoro-11, 17, 21-trihydroxy-16-methylpregna-1, 4-diene-3, 20-
dione) ≥ 98% and the internal standard triamcinolone acetonide (9-fluoro-16-
hydroxyprednisolone 16, 17-acetonide) ≥ 99% (Figure 2.2) were purchased from 
Sigma–Aldrich (Poole, UK). Triamcinolone was selected as the internal standard (IS) 
due to its structural similarity to the analyte of interest and demonstrated suitability in 
dexamethasone quantification work (Taylor et al., 2004, Kumar et al., 2006). As 
triamcinolone is not used on the NICU there is no potential for alteration of the analyte 
to IS ratio and therefore to affect dexamethasone quantification. HPLC grade water, 
acetonitrile and methanol and formic acid ≥ 98% were obtained from Fisher Scientific 
(Loughborough, UK). Autosampler vials with 0.3 ml inserts, eppendorf cups and 
volumetric pipettes (Eppendorf Research) were obtained from Fisher Scientific 
(Loughborough, UK). The vortex (TopMix Wizard X), centrifuge (Eppendorf 5415R), 
shaker (IKA VXR Vibrax) and weighing scales (Mettler Toledo XS105) were obtained 
from Fisher Scientific (Loughborough, UK). Specimen collection filter paper S&S 903 
was obtained from Fisher Scientific (Loughborough, UK). FTA Elute filter paper was 
obtained from Whatman, UK (part of GE Healthcare) and filter paper Ahlstrom 226 was 
supplied by ID Biological systems (South Carolina, USA). Sample glass tubes and 
polythene bags for storage of blood spot specimens were obtained from Richardson’s of 
Leicester (Leicester, UK). The punching device was obtained from Maun Industries Ltd. 
(Nottingham, UK) and desiccant sachets were supplied by Sud-Chemie (Northwich, 
UK). Lithium heparin coated capillaries were obtained from Sangius Counting 
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(Numbrecht, Germany) and blood collection tubes (containing lithium heparin) were 
obtained from Sarstedt (Leicester, UK). Blank human venous blood for method 
development and patient sample analysis was obtained from healthy adult volunteers.  
                
Figure 2.2 Chemical structures of dexamethasone (left) and                    
triamcinolone acetonide (right) 
2.3.2 Preparation of dexamethasone stock, working and spiking solutions 
Stock solutions of dexamethasone were prepared by dissolving 5 mg in 5 ml of 
methanol:water (80:20, v/v) to produce a 1 mg/ml concentration. A relatively high 
concentration of methanol was used in the preparation of stock solutions to ensure 
complete dissolution of the corticosteroid. The stock solution was diluted to produce a 
concentration of 20 g/ml in methanol:water (50:50, v/v), this was further diluted with 
methanol:water (50:50, v/v) to produce a series of working solutions of concentrations 
315, 1050, 2100, 5250, 10500 and 16800 ng/ml. All solutions were freshly prepared on 
the day of analysis. Samples stored at 4C were allowed to reach room temperature 





























2.3.3 Preparation of internal standard, extraction solution and mobile phase  
Stock solutions of IS were prepared by dissolving 2 mg in 10 ml of methanol:water 
(80:20, v/v) to produce a 200 µg/ml concentration. The stock solution was diluted to a 
concentration of 10 g/ml in methanol:water (50:50, v/v), which was then further 
diluted with methanol:water (70:30, v/v) to produce an extraction solvent containing 5 
ng/ml of IS. 
Mobile phase A was made by adding 650 µl of formic acid to 500 ml of water to 
produce a 0.13% formic acid aqueous solution. Mobile phase B consisted of 100% 
acetonitrile.  
2.3.4 Preparation of calibration and validation dried blood spots 
Haematocrit levels are initially higher in the newborn and decrease with PNA. As 
dexamethasone is now reserved for use late in the neonatal period and the treatment 
population are preterms lower haematocrit values of approximately 30 to 40% are 
expected (Jopling et al., 2009). A haematocrit level of 35% was selected for the 
preparation of DBS samples to represent the average value expected in the target 
population planned for study and limit any haematocrit related effects on filter paper. 
Blank human whole blood was centrifuged at 7,000 x g for 4 minutes and the plasma 
generated transferred to a clean eppendorf. The red blood cell (RBC) suspension and 
plasma were mixed in proportions (35:65, v/v) to give whole blood with an adjusted 
haematocrit of 35%. Calibration and validation DBS samples were prepared fresh on a 
daily basis by diluting 25 µl of each dexamethasone spiking solution with 500 µl of 
control human whole blood adjusted to a haematocrit of 35%. The final concentration of 
calibration standards were 15, 50, 100, 250, 500 and 800 ng/ml. These concentrations 
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were selected on the basis of plasma concentrations reported in neonates and performed 
simulations (Lugo et al., 1996). 30 µl aliquots of spiked whole blood were spotted onto 
filter paper S&S 903 using a volumetric pipette and allowed to air dry overnight at room 
temperature prior to processing. A 30 µl volume applied onto filter paper gave a spot 
size of approximately 10 mm in diameter. 
2.3.5 Single quadrupole mass spectrometry 
2.3.5.1 Selection of ions for monitoring  
In the initial stages of method development experiments were focused on studying the 
behaviour of dexamethasone and IS in the ESI source and establishment of the 
respective base peak. A positive full scan was performed across a range of 200 to 500 
m/z for each steroid at a concentration of 1000 ng/ml in solvent. The mass spectrum 
obtained for each steroid under optimised MS conditions is shown in Figure 2.3. For 
dexamethasone, a predominant peak was observed at m/z 393 corresponding to the 
molecular ion [M+H]
+
. Characteristic of dexamethasone a fragment ion at m/z 373 
[M+H-HF]
+
 was observed in the spectra at 5% relative abundance. The formation of 
sodium adducts [M+Na]
+
 was evidenced by the peak at m/z 415, however, this 
corresponded to less than 20% of the base peak. The mass spectra of the IS revealed a 




The behaviour of dexamethasone in the ESI source was also investigated in negative 
mode. However, due to better signal intensity subsequent ion transmission optimisation 
was conducted in positive ESI mode.  
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2.3.5.2 Optimisation of ion transmission 
Ion transmission optimisation was undertaken using the protonated molecular ion for 
dexamethasone (m/z 393) in SIM mode to optimise the detection sensitivity of analyte. 
The parameters known to have the greatest effect on the performance of ESI are 
capillary voltage, fragmentor voltage, nebuliser gas pressure, gas flow rate and drying 
gas temperature. The effect of each of these on analyte signal intensity was thus 
investigated using flow injection analysis. The optimum fragmentor voltage is known to 
be compound dependant and was therefore studied between 5 and 110 V in 15 V 
increments. An increase in signal intensity was observed with increasing fragmentor 
voltage up to a value of 65 V, thereafter the signal intensity dropped significantly 
(Figure 2.4). The trend observed can be explained by the effect of fragmentor voltage on 
ion transmission and fragmentation. Fragmentor voltage can improve ion transmission 
and thus sensitivity by facilitating the passage of ions through the high pressure region 
between the exit of the capillary and skimmer. When the compound specific threshold 
for this effect is reached (approximately 65 V for dexamethasone) fragmentation 
dominates and a decrease in signal intensity is observed. Full scans revealed the 
fragment ion at m/z 373 [M+H-HF]
+
 dominated the mass spectrum at fragmentor 
settings above 65 V. Other studied operating parameters had little effect on the overall 








Figure 2.3 Full scan mass spectra under optimised MS conditions for dexamethasone 
(A) and internal standard triamcinolone acetonide (B) in solvent 
  













































































































































Figure 2.4 Effect of fragmentor voltage on dexamethasone signal intensity using a 
100 ng/ml solution in SIM mode 
2.3.5.3 Final conditions and instrumentation 
Detection of samples was achieved using an Agilent 1200 mass spectrometer with a 
positive ESI source. The LC-MS system was calibrated daily using a tuning mixture 
supplied by Agilent Technologies. The ionisation source parameters optimised to give 
maximum analyte signal intensity were: fragmentor voltage, 65 V; drying temperature, 
300C; capillary voltage, 3500 V; nebuliser pressure, 25 psig; nitrogen gas flow, 7 
l/min. The mass spectrometer was operated in SIM mode for the protonated molecular 
ion [M+H]
+
 of dexamethasone at m/z 393 and IS at m/z 435. A dwell time of 289 msec 
was used for each ion. The analytical software programme Chemstation (series B.1.3, 
Agilent Technologies) was used to operate the system and aquire all data. Microsoft 


















Fragmentor voltage (V) 
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2.3.6 Liquid chromatography 
2.3.6.1 Final conditions and instrumentation 
The chromatographic system consisted of an Agilent 1100 series quaternary solvent 
delivery pump, autosampler and vacuum degasser. Dexamethasone was analysed on a 
Zorbax Eclipse Plus C18 column (Agilent Technologies, Cheshire, UK; 150 mm x 2.1 
mm i.d., 3.5 m) attached with a C18 guard column (Phenomenex, Macclesfield UK; 
3.0 x 4.0 mm). Under isocratic conditions dexamethasone and the IS eluted at 
overlapping retention times. Separation could not be achieved with changes in the 
mobile phase organic solvent, the organic to aqueous ratio or flow rate. Gradient elution 
was therefore implemented to improve the resolution between steroids. Variations in 
starting mobile phase composition and gradient steepness were studied to separate the 
steroids within a relatively short run time. Gradient elution was carried out using a 
combination of water with 0.13% formic acid (A) and acetonitrile (B). The mobile 
phase was initiated at 40% B and maintained for 0.15 minutes before increasing to 70% 
B by 3.0 minutes. A final increase to 80% B was achieved by 6.0 minutes before 
returning to 40% B. Thereafter, a 7.5 minute post-run at 40% B was maintained prior to 
the next injection. The flow rate was 200 µl/min and injection volume 25 l. The 
column oven temperature was set to 22C.  
2.3.7 Dried blood spot extraction 
2.3.7.1 Optimisation of extraction procedure 
Initial extraction conditions using methanol:water (50:50, v/v) with gentle shaking for 
50 minutes resulted in almost 100% recovery of dexamethasone from an entire 30 µl 
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250 ng/ml DBS sample. The effect of varying methanol concentration within a range of 
30 - 100% in increments of 10% did not significantly affect analyte recovery. However, 
as the ratio of methanol to water increased the extract appearance changed significantly 
from reddish and cloudy to clear and straw like in appearance. The darker extracts 
arising with a lower methanol concentration were due to the extraction of water soluble 
components of whole blood and effectively resulted in the reconstitution of the blood 
spot. Due to better selectivity, 70% methanol was chosen for DBS extraction. Further 
investigations revealed that maximum recovery was achieved within 20 minutes using 
70% methanol thereby enabling a reduction in the extraction time. Similar extraction 
efficiencies were noted on changing the organic component of the extraction solution to 
acetonitrile.   
2.3.7.2 Punch size 
To determine the suitability of using S&S 903 filter paper for dexamethasone analysis 
different sized disc diameter punches (3, 6, 8 and 10 mm) were investigated using a 
slightly larger 35 µl DBS sample at a concentration of 800 ng/ml. The analyte peak area 
increased linearly with increasing punch size explained by the larger volume of blood 
sampled from the DBS (Figure 2.5). This indicated the appropriateness of filter paper 
S&S 903 for dexamethasone quantification work and the validity of using a punch 
diameter between 3 and 10 mm. An 8 mm punch size was chosen as it enabled a disc of 
blood to be sampled from a 30 µl spot (approximately 10 mm in diameter) with relative 





Figure 2.5 Effect of punch size (radius
2
) on dexamethasone signal intensity 
2.3.7.3 Final extraction method 
An 8 mm diameter disc (equivalent to approximately 21μl of blood) was punched from 
the centre of a 30 µl DBS sample and transferred to a clean glass tube. A 250 µl volume 
of extraction solvent consisting of methanol:water (70:30, v/v) plus IS (5 ng/ml) was 
added and the tube was shaken at 300 rpm for 20 minutes. The extract was centrifuged 
at 13,500 x g for 10 minutes to remove any insoluble residues arising from the filter 
paper and the supernatant was transferred to an autosampler vial for analysis by LC-
MS. 
2.3.8 Filter paper selection 
During method development two other filter papers FTA Elute and Ahlstrom 226 were 
investigated to determine their respective performances for dexamethasone 
quantification. DBS calibration standards within the range of 15 to 800 ng/ml (n=3) 
were prepared using S&S 903, FTA Elute and Ahlstrom 226 paper. The spots produced 
 























Radius squared (mm)2 
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were of similar size and shape, however, as previously noted a corona edge was 
observed with the FTA Elute paper. Extraction was carried out using the final method 
developed for recovery of dexamethasone from paper S&S 903 (section 2.3.7.3). High 
recoveries and acceptable precision (CV ≤ 15%) was observed for each filter paper type 
at the tested concentrations (Table 2.2). Furthermore, on comparison there was little 
difference in assay performance between the different specimen collection papers and 
therefore subsequent method development work was continued using S&S 903 filter 
paper.  
Table 2.2 Assay precision results with filter paper S&S 903, FTA Elute and Ahlstrom 
226 at low, medium and high dexamethasone concentrations n=3 
 Precision (CV%) 
Nominal Conc. (ng/ml) S&S 903 FTA Elute 226 Ahlstrom 
50 5.0 5.8 9.7 
250 3.4 9.9 3.6 
800 6.1 10.3 3.8 
 
2.4 Validation results and discussion 
Following the development of an LC-MS method, a suitable blood collection method 
and optimisation of extraction conditions the microanalytical method was validated 
using FDA regulatory guidelines (Shah et al., 2000, Guidance for Industry: 
bioanalytical method validation, 2001). Other tests specific to DBS analysis such as the 
influence of spot volume and haematocrit on analyte recovery were performed to 
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provide an assessment of the robustness of the developed method for dexamethasone 
quantification and its suitability for application to PK studies involving neonates.  
2.4.1 Extraction efficiency 
The overall recovery of dexamethasone was assessed at DBS concentrations of 50, 250 
and 800 ng/ml in replicate (n=5). To determine recovery 30 µl spots were produced and 
allowed to dry. The entire spot on the filter paper was then extracted with 
methanol:water (70:30, v/v). The analytical results from extracted samples were 
compared to those obtained from the same amount of dexamethasone in solvent 
methanol:water (70:30, v/v). Recovery was calculated using peak area by the equation: 
          
                      
                        
       
The overall recovery for dexamethasone varied between 94 to 106% (Table 2.3, SD = 
standard deviation). Consistent and precise (CV% ≤ 15%) recovery values at low, 
medium and high concentrations indicate the extraction process is acceptable across the 
calibration range and reproducible. The high mean recovery (99%) observed indicate 
analyte stability under the extraction conditions applied. 
Table 2.3 Recovery of dexamethasone from DBS samples n=5 
 Nominal conc. (ng/ml) 















2.4.2 Matrix effects 
Matrix effects can alter the detector response of an analyte due to the presence of other 
compounds in the ionisation source and is particularly associated with ESI (Venn, 
2008). Signal suppression rather than enhancement is often observed with MS based 
techniques which can have a detrimental effect on the detection sensitivity (Rogatsky 
and Stein, 2005). To evaluate suppression or enhancement of the detector response due 
to constituents within the DBS matrix replicate (n=5) samples of dexamethasone spiked 
in extracted blank DBS samples at concentrations of 50 and 800 ng/ml were produced. 
These samples were compared to standards of the same concentration spiked into pure 
methanol:water (70:30, v/v). Sample preparation involved the addition of 10 µl of 
spiking solution to 90 µl of either solvent or matrix solution. The matrix effect was 
calculated using dexamethasone peak area by the equation: 
               
                      
                        
         
No significant (< 15%) ion suppression or enhancement of the analyte signal due to 
endogenous components of blood or the filter paper was observed at the two tested 
concentrations (Table 2.4). These results provide assurance on the selectivity of the 
extraction procedure and the ionisation method. 
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Table 2.4 Matrix effects arising from dried blood spots on dexamethasone signal 
intensity n=5 
 Nominal conc. (ng/ml) 
 50 800 
Matrix effect % (mean) -0.4 3.4 
Precision (CV%) 4.3 4.9 
 
2.4.3 Linearity, selectivity and sensitivity 
Dexamethasone calibration standards were prepared in replicate (n=5) and analysed on 
three separate days. A calibration plot of analyte/IS peak area ratio against nominal 
dexamethasone concentration was produced and an equally weighted linear regression 
applied. The assay showed linearity (r
2
 ≥ 0.99) within the tested concentration range of 
15 to 800 ng/ml (Figure 2.6). 
Chromatographic conditions used provided sufficient resolution with elution of 
dexamethasone and IS at 4.8 and 5.9 minutes, respectively. The selectivity of the 
method was determined by analysing DBS samples (n=1) collected from five individual 
human subjects. There were no significant interferences (≥ 20% of LLOQ peak area) at 
either of these retention times in any chromatograms. The selectivity of the method is 
demonstrated by the representative LC-MS chromatogram presented in Figure 2.7.  
The LLOQ was defined by the lowest concentration that gave a signal-to-noise ratio 
equal to or greater than 10 whilst exhibiting a RE% and CV% of ≤ 15%. Signal-to-noise 
ratios were calculated by dividing peak height by the baseline noise (where noise is 
given as six times the standard deviation of the linear regression). The LLOQ was 
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determined to be 15 ng/ml in whole dried blood (Figure 2.7). This detection limit was 
not sufficient for the quantification of dexamethasone during the entire 10-day treatment 
course. The sensitivity of the assay was however, considered to be sufficient to capture 
the PK profile during the first 6 days when concentrations were predicted within the 
quantifiable range of the assay (section 2.2.1, Figure 2.1). The sensitivity of the assay 
was therefore considered to be acceptable for the purposes of the study objectives. 
To improve the LLOQ the incorporation of a sample concentrator step during sample 
preparation was investigated. DBS calibration standards at concentrations of 7.5, 15, 50, 
100, 250, 500, and 800 ng/ml were prepared in replicate (n=5). Samples were processed 
as described in section 2.3.7.3 except IS in 100% methanol was used as the extraction 
solvent. This was to facilitate evaporation of the extract to a residue. A 180 μl aliquot of 
the methanol extract was transferred to an eppendorf and evaporated to dryness under a 
stream of nitrogen. The residues were reconstituted with 72 μl of methanol:water 
(70:30, v/v) and vortexed for 2 minutes. Samples were then centrifuged at 13,500 x g 
for 5 minutes prior to LC-MS analysis. This resulted in an improvement in detection 
sensitivity of at least 2 fold but insufficient precision, particularly at the lower end of 
the calibration line (CV%, 23.2 for 7.5 ng/ml level) was observed. Further 




Figure 2.6 A calibration plot of nominal dexamethasone DBS concentration against 







Figure 2.7 Representative LC-MS chromatogram of (a) a blank DBS sample 
extracted without IS and (b) a DBS sample spiked with dexamethasone (Dex) at 15 
ng/ml (LLOQ) and extracted with IS
y = 0.0072x 



























2.4.4 Accuracy and precision 
2.4.4.1 Calibration  
Intraday and interday assay accuracy and precision was determined from the analysis of 
replicate (n=5) calibration standards at six dexamethasone concentrations within the 
range of 15 to 800 ng/ml on three separate days. A RE and CV of ≤ 20% at the LLOQ 
and ≤ 15% at all other concentrations was considered acceptable. RE% and CV% values 
were within these pre-defined limits at each concentration for all runs (Table 2.5). The 
overall variation in assay performance between runs (interday) was within 15%.  
2.4.4.2 Carryover and injector precision 
The effect of sample carryover on assay accuracy and precision was assessed by 
injecting two blank matrix extracts into the LC-MS system following the analysis of the 
highest (800 ng/ml) DBS calibration standard (Hughes et al., 2007). The extent of 
carryover observed was acceptable with peak areas in the blank chromatograms at less 
than 20% of the peak area of the lowest DBS concentration (15 ng/ml). To determine if 
there was any carryover due to the punch, the device was used to cut out 10 discs from 
800 ng/ml DBS samples followed by 2 discs from blank DBS samples. A peak 
attributable to dexamethasone was not observed in the resulting blank DBS extract 
chromatograms and therefore the punching device was excluded as a source of 
carryover during the extraction procedure.  
Injector precision was determined by analysing 5 repeat injections of the lowest DBS 
concentration. The injection-to-injection precision (CV%) was 2.2% and the variability 
in retention time for dexamethasone and IS was 0.6% and 1%, respectively (Table 2.6). 
68 
 
Table 2.5 Intraday and interday accuracy and precision data for dexamethasone n=5 
  Intraday 
 Nominal conc. (ng/ml) 15 50 100 250 500 800 





























run 2 Mean conc. (ng/ml) 
SD 
Accuracy (RE%) 























































  Interday 
 Mean conc. (ng/ml) 
SD 
Mean accuracy (RE%)    





























Table 2.6 Injector precision and retention time variability results 
Injection 
number 
Peak area ratio 
Dexamethasone 
retention time 
IS retention time 
1 0.417 4.873 5.944 
2 0.433 4.825 5.839 
3 0.408 4.833 5.902 




Mean  0.422 4.857 5.923 
SD 0.009 0.029 0.057 
Precision 
(CV%) 
2.2 0.6 1.0 
  
2.4.5 Petroleum jelly application 
Petroleum jelly is often used on the NICU to facilitate the collection of capillary blood. 
It is applied as a thin layer onto the heel of the infant before skin puncture with an 
automated lancet. The hydrophobicity of the petroleum jelly encourages the formation 
of a droplet of blood on the skin surface which can be neatly collected into a capillary 
tube for routine clinical blood tests. This helps to minimise blood loss due to overflow 
and reduces the blood collection time. Although blood is sampled from the droplet 
formed there is potential for chemical moieties to interfere with drug quantification.  
The effects of petroleum jelly on dexamethasone quantification were investigated using 
blood spiked at 50 and 800 ng/ml (n=5). A thin layer of petroleum jelly was used to coat 
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a glass slide and 45 μl aliquots of spiked blood were applied. After 10 minutes 30 μl 
volumes of blood were collected using a pipette and spotted onto S&S 903 paper. This 
process was repeated without the application of petroleum. An 8 mm disc was punched 
from the centre of DBS samples and extracted with IS. The difference in peak area ratio 
between samples exposed to petroleum with those that were not was less than 15% at 
both concentrations (Table 2.7). In addition all precision values were within 15%. This 
would suggest that the use of petroleum jelly during capillary blood collection does not 
significantly affect dexamethasone quantification.  




2.4.6 Blood collection and spotting device 
Quantification of analyte in the DBS relies on the assumption of an even distribution of 
blood across the filter paper. The method of DBS sampling in clinical practice therefore 
becomes a critical factor in ensuring the collection of samples of an acceptable standard. 
Different DBS sampling approaches have been implemented one of which is skin 
puncture with direct application of blood and has been the method of choice in newborn 
screening programmes (Guidelines for Newborn Blood Spot Sampling, UK Newborn 
Nominal conc. (ng/ml) 50 800 
 None Petroleum jelly  None Petroleum jelly  
















            -9.2            -9.4 
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Screening Programme, 2008). This method must be performed whilst avoiding skin 
contact with the collection paper and relies on the skill of the operator to ensure there is 
no double spotting i.e. blood is not applied to the same area twice. A potential problem 
with this approach is that the concentration of analyte in DBS samples is determined 
from a calibration line prepared using whole blood containing anticoagulant, whereas 
patient samples do not contain anticoagulant. This is important as anticoagulants can 
affect analyte quantification through matrix effects (Mei et al., 2003, Holtkamp et al., 
2008, Bergeron et al., 2009). Alternatively, blood may be collected into a capillary tube 
containing anticoagulant before spotting. The blood contained within the capillary tube 
is then dispensed in one smooth application using a suction bulb. Capillary tubes are 
already used in neonatal practice as they provide a convenient and practical way of 
collecting micro blood volumes. Due to better control offered by the latter technique 
capillary tube sampling was incorporated into the blood collection methodology for this 
study. 
The influence of spotting device on the formation of blood spots was tested by 
producing 30 µl blood spots in replicate (n=5) using a capillary tube or a pipette 
(eppendorf) at two concentrations (50 and 800 ng/ml). The concentrations of 
dexamethasone were determined from a calibration line generated from DBS standards 
spotted using a pipette. A comparison of the accuracy and precision of dexamethasone 
quantification when samples were spotted using either a pipette or capillary is given in 
Table 2.8. An acceptable and comparable assay performance was observed suggesting 
the suitability of a capillary tube for blood collection and spotting. 
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2.4.7 Blood spot volume 
Experiments conducted by the NSQAP using an isotopic method have demonstrated 
that the volume of blood applied onto filter paper S&S 903 can affect absorption 
reproducibility and is therefore an important variable to consider in DBS sampling (Mei 
et al., 2001). They reported a 13% increase in serum held by a 6 mm disc when 
increasing blood spot size from 25 to 125 µl with constant haematocrit. This is 
corroborated by the results obtained by Liang et al 
 
who found varying the blood 
volume spotted on FTA Elute within a 10 to 50 µl range for dextromorphan 
quantification yielded a maximum assay inaccuracy of < 19%, however this difference 
was less than 10% when limiting the variability of blood volume collected to between 
25 to 50 µl (Liang et al., 2009). These results indicate that although a consistent volume 
is important for assay accuracy a degree of flexibility around the blood volume 
collected is acceptable.  
To assess the effect of blood volume collected on dexamethasone quantification, 25, 30 
and 35 μl DBS samples at 50 and 800 ng/ml were prepared in replicate (n=5). An 8 mm 
diameter disc was punched from the centre of each sample and extracted. The 
concentrations of extracts were determined using the linear regression equation 
generated from a calibration produced from 30 μl DBS samples. The accuracy and 
precision data as shown in Table 2.9 was within the 15% limit for 25 and 35 µl spot 
sizes at the two tested concentrations. Furthermore, the maximum variation in accuracy 
between spot sizes of 25 to 35 µl was 7%, indicating that the amount of blood spotted 
did not significantly affect the distribution of dexamethasone across the filter paper and 
therefore drug quantification. Others have also shown an acceptable assay performance 
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with small variations in sample volume spotted (ter Heine et al., 2008, Spooner et al., 
2009). 
Table 2.8 Effect of spotting device on accuracy and precision of             
dexamethasone assay n=5 
Spotting device Pipette Capillary 
Nominal conc. (ng/ml) 50 800 50 800 





















Table 2.9 Effect of varying blood spot volume on accuracy and precision of 
dexamethasone assay n=5 
Nominal conc. (ng/ml) 50  800 
Volume  25 µl 30 µl 35 µl  25 µl 30 µl 35 µl 






























                                                                                                                                       
2.4.8 Haematocrit 
Haematocrit has been identified as a factor with potential to affect drug quantification 
when using DBS. The effect is directly related to viscosity and the resulting 
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spreadability of blood on cellulose based paper. With high haematocrit values (due to a 
greater cellular composition) blood is more viscous and may lead to smaller blood spots 
being formed. For a fixed volume of blood, changes in haematocrit can therefore affect 
the absorption of blood per unit area of filter paper and consequently the final spot size. 
For methodologies based on taking a disc from within a DBS sample, the amount of 
analyte recovered can theoretically vary which has important implications for the 
accuracy of the concentration measurement. The haematocrit range varies according to 
age, for healthy adult males and females it is 42 to 52% and 37 to 47%, respectively 
(Hillman et al., 2005). Values may deviate outside of these ranges in certain disease 
states and critically ill patients. Neonates exhibit considerable inter and intraindividual 
variation in haematocrit values during the first 28 days of life (Alur et al., 2000, 
Christensen et al., 2009, Jopling et al., 2009). They are initially higher in the newborn 
(42 to 65%) and gradually decrease with increasing PNA. In addition, increased 
haematocrit values (greater than 65%) are observed in a small percentage of neonates 
due to polycythaemia. Changes in haematocrit during the neonatal period are also 
affected by GA and illness severity with lower values observed in more premature and 
critically ill infants (Alkalay et al., 2003). Dexamethasone therapy is now reserved for 
use late in the neonatal period and since the majority of patients receiving treatment are 
critically ill preterms lower haematocrit levels of around 30 to 40% are expected.  
Accordingly, the influence of haematocrit on the assay performance was determined at 
50, 250 and 800 ng/ml in replicate (n=5) using 30 µl blood spots with an adjusted 
haematocrit of 30, 35 and 40%. The plasma and RBC components of whole blood were 
separated as previously described (section 2.3.4) and recombined in the correct 
proportions to give bloods of differing haematocrit %. An 8 mm disc was punched from 
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each spot and analysed. Concentrations of extracts were determined using the linear 
regression equation generated from a calibration produced from standards of 35% 
haematocrit. 
A decrease in the size of the blood spot formed was noticeable with increasing 
haematocrit value. Other investigators have found similar relationships between 
haematocrit and spot size or volume held by a fixed diameter disc. Investigations on the 
performance of S&S 903 filter paper by the NSQAP found haematocrit to be the most 
important determinant of overall variation with results indicating 47% less serum 
volume for 6.0 mm punches taken from 100 µl DBS samples made with 30% 
haematocrit compared with those made with 70% haematocrit (Mei et al., 2001). 
O’Broin et al using blood labelled with [125I]-thyroxine showed that the volume of 
blood in a 6.35 mm diameter punch taken from a 100 µl spot on 903 paper increased by 
32% (from 8.2 to 10.8 µl) when haematocrit varied between 24 to 50% (O'Broin, 1993, 
O'Broin et al., 1995).  
The results from the haematocrit investigation gave RE% and CV% values within the 
pre-defined limit of ≤ 15% at all haematocrit levels for each tested dexamethasone 
concentration (Table 2.10). A haematocrit effect was however noticeable with higher 
haematocrit levels associated with an increase in the amount of drug recovered at all 
three concentrations. This suggests an altered distribution of analyte across the filter 
paper determined from an 8 mm disc. The positive correlation could be explained by 
blood viscosity, with blood of higher viscosity leading to smaller spots which results in 
a greater volume of blood being sampled and higher dexamethasone concentration 
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measurements. The effect of haematocrit changes on blood and analyte distribution, 
spot size and drug recovery from a fixed punch size have been reported by others. 
Table 2.10 Influence of haematocrit on the accuracy (RE%) of dexamethasone 
measurements presented as the difference from the analyte/IS peak area ratio at the 
35% haematocrit level. Precision (CV%) values for respective values are shown in 
brackets n=5. 
 Nominal conc. (ng/ml) 
Haematocrit 50 250 800 
40% +11.6% (12.6%) +13.8 (7.9%) +4.1 (5.2%) 
35% Normalised (2.5%) Normalised (7.4%) Normalised (4.3%) 
30% -3.4% (7.0%) +3.6 (3.4%) -3.2 (4.3%) 
 
Investigations by Adams et al using S&S 903 paper found a 3.1% increase in 
phenylalanine recovery from 3 mm discs taken from 100 µl DBS samples prepared 
using 53% haematocrit compared with samples of a lower haematocrit (50%) (Adam et 
al., 2000). Holub et al investigated the effects of haematocrit on the measurement of 
numerous amino acids using S&S 2992 paper by taking 3 mm punches from the centre 
and periphery of 15 mm DBS samples prepared from blood adjusted to give a 
haematocrit value of 20, 30, 50 and 60% (Holub et al., 2006). Significantly higher 
levels of amino acids were measured in discs with increasing haematocrit. However, for 
some amino acids the effect was either less pronounced or no significant correlation was 
observed. Wilhelm et al studied the effect of haematocrit on cyclosporin A 
measurements with 903 paper over a haematocrit range of 20 to 72% with normalisation 
at 35%. A haematocrit effect was noted, however, the overall variation in assay bias was 
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within 15% (-12 to 14%) across the range (Wilhelm et al., 2009b). No influence on 
assay bias was detected when haematocrit varied from 29 to 59%. This is in contrast to 
the findings for dexamethasone where relatively small changes in haematocrit (± 5%) 
influenced drug quantification. Nevertheless, the maximum difference in the accuracy 
of the dexamethasone assay when changing haematocrit from 30 to 40% was less than 
15%. An acceptable % bias has been reported for other analytes with relatively small 
variations in haematocrit (Butter et al., 2001, Wilhelm et al., 2009a, Al-Ghazawi and 
AbuRuz, 2010).  
The importance of filter paper type on the observed haematocrit effect has been reported 
by Denniff and Spooner using test compounds paracetamol and sitamaquine (Denniff 
and Spooner, 2010a). In this study, the influence of varying haematocrit between 20 and 
80% on spot appearance and drug recovery (determined against a 44% calibration line) 
was investigated using 15 μl DBS samples prepared on three different filter papers (903, 
FTA and FTA Elute). A clear inversely proportional relationship was observed between 
blood spot size (surface area) and haematocrit with all filter papers. Subsequent 
investigations highlighted a general trend towards an increased % bias with increasing 
haematocrit for both analytes on S&S 903 paper. Interestingly, for paracetamol the 
effect decreased between 60 and 80% indicating additional factors other than spot size 
(or blood viscosity) must account for the effect observed. It is noteworthy that the % 
bias observed for sitamaquine on 903 was within the acceptable limit (± 15%) across the 
haematocrit range studied and for the majority of haematocrit values for paracetamol. 
An initial increase in bias % followed by a decrease between 60 and 80% was also 
observed for sitamaquine on FTA paper. The difference in % bias, however, with FTA 
paper varied between approximately -30 and 10%. In contrast, the % bias was within ± 
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5% for paracetamol on FTA paper. A strong haematocrit effect was noted for 
sitamaquine using FTA Elute with a bias of ± 20%, however, there was no clear trend 
observed to enable a correlation between haematocrit and % bias. The results from this 
work highlight the complexity of the relationship between haematocrit and % bias and 
in turn the difficulties of predicting the amount of drug recovered. There appears to be a 
distinct relationship between the volume of blood held by a fixed diameter disc and 
haematocrit, however, this does not necessarily translate into a linear relationship that 
can be easily extrapolated for prediction of the amount of drug recovered. 
This provides evidence that the nature and magnitude of a haematocrit effect is linked to 
the properties of the analyte under investigation as well as the characteristics of the 
selected specimen collection paper. O’Broin investigated the distribution of 
erythrocytes using an isotopic method by measuring counts of 
51
Cr. Unlike serum, 
erythrocyte absorbency (or volume) appeared to remain constant with increasing 
haematocrit (O'Broin, 1993). Therefore the distribution of a drug between RBCs and 
plasma, and the extent of binding to components in each phase may be influential in the 
resulting haematocrit effect. 
The current validation data and findings of other investigators highlight the importance 
of investigating haematocrit effects. This is of even greater importance in cases where 
the study population is expected to exhibit a large variability in haematocrit.   
2.4.9 Red blood cell association 
It is usually the free fraction or unbound drug in plasma that exerts a pharmacological 
effect and is available to be cleared from the body. The relationship between bound and 
unbound drug in plasma and RBCs is shown in Figure 2.9. The majority of drug assays 
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whether they are based on plasma or whole blood samples measure unbound and bound 
drug i.e. total concentration due to the difficulties associated with measurement of 
unbound concentrations. Therefore in most situations the total drug concentration is 
measured and used as a surrogate for unbound drug. The unbound concentration, 
plasma concentration and blood concentration at equilibrium are related by the 
equations below (Rowland and Emmons, 2010): 




                             
 
  
          
Where, Cu = unbound concentration          
   fu = fraction unbound in plasma      
   H = haematocrit        
    p = red blood cell to plasma concentration ratio 
In plasma, the total drug concentration is proportional to the unbound concentration 
(Cu) provided the fraction unbound in plasma remains (fu) constant. Factors which may 
alter the extent of protein binding would therefore need to be considered when using 
plasma. In blood, the total drug concentration is proportional to the unbound 
concentration (Cu) provided the fraction unbound in plasma (fu) does not change and 
haematocrit (H) and partitioning (p) also remain constant. Based on these principles 
either blood or plasma could potentially be used to measure drug concentrations 
provided the ratio of total drug to unbound drug does not change. If there is a large 
degree of variability in these variables, using the total whole blood concentration as a 
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surrogate for unbound concentration has the potential to affect PK and PK-PD 
interpretation. When using DBS it therefore becomes important to understand the 
distribution kinetics of a drug in whole blood. 
Knowledge of the blood-to-plasma ratio is useful for understanding the distribution of a 
given drug between RBCs and plasma. It can be used to make an assessment of the 
variable (fu, H or p) that is most likely to govern the ratio of total drug concentration to 
unbound drug concentration in plasma or whole blood and the suitability of each 
respective matrix. This value is also useful when a comparison or conversion between 
plasma and whole blood drug concentration data is required. To investigate the 
partitioning of dexamethasone into RBCs a conventional in-vitro method was 






Figure 2.9 An illustration of the potential distribution of drug in whole blood 
 
The rate of partitioning was studied to determine equilibration time between RBCs and 
plasma under controlled conditions. The determined time period was then used in a 












subsequent experiment which focused on the extent of partitioning (p) with changes in 
dexamethasone concentration.  
2.4.9.1 Time to reach equilibrium 
Whole unadjusted blood of haematocrit 43% was spiked with dexamethasone to 
produce a single concentration of 250 ng/ml and incubated at 37°C with gentle agitation 
for 120 minutes. At 0, 15, 30, 60 and 120 minutes a 150 µl aliquot of blood was 
removed to determine the blood-to-plasma ratio. Whole blood was spotted onto filter 
paper in triplicate to produce 15 µl DBS samples and the remaining whole blood was 
centrifuged at 7,000 x g for 2 minutes. The plasma generated was applied onto filter 
paper in triplicate to produce 15 µl dried plasma spot (DPS) samples. Once dried, the 
entire DBS or DPS was punched from the filter paper and extracted using 
methanol:water (70:30, v/v). Concentrations of dexamethasone in the resulting extracts 
were analysed using LC-MS. The equilibration time was selected when no further 
increases in the blood-to-plasma ratio were observed. The blood-to-plasma ratio was 
calculated by the equation: 
                        
   
   
  
Where PAb = peak area in blood 
             PAp = peak area in plasma 
An increase in the blood-to-plasma ratio was observed between 0 and 30 minutes after 
which no further increases were observed (Table 2.11). Therefore equilibrium between 
RBCs and plasma appears to occur between 0 and 30 minutes but no further 
experimentation was conducted to determine a more accurate equilibration time. The 
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maximum incubation period was set to 120 minutes to avoid problems in interpreting 
results as with longer incubation times (of 180 minutes) the plasma generated was 
slightly pink in colour indicative of haemolysis. At 120 minutes, the ratio decreased by 
approximately 10% and although a change in the colour of plasma was not observed 
this could be due to haemolysis that cannot be detected visually. To ensure whole blood 
stability of dexamethasone under the experimental conditions a control blood sample 
spiked at 250 ng/ml was tested after incubation at 37°C for 120 minutes. In comparison 
to freshly prepared blood the difference in dexamethasone concentration was less than 
5% indicating analyte stability under the experimental conditions used.  
Table 2.11 Effect of incubation time on whole blood-to-plasma ratio of 
dexamethasone 
 Time (minutes) 
0 15 30 60 120 
Blood-to-plasma ratio 0.75 0.96 1.00 0.99 0.91 
SD 0.08 0.05 0.05 0.01 0.02 
Precision (CV %) 10.5 5.2 4.7 1.1 1.8 
 
An extraction efficiency experiment was conducted as described in section 2.4.1 using 
15 μl spots to determine the % recovery from DBS and DPS samples at a single 
concentration of 250 ng/ml in replicate (n=5). Recoveries were 100.4% (CV%, 2.5%) 
and 104.7% (CV%, 3.8%) for dexamethasone from DPS and DBS, respectively. On 
investigation of matrix effects (using the method outlined in section 2.4.2) the DPS 
matrix was not found to significantly (≤ 15%) affect dexamethasone signal intensity 
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(Table 2.12). Comparisons between DPS and DBS measurements could therefore be 
based on the assumption of equal recoveries of dexamethasone from each dried matrix.   
Table 2.12 Matrix effects arising from dried plasma spots on dexamethasone signal 
intensity n=5 
 Nominal conc. (ng/ml) 
 50 800 
Matrix effect % (mean) 14.7 0.5 
Precision (CV%) 8.2 3.0 
 
 2.4.9.2 Extent of red blood cell partitioning 
The extent of RBC partitioning was assessed using blood spiked to produce a single 
sample of dexamethasone at 50, 250 and 800 ng/ml. Liquid blood samples were 
incubated at 37°C with mild agitation. After a pre-determined incubation time of 30 
minutes, replicate (n=3) 15 µl DBS and DPS were produced at each concentration and 
allowed to dry prior to extraction. The whole blood-to-plasma ratio was calculated as 
described in section 2.4.9.1. The following equation formed the basis for the RBC 
association calculation (Rowland and Tozer, 1995): 
                           
            Amount       Amount         Amount    
                        in blood       in plasma       in blood cells  
   
Where Cb = blood concentration of drug                                                                                      
 Vb = blood volume        
 Cp = plasma concentration of drug      
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 Vp = plasma volume        
 Cbc = blood cell concentration of drug     
 Vbc = volume occupied by blood cells 
The volume occupied by blood and plasma is related to haematocrit (H) and therefore 
the above equation can be re-written as: 
                       
Rearrangement of the equation gives: 
      
     
  
                                    
Using the haematocrit value of the control blood (packed cell volume, 0.43) and 
substitution of concentration with peak area the equation below was used to calculate 
the extent of association with RBCs. The fraction calculated was multiplied by 100 to 
give the percentage association value. 
       
     
   
         
Factors which affect the extent of RBC partitioning include the chemical nature of the 
compound, pH, temperature and concentration (Hinderling, 1997). Drug lipohilicity has 
been identified as the most important factor determining the extent of partitioning. 
Dexamethasone is a lipophilic compound (log P, 1.83) and therefore would be expected 
to associate with RBCs (Núñez and Yalkowsky, 1997). The blood-to-plasma ratio 
determined for dexamethasone was close to 1 indicating a degree of association with 
RBCs. The determined value is comparable to the reported literature in-vitro values of 
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0.80, 0.81 and 0.93 in healthy adults (Araki et al., 1966, Tsuei et al., 1980, Petersen et 
al., 1983). Dexamethasone has been reported to be 68% and 77% bound to proteins, 
mainly albumin in the plasma component of whole blood (Peets et al., 1969, Tsuei et 
al., 1980, Cummings et al., 1990). Therefore protein binding may be restricting a more 
extensive RBC association. For dexamethasone, plasma protein binding is likely to be 
the most important factor in interpreting PK data when using either plasma or whole 
blood measurements. Previous studies have shown linear protein binding kinetics for 
dexamethasone in plasma at therapeutic drug concentrations between 10 and 1000 
ng/ml (Peets et al., 1969, Cummings et al., 1990). However, a decrease in albumin 
concentration or displacement of bound drug can result in decreased protein binding and 
therefore an increase in unbound drug that is available to associate with RBCs 
(Cummings et al., 1990). Under these circumstances, changes in the extent of 
partitioning would depend on the binding affinity and capacity of RBCs for 
dexamethasone (Brinkmann et al., 1972). Studies involving other steroids have shown 
differing extents of RBC association (20 - 60%) according to compound polarity 
(Holzbauer, 1972). In the current study, the percentage of dexamethasone associated 
with RBCs did not change significantly with increasing concentration indicating linear 
distribution kinetics over the calibration range of the assay (Table 2.13). Similar 
findings have been previously reported for dexamethasone under in-vitro conditions for 
concentrations between 100 and 300 ng/ml (Tsuei et al., 1980).  
A blood-to-plasma ratio of 1 suggests an equal distribution of drug between plasma and 
RBC components of whole blood. Furthermore, the partitioning of dexamethasone does 
not appear to be concentration dependent over the concentration range studied. 
Therefore either blood or plasma could potentially be used to measure dexamethasone 
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Table 2.13 Effect of concentration on the extent of dexamethasone partitioning 
 Nominal conc. (ng/ml) 
 50 250 800 
Blood-to-plasma ratio 1.05 1.11 1.06 
SD 0.11 0.04 0.12 
Precision (CV %) 10.1 3.9 11.3 
Red blood cell association (%) 45.7 48.8 46.3 
 
drug concentrations provided there are no significant changes in plasma protein binding. 
Additionally, DBS PK estimates can be compared with those in plasma without a prior 
need for conversion of concentration measurements.  
The results obtained from the current experiment reflect the partitioning behaviour of 
dexamethasone in adult blood. RBC association affinities have however, been shown to 
vary between neonates and adults. For example in infants the blood-to-plasma ratio of 
digoxin is 3 fold higher compared to adults (Kelly et al., 1983). Due to obvious ethical 
reasons all experiments were carried out using adult venous blood. A practical solution 
could be to use umbilical cord blood as a surrogate for neonatal blood. This approach 
was used by Tsuei et al to investigate in-vitro differences in dexamethasone RBC 
association between adults and neonates. A small but significant difference in blood-to-
plasma ratio between adult venous blood (0.81) and umbilical venous blood (1.04) was 
reported (Tsuei et al., 1980). The investigators went on to show differences in 
dexamethasone protein binding between adult venous plasma (67%) and umbilical 
venous plasma (61%). This could explain the greater blood-to-plasma ratio found in 
umbilical vein blood. The difference was not as large as that reported for digoxin but 
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highlights the importance of considering differences which may exist in blood cell 
association between adults and neonates. 
2.4.10 Stability 
2.4.10.1 Solvent 
The stability of dexamethasone in stock solution was determined in replicate (n=5) by 
comparing the peak area of solutions analysed after storage to those which had been 
freshly prepared. Stock solutions were considered stable if differences in peak area were 
≤ 15%. To test stability the lowest spiking concentration (315 ng/ml) was prepared 
using stock solutions as described in section 2.3.2. Dexamethasone was determined to 
be stable in solvent for at least 9 days stored at 4C and 48 hours at room temperature 
with a difference of less than 11.7% (CV%, 6.5%)  and 6.1% (CV%, 7.9), respectively. 
2.4.10.2 Dried blood spot 
The stability of dexamethasone in DBS samples was investigated following storage at 
4°C and room temperature (22°C) with and without desiccant. Samples for stability 
assessment were prepared by applying 30 µl aliquots of blood at concentrations of 50 
and 800 ng/ml onto filter paper. Following storage under various conditions the entire 
spot on the filter paper was extracted with a 250 µl volume of methanol:water (70:30, 
v/v). DBS samples were considered stable if differences in peak area between stored 
and fresh samples were ≤ 15%. Dexamethasone was found to be stable within a DBS 
sample for at least 7 days at room temperature and 28 days at 4°C. Differences in peak 
area between samples stored at 4°C for 28 days and fresh samples were -7.5 and -1.6% 
at 50 and 800 ng/ml, respectively, indicating analyte stability under these storage 
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conditions (Table 2.14). The stability of samples was not affected by storage with 
desiccant. 
Table 2.14 Stability of dexamethasone in DBS samples stored at 4°C for 28 days n=5 
Nominal conc. (ng/ml) 50 800 
 Fresh Stored Fresh Stored 
Peak area (mean) 3134.30 2899.59 44572.92 43838.61 
SD 387.62 396.26 2299.82 2557.30 
CV% 12.4 13.7 5.2 5.8 
% Difference -7.5 -1.6 
 
2.4.10.3 Drying temperature 
In comparison to laboratory drying conditions the NICU can be warmer with 
temperatures ranging between 22 and 25°C (Thomas et al., 2010). To determine the 
effect of drying temperature on dexamethasone stability 30 µl DBS samples at 50 and 
800 ng/ml were prepared and immediately transferred to an oven set to 30°C (n=5). 
Following storage for a period of 48 hours under these conditions, 8 mm discs from 
DBS samples were extracted and the resulting peak area ratios compared with those 
obtained from the analysis of DBS samples left to dry at room temperature (22°C). The 
difference in peak area ratio between samples at 50 and 800 ng/ml was 1.8% and 4.6%, 
respectively (Table 2.15). This indicates that dexamethasone is stable in DBS samples 
at the temperatures expected in the environment where sample collection and drying 
will take place. There is an increased potential for shorter drying times and 
consequently smaller spot sizes at elevated temperatures. The results do not suggest 
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dexamethasone quantification was adversely affected and noticeable differences in spot 
size were not apparent.  
Table 2.15 Stability of dexamethasone in DBS following drying and storage at 30°C 
for 48 hours n=5  
Nominal conc. (ng/ml) 50 800 
 22°C 30°C 22°C 30°C 
Peak area ratio (mean) 0.55 0.56 8.51 8.91 
SD 0.03 0.08 0.56 0.83 
CV% 5.2 14.4 6.6 9.3 
% Difference +1.8 +4.6 
 
2.4.10.4 In-process 
The stability of extracted DBS samples were tested at concentrations of 50 and 800 
ng/ml. Replicate (n=5) 8 mm discs taken from DBS samples at each concentration were 
extracted, transferred to an LC vial and stored at room temperature for 48 hours. In-
process stability was determined by comparing the peak area ratios of fresh extracts 
with those stored for 48 hours. Differences at each concentration were within 7% giving 






Table 2.16 Stability of dexamethasone in processed samples for 48 hours at 22°C n=5  
Nominal conc. (ng/ml) 50 800 
 Fresh Stored Fresh Stored 
Peak area ratio (mean) 0.52 0.56 6.67 6.61 
SD 0.02 0.08 0.84 0.45 
CV% 4.1 13.7 12.5 6.8 
% Difference +6.7 +1.0 
 
2.5 Conclusion 
A simple LC-MS method utilising DBS sampling has been developed for the 
quantification of dexamethasone in human whole blood based on the requirement of a 
30 µl blood sample. The validated method was determined to be accurate and precise 
with a RE and CV ≤ 15% at all tested concentrations. High recovery of dexamethasone 
(99%) was observed from DBS samples using a simple liquid extraction method. This is 
similar to the reports of Christianson et al who reported a recovery of 83 to 94%  for 
dexamethasone from dried synovial fluid spots on Ahlstrom paper 226 (Christianson et 
al., 2010). The LLOQ of 15 ng/ml is not as low as some previously reported methods, 
however, the degree of sensitivity conferred was considered acceptable for application 
to the current study objective.  
The degree of flexibility around blood volume collection and the spotting device used is 
particularly advantageous to test sites such as the clinical environment where accurate 
pipetting may be difficult to achieve. Exposure of blood to petroleum jelly did not affect 
the quantification of dexamethasone in DBS samples and therefore its use on the NICU 
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during capillary blood collection is not considered to be a problem. In agreement with 
the findings of others the most noticeable effect on assay performance was observed 
with changing haematocrit. However, the overall variation in % bias was within the 
accepted criteria of ≤ 15% for the tested haematocrit range and therefore the developed 
method was considered to be robust. Stability of dexamethasone within DBS samples 
has been shown following storage at room temperature for 7 days and up to 28 days for 
samples kept at 4°C in a refrigerator. In addition, an elevated drying temperature of 
30°C with subsequent storage for 48 hours in this warmer environment does not affect 
the stability of dexamethasone.    
The validated DBS method was used for the measurement of circulating dexamethasone 
concentrations in preterm neonates on the NICU. The study design and results from 












Chapter 3  
Pharmacokinetics of Dexamethasone in Preterm Neonates Using Dried 





Several studies have shown that prenatal corticosteroids in women at risk of preterm 
delivery reduce the incidence of respiratory distress syndrome and infant mortality 
(Roberts and Dalziel, 2010). The beneficial effects of exogenous surfactants in reducing 
the incidence of CLD and mortality are also clear (Stevens et al., 2007). Despite the use 
of these treatments CLD of the newborn remains a major problem on the NICU. 
Inflammation has been identified as central to the pathogenesis of the disease and many 
of the prevention and treatment modalities have been focused on potential anti-
inflammatory drugs (Watterberg, 2006). Postnatal dexamethasone is a proven effective 
anti-inflammatory treatment for the prevention and treatment of CLD (Halliday et al., 
2009b, Halliday et al., 2009a, Halliday et al., 2010). It is now apparent that modulation 
of the inflammatory response and protection of the lungs afforded by dexamethasone 
may occur at the expense of other organs including the brain. Routine use in neonatal 
practice is not recommended until there is sufficient scientific knowledge to support the 
selection of the optimal dose, frequency of administration and corticosteroid in CLD 
(Halliday, 2001). At present, our understanding of the PK of dexamethasone in neonates 
is limited to two small studies and therefore further investigations are necessary 
(Charles et al., 1993, Lugo et al., 1996). 
3.2 Aim 
The aim of this study was to clinically evaluate the potential of DBS analysis for the 
quantification of dexamethasone in PK studies involving preterm neonates. For this 
purpose DBS samples were collected from preterms receiving dexamethasone treatment 
for CLD. Dexamethasone levels determined from DBS samples using LC-MS 
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quantification (Chapter 2) were used to estimate individual PK parameter estimates 
(CL, V and half life). DBS derived estimates were then compared with plasma PK 
values reported in neonates. 
3.3 Patients and study design 
3.3.1 Patients 
Patients were recruited from the NICU at University Hospitals of Leicester NHS Trust. 
A significantly smaller percentage of patients were treated with dexamethasone than 
expected based on the results of an audit of dexamethasone usage in CLD over 2007 to 
2008. It therefore became necessary to include a second NICU centre located at 
Sheffield Teaching Hospitals NHS Trust to provide support with patient recruitment. 
Ethical approval for the conduct of the research and study protocol was granted by the 
Leicestershire, Northamptonshire and Rutland NHS Research Ethics Committee 2, the 
Research and Development departments at Leicester and Sheffield hospitals and De 
Montfort University Research Ethics Committee. All patients prescribed dexamethasone 
for the treatment of CLD were eligible for study participation on the provision of 
informed written consent from their parents or guardians (Appendix I). Exclusion 
criteria included infants whose parents or guardians refused consent for participation 
and any infant whom the neonatology consultant responsible for their care considered 
unsuitable for study. 
3.3.2 Study protocol 
Patients recruited received IV dexamethasone according to local NICU protocol. The 
dosing protocol at Leicester was 250 µg/kg twice a day for three days, then 100 µg/kg 
95 
 
twice a day for three days, then 50 µg/kg twice a day for two days, and finally 25 µg/kg 
twice a day for two days. Patients recruited at the Sheffield NICU received 150 µg/kg 
once a day for four days, then 100 µg/kg once a day for two days, then 50 µg/kg once a 
day for two days followed by 20 µg/kg once a day for two days. Blood spots (30 µl) for 
dexamethasone quantification were collected at random time intervals from each patient 
during the course of dexamethasone treatment. Where possible a single DBS sample 
was collected prior to dexamethasone treatment and after discontinuation. Samples were 
collected into lithium heparin coated capillary tubes and immediately spotted onto 903 
paper with the aid of a suction bulb (Figure 3.1). All blood samples were collected 
opportunistically after bloods had been obtained for the clinical care of the patient. 
Therefore patients were not subjected to extra needles for the purposes of the study. In 
cases where blood flow ceased further attempts to obtain blood via a second skin 
puncture were not made. The number of samples collected per day was therefore 
governed by the number of sampling opportunities available. No more than three DBS 
samples were collected on any single day and the total number of DBS samples that 
could be collected during the entire study period was limited to twenty (equivalent to 
0.6 ml of whole blood). A record of blood volumes collected was kept on a daily basis 
for each patient for the duration of the study. All dexamethasone dosing and DBS 
sampling information along with patient data collected during the study was recorded 
on case report forms (Appendix II).  
3.3.3 Capillary blood collection procedure on the neonatal unit 
In the first stage the infant’s heel is cleaned, usually with an alcohol swab and allowed 
to dry. A thin layer of petroleum jelly may be applied onto the skin surface to facilitate 
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blood collection. An automated disposable lancet device is used to obtain blood from 
the lateral part of the heel. All blood including the first droplet is collected into a 
capillary tube or blood tube for clinical tests. In the process of blood collection gentle 
squeezing is used if necessary to encourage blood flow. After all clinical samples had 
been obtained capillary blood for the PK study was collected from the sampling site into 
a capillary tube.  
3.3.4 Sample storage and analysis 
Blood samples collected onto 903 paper were transferred to a dedicated research room 
on the NICU for drying. To avoid risk of contamination from the bench surface samples 
were dried on an elevated rack. Once dried, samples were sealed in plastic bags and 
transported to De Montfort University laboratories for storage at 4°C. Patient samples 
were analysed by LC-MS using the method outlined in Chapter 2 (section 2.3). 
Concentrations of dexamethasone within DBS samples were determined from the 
equation generated from a DBS calibration line analysed alongside the patient samples. 
              
Figure 3.1 An example of a DBS sample collected from a patient (A) and a capillary 




3.4 Pharmacokinetic and statistical analysis 
Non-linear regression analysis was performed using NONMEM (version 7.0) with a 
GNU Fortran Compiler 95. Post processing of NONMEM data was undertaken with 
PDx-POP (version 4.0, ICON Development Solutions, USA) and Microsoft Excel 2007 
(Microsoft Corporation, USA). Initial parameter estimates for dexamethasone were 
obtained from previous PK studies conducted in neonates (Charles et al., 1993, Lugo et 
al., 1996). The IV administration of dexamethasone was duration modelled using a 
fixed value of 0.08 h. This value was suitable since the drug is routinely administered as 
a bolus dose over approximately 5 minutes. There are various methods that can be used 
to deal with concentration levels which fall below the LLOQ of an assay. In the current 
study, for data below the limit of quantification (BLOQ) a replacement approach with 
BLOQ/2 was implemented where the observed concentration is replaced with a value 
corresponding to half the LLOQ (i.e. 7.5 ng/ml) (Beal, 2001). For all patients, levels of 
dexamethasone were undetectable during the last few days of therapy when the lowest 
doses were administered. Due to the limited information gained from inclusion of all 
BLOQ values during this period the following criteria was applied. The first two levels 
BLOQ following a level above the LLOQ were incorporated in the analysis using a 
BLOQ/2 approach. Subsequent levels BLOQ were removed from the PK analysis. 
Despite efforts to include a second study centre a limited number of patients were 
recruited over the 18 month study duration which precluded the execution of the 
planned population based PK analysis or a formal investigation of covariate effect. 
Instead, an individual PK analysis was undertaken where DBS concentration data from 
each patient were separately fitted to a one and two compartment model in the first 
stage (Appendix III). The First Order estimation method was used as the model fitting 
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algorithm. Once individual estimates of CL and V were determined these were pooled 
to determine the mean and variability (SD, CV%) of PK estimates for the study group.  
3.5 Results 
3.5.1 Demographic and clinical characteristics of study patients 
A total of six patients were enrolled onto the study over an 18 month period. Patient 6 
was excluded from the PK analysis as dexamethasone concentrations were undetectable 
in all three DBS samples collected (on days 9 to 10 of treatment). The demographic and 
clinical characteristics of patients 1 to 5 are presented in Table 3.1. The majority of 
patients studied were extremely low birth weight (≤ 1 kg) infants. The GA varied 
between 23.7 and 28.7 weeks and the mean PNA at which patients received 
dexamethasone treatment was 20 days. No known inhibitors or inducers of 
dexamethasone metabolism were identified in co-medications prescribed to patients. 
Clinical data including haematocrit and albumin were recorded with each DBS sample 
if available from the results of tests ordered for routine care purposes. The range of 
haematocrit values measured in patients during DBS collection is shown in Figure 3.2. 
With the exception of a few, haematocrit values were centred around the assay 
calibration line (haematocrit 35%) and thus within the acceptable ± 5% validation limit. 
3.5.2 Dried blood spot samples 
A total of 69 DBS samples were collected from patients 1 to 5 (mean 14, range 3 - 20). 
Five of these samples were collected whilst patients were not on dexamethasone 
treatment and three samples were below the required standard of quality (due to 
insufficient sample or visual coagulation) and were therefore not included in the 
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analysis. The sampling times of the remaining 61 samples collected during 
dexamethasone treatment are shown in Figure 3.3.  
 
Table 3.1 Characteristics of study patients 












1 F 23.7 0.57 23 27 0.59 CA, ER, CE, RA, VA, IN 
2 M 24.3 0.75 12 26 0.88 CE, VA, IN, FZ, DO, MO 
3 M 28.7 1.30 16 31 1.44 CA, GE, FL, JO, NY, CL 
4 F 24.1 0.64 28 28.1 1.12 CA, NY, FU, ME, MI, SP 
5 
 
F 27.6 0.57 23 30.9 0.68 CA, RA, FZ  
Mean  25.7 0.77 20.4 28.6 0.94  
SD  2.3 0.31 6.4 2.3 0.34  
 
a. Weight on day of study recruitment. 
GA = gestational age; BW = birth weight; PNA = postnatal age; PMA = postmenstrual age. 
Co-medications: CA = caffeine, ER = erythromycin, CE = cefotaxime, RA = ranitidine, VA = 
vancomycin, IN = insulin, FZ = fluconazole, DO = dopamine, MO = morphine, GE = 
gentamicin, FL = flucloxacillin, JO = Joulie’s phosphate, NY = nystatin, CL = clotrimazole, FU 









Figure 3.3 DBS sampling times post dexamethasone administration at the Leicester 































































3.5.3 Pharmacokinetic analysis 
A substantial number (32, 52%) of the (61) DBS samples collected during 
dexamethasone treatment were determined to be BLOQ. 17 of these were replaced with 
BLOQ/2 and kept in the PK data set and 12 were excluded. Thus the final number of 
samples used in the PK analysis was 49. The majority of DBS samples BLOQ were 
collected during the last few days of treatment when the lowest dexamethasone doses 
were administered or at the end of a dosing interval (Figure 3.4). The sampling times of 
the 49 DBS concentration measurements used in the PK analysis are shown in Figure 
3.5 according to patient number. Samples were collected at a range of time points post 
dexamethasone administration necessary for the estimation of CL and V.   
Three common approaches to handling data reported as BLOQ include omitting data, 
imputing zero and imputing BLOQ/2 (Beal, 2001). Each of these methods was 
investigated for their influence on PK parameter estimation. The residual error 
(difference between model predicted and observed concentrations) was used as an 
indication of the goodness of fit of the data. A complete omission of data BLOQ 
resulted in an increase in the estimation of V and a decrease in the estimated CL value 
for some patients. This type of effect can occur with this method due to an under 
prediction in the decline of the terminal phase of the slope resulting in a lower CL and a 
larger V (Duval and Karlsson, 2002). There was no significant difference between the 
replacement with zero method and BLOQ/2 method on either parameter estimation or 
residual error. A replacement with BLOQ/2 was applied to the data as previous 
investigations have shown the zero method can bias estimates. A one compartment 
model with duration modelled IV infusion and first order elimination was used to fit the 
data. The primary PK parameters (CL, V) and calculated half life for each patient is 
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shown in Table 3.2. A mean CL of 0.18 l/h/kg and an interindividual variability of ± 
0.05 l/h/kg SD (CV%, 27.8) were estimated for the study group. The interindividual 
variability in V (CV%, 52.6) was larger in comparison and the half life varied 
significantly between individuals (1.5 to 7.6 h). The parameter estimates were used to 
                 
Figure 3.4 Day and time (post dexamethasone dose) of DBS samples for which 
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simulate a model predicted concentration-time profile under the weight individualised 
dosing regimen for each patient. An overlay of individual model predicted PK profiles 
with observed DBS concentration data show the goodness of fit of the concentration-
time data to a one compartment model following non-linear regression (Figure 3.6). For 
patient 4, DBS samples were collected over two dosing periods (days 3 to 5 and 1 to 5, 
respectively) separated by a 2 week interval where no dexamethasone was administered. 
The PK profiles during the first and second dosing period are therefore presented 
separately in Figure 3.6. From the visual examination of these plots it would appear that 
a one compartment model provided a reasonably good fit of the DBS data. The under 
predictions of dexamethasone concentration observed during peak times may suggest 
distribution into a second compartment prior to a decline in concentration. Supporting 
this possibility, for patient 2 a two compartment model captured peak concentrations 
and provided a better fit of the data evidenced by a significant drop in the residual error 
(Figure 3.7). The sparse nature of the data and limited sampling during the early phase 




Table 3.2 Pharmacokinetic parameters of dexamethasone during multiple dose 













1 1 (6) 0.24 2.14 6.1 
2 1 (1) 0.12 0.75 4.2 
3 1 (1) 0.21 0.47 1.5 
4 2 (1) 0.14 1.50 7.6 
5 
 
2 (3) 0.18 1.79 6.0 
Mean  0.18 1.33 5.1 
SD  0.05 0.70 2.3 
CV%  27.8 52.6  
 
a. Dosing regimen 1 (Leicester NICU) : dexamethasone 250 µg/kg twice a day for three days, 
then 100 µg/kg twice a day for three days, then 50 µg/kg twice a day for two days, and finally 
25 µg/kg twice a day for two days. 
Dosing regimen 2 (Sheffield NICU): dexamethasone 150 µg/kg once a day for four days, then 
100 µg/kg once a day for two days, then 50 µg/kg once a day for two days followed by 20 µg/kg 
once a day for two days. 
b. Day on which DBS sampling commenced. 





































































































































Figure 3.6 Predicted dexamethasone DBS-concentration time profiles (―) and 





























































Figure 3.7 Predicted dexamethasone DBS concentration time profile (―) and 
observed concentration data (•) for patient 2 data fitted to a two compartment model 
 
The limited number of patients studied precluded a formal covariate regression analysis 
to facilitate an understanding of the variability in parameter estimates. Instead, 
covariate-parameter relationships were explored by simple linear regression of 
individual estimates against age (GA, PNA and PMA) and weight. A positive 
correlation (r
2
 = 0.531) between GA and CL was observed but this was no longer 
evident after the weight normalisation of CL estimates. Figure 3.8 shows the regression 
of weight on study enrolment against PK parameter estimates. A correlation (r
2 
= 0.644) 
was observed between weight and CL highlighting the justification for normalising CL 
by incorporating weight into the dosage calculation. After weight normalisation of CL 
estimates, the correlation between CL and weight was no longer evident. An inverse 
correlation (r
2 































normalisation of V. In addition, the elimination half life decreased with increasing 
weight. Based on the positive correlation observed between V and half life (Figure 3.9), 
it appears that a larger V significantly contributes to the extended half life in low weight 





                                                                  
                                                                   
Figure 3.8 Relationship between dexamethasone PK parameters (CL, V, weight normalised V and t1/2) and weight on study enrolment 



































































Figure 3.9 Relationship between V and t1/2 
3.6 Comparison with plasma pharmacokinetic estimates 
The measured dexamethasone DBS concentrations (7.5 to 353.3 ng/ml) were 
comparable to values of 3.4 to 406.9 ng/ml previously reported in plasma for this age 
group after administration of the same weight normalised dose (250 μg/kg). A 
comparison of PK estimates determined using DBS analysis with those obtained in two 
previously reported plasma based non compartment studies in neonates is shown in 
Table 3.3 (Charles et al., 1993, Lugo et al., 1996). The mean CL estimated (0.18 l/h/kg 
(SD, 0.05)) was similar to the mean value of 0.14 l/h/kg (SD, 0.03) reported in the study 
by Charles et al (n=7). In a later study by Lugo et al (n=9) a mean CL value of 0.30 
l/h/kg (SD, 0.25) was found which is almost twice the value obtained here. A large 
degree of variability in CL was observed amongst the study population reported by 
Lugo et al with estimates ranging between 0.06 and 0.73 l/h/kg. Following an analysis 
of CL stratified according to GA the authors noted a significant difference in CL 
between neonates ≤ 27 weeks (mean, 0.10 l/h/kg; SD, 0.05) and above 27 weeks (mean, 
0.45 l/kg/h; SD, 0.22). This suggests that the greater mean GA of the patients in the 















study by Lugo et al (27.3 weeks) compared with that of Charles et al (25.6 weeks) and 
the present study (25.7 weeks) may account for the differences in mean CL estimates. 
The mean CL was lower than the values of 0.23 l/h/kg and 0.34 l//h/kg in healthy adults 
(Tsuei et al., 1979, Rose et al., 1981) and 0.33 l/h/kg reported in children with croup or 
head injury (Richter et al., 1983). The mean V (1.33 l/kg) in the current study was lower 
than that reported by Lugo et al (1.78 l/kg) and Charles et al (1.91 l/kg). However, 
when the V estimates in the study by Lugo et al were examined according to GA the 
authors found that for infants born at less than 27 weeks (mean, 25.8 weeks) the V was 
considerably smaller compared with infants born after 27 weeks (mean, 28.5 weeks) 
gestation (1.26 versus 2.19 l/kg). The distribution volume obtained in the current study 
was therefore very similar after consideration of GA.  
The mean half life determined for the study group (5.1 h) was lower than previous 
reports of 6.8 and 9.3 h. The elimination half life is not an independent PK parameter 
and is determined by both CL and V. The reason for the shorter mean half life in the 
current study appears to be due to the smaller V determined in patients. In healthy 
adults, mean half lives of 2.9 h (SD, 0.8), 3.1 h (SD, 1.1) and 5.6 h (SD, 1.4) have been 
reported (Tsuei et al., 1979, Rose et al., 1981, O'Sullivan et al., 1997). The difference in 
half life between neonates and adults determined by the current study is thus less 
marked compared with previous findings. However, if the range of half lives (1.5 to 7.6 
h) is considered, the results of this study like previous ones highlight the large 
interindividual variability of PK parameters and the prolonged half life that can be 
expected in low weight neonates.     
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Table 3.3 A comparison of PK estimates obtained using DBS quantification with previous studies in plasma. PK estimates are reported 






 GA     BW      PNA    PMA     WT 
(wk)   (kg)     (days)   (wk)     (kg) 
Sampling design 
CL    
(l/h/kg) 
V       
(l/kg) 





Tapering regimen  
250 to 25 µg/kg  
twice daily or  
150 to 20 µg/kg 












9 (mean) samples  
30 µl capillary DBS  



















on day 1 after a 
400 µg/kg once 











5 time points (0.5, 1, 
2, 6, 12, 24 h)  
~0.2 ml arterial 
blood  
0.1 ml plasma, LC-


















on day 1, 2 or 3 
of treatment. 
Dose range of 208 
to 503 µg/kg 











5 time points post 
single dose (0.5, 1, 
3, 6, 12 h)  
Arterial/venous 
blood, plasma 
volume not given, 
















Both compartment and non compartment PK analysis has been previously used to 
describe the disposition of dexamethasone in humans. In children and adults 
dexamethasone has been shown to display one and two compartment disposition (Tsuei 
et al., 1979, Richter et al., 1983). Whilst in neonates PK analysis has been performed 
using a non compartmental approach (Charles et al., 1993, Lugo et al., 1996). In the 
current study a one compartment model provided a reasonable fit of the DBS 
concentration-time data across the duration of a dexamethasone dose reducing regimen 
(Figure 3.5). With sparse data the model selected is often an oversimplification of the 
underlying true PK model (Aarons et al., 1996). A more complex model may have been 
more suitable but was not supported by the data. Model misspecification is thus a 
potential contributory factor to the differences between predicted and observed 
concentration data. Other sources of error are inaccuracies in records of time of drug 
administration and sample collection and analytical measurement error. Random 
biological variability in CL and V parameters on different sampling occasions will also 
contribute to the difference between model predicted and observed concentrations 
(Karlsson and Sheiner, 1993). 
In agreement with previous PK reports in neonates a significant degree of variability in 
dexamethasone disposition was observed amongst the patients in the present study. The 
results from the linear regression of covariates against individual parameter estimates 
indicated the higher V in the lowest weight neonates accounted for their relatively 
greater half life. It should be noted that the correlation found between V and half life is 
limited to 5 patients and therefore it is not possible to draw any conclusions on the 
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relationship observed. As dexamethasone exhibits low aqueous solubility, differences in 
V would most certainly be expected to arise from differences in tissue binding and not 
because of distribution into the extracellular fluid compartment. The large 
interindividual variability in dexamethasone PK in neonates and extended half life in 
the smallest neonates do however, demonstrate the sub-optimal dosing schedule 
currently adopted based on body weight alone. 
There is only limited information available on the elimination pathway of 
dexamethasone during the neonatal period. Studies by Araki et al in adults have 
highlighted the difficulties of conjugating synthetic steroids to more water soluble 
derivatives within the human body (Araki et al., 1966). Subsequent studies in adults 
have shown that a large percentage (~ 60%) of an administered dexamethasone dose is 
eliminated renally, mainly in the form of unconjugated polar steroids (Haque et al., 
1972). The major urinary metabolite has been identified as 6β-hydroxydexamethasone 
with dexamethasone or conjugated dexamethasone accounting for only 2.3% of the total 
dose (Minagawa et al., 1986). Evidence suggests that cytochrome P450 3A4 (CYP3A4) 
is the key enzyme responsible for the 6β-hydroxylation of dexamethasone (Gentile et 
al., 1996, Puisset et al., 2007). Enzymes from the CYP3A family make up the largest 
percentage of enzymes in the adult and foetal liver of which CYP3A7 is the most 
abundant detected as early as 7 to 8.5 weeks gestation (Yang et al., 1994). After birth 
levels of CYP3A7 begin to gradually decrease throughout the neonatal period into 
infancy (Lacroix et al., 1997). In contrast, very low CYP3A4 amounts are detectable 
prior to birth. Expression of this enzyme steadily increases during the postnatal period 
reaching adult levels not until after 1 year of age (Stevens et al., 2003). Although it is 
clear that a transition between CYP3A7 and CYP3A4 expression occurs after birth, 
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because of the variability in expression observed the exact time course of these changes 
are not yet fully understood (Hines, 2007). To assess CYP3A activity in neonates 
Nakamuru et al measured the 6β-hydroxycortisol to cortisol (6β-OHC/C) ratio in the 
urine of preterm and term neonates (Nakamura et al., 1998). A positive correlation was 
found between GA and the 6β-OHC/C ratio with term neonates showing the highest 6β-
OHC/C ratios on day one of life compared to preterm neonates and adults. By day 5 the 
ratio of 6β-OHC/C had dropped to that below adults in term neonates, perhaps due to 
changes in CYP3A expression whilst no change was observed during the first 14 days 
in neonates born prematurely. Although neonates may at least have some capacity these 
studies suggest that their metabolic capacity for drugs metabolised via CYP3A is likely 
to be significantly reduced and most pronounced in premature neonates. It is possible 
that alternative metabolic routes predominate in the neonate to compensate for 
immaturity of CYP3A enzyme activity and or renal excretion of dexamethasone in the 
unchanged form plays an important role. Investigations to identify covariates which 
reflect differences in dexamethasone disposition amongst neonates will be important for 
determining the most appropriate treatment dose. The findings of a previous study 
strongly indicate factors other than weight alone (such as GA) are likely to be of 
importance in accounting for interindividual differences in dexamethasone PK (Lugo et 
al., 1996). In a recent study, Yang et al reported on the population PK of 
dexamethasone in children with acute lymphoblastic leukaemia (Yang et al., 2008). The 
regression analysis results from this study indicated age, and to a greater extent albumin 
to be the most important covariates accounting for the large intraindividual and 
interindividual variability in CL. The positive correlation between CL and albumin 
concentration was assigned to differences in hepatic function rather than to changes in 
117 
 
protein binding. In this study, albumin was therefore suggested as a biomarker of 
hepatic function. The variability in albumin concentration observed was thought to be 
secondary to prior asparaginase in some children which is known to cause 
hypoalbuminaemia. Thus albumin may also be of importance in explaining the 
variability in dexamethasone PK that results from developmental processes and 
potentially protein binding. On the other hand, if renal mechanisms of drug CL 
predominate indicators of renal development such as GFR may provide a better 
understanding of the interindividual variability in PK parameters. 
The primary aim of this study was to evaluate the potential of DBS analysis for the 
determination of dexamethasone PK parameters (CL, V and half life) in neonates. To 
avoid the practical and ethical difficulties of performing a direct comparison between 
plasma and blood, a method of validation by comparison with literature plasma PK 
estimates was chosen. Furthermore, opportunistic sampling provided a minimally 
invasive study design thereby helping to reduce patient discomfort and improve parental 
and clinical staff acceptability. The PK estimates determined in the current study were 
found to be comparable with values reported in studies that have utilised conventional 
plasma analysis. This indicates the usefulness of DBS in providing information on the 
PK of dexamethasone in a population that is extremely difficult to study. There is 
however, potential for the PK of dexamethasone to be complicated by a number of 
factors specific to normal developmental changes which occur in the neonatal age 
group. The presence of foetal plasma proteins, qualitatively different albumin and 
presence of endogenous compounds e.g. bilirubin able to compete for binding sites will 
invariably lead to unexpected changes in the fraction of unbound drug (Notarianni, 
1990). The potential for misinterpreting dexamethasone PK and difficulties in studying 
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PK-PD (dose-effect) correlations thus hold true whether plasma or whole blood is used 
to measure drug concentration under these conditions. When the measured total 
concentration no longer reflects the unbound fraction of drug, it may be difficult to 
predict a pharmacological effect or make dosing recommendations. The additional 
variables to consider when using DBS measurements are blood cell partitioning and 
haematocrit. Changes in haematocrit would not be expected to alter the drug distribution 
ratio according to the results from the RBC association experiment (Chapter 2, section 
2.4.9.2). In the presence of an increased free fraction of dexamethasone in plasma it is 
possible that an affinity for RBCs drives the movement of increased amounts of 
dexamethasone into RBCs thereby altering the blood-to-plasma ratio. There is at least 
some evidence of this possibility from the reported lower plasma protein binding of 
dexamethasone in conjunction with a higher blood-to-plasma ratio in umbilical venous 
blood compared with venous blood from adults (Tsuei et al., 1980). Therefore with 
changes in protein binding, haematocrit may become an influential determinant in the 
percentage of dexamethasone that associates with RBCs. Partitioning in blood and 
plasma as a function of albumin concentration was not investigated, but would enable a 
better understanding of the distribution kinetics of dexamethasone.  
 Although current data would suggest DBS to be a suitable matrix for the investigation 
of dexamethasone PK, the study design used has some limitations. Firstly, a larger 
number of subjects are required to enable an informative conclusion to be made 
regarding the accuracy as well as precision of dexamethasone PK estimation using 
DBS. Secondly, a more informative study design would involve simultaneous plasma 
and DBS concentration measurements to determine the correlation between DBS and 
plasma concentration-time profiles in neonates themselves. A PK sampling design 
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involving the collection of a limited number of samples (~3 to 4) at pre-determined time 
intervals post dose would be suitable for this purpose. Extension of the current 
dexamethasone DBS method to include DPS analysis would be useful for the 
simultaneous determination of drug levels using a single methodology. Thirdly, an 
improvement in the current sensitivity of the DBS assay will be essential prior to future 
application. The doses received by patients in the current study are relatively high 
compared with some NICUs where doses as low as 50 μg/kg once a day are used (Yates 
and Newell, 2010). It is clear that a successful population PK study of dexamethasone 
in CLD will only be possible through a multi-centre study. Therefore DBS analysis will 
only be useful if it is adequately sensitive to measure dexamethasone levels in neonates 
following the range of doses used in clinical practice. A LLOQ of at least 1 ng/ml 
would be required to support a population PK study and subsequent PK-PD dose 
finding studies.   
The contrasting accumulative doses administered to neonates at the Leicester and 
Sheffield NICU (2400 and 940 µg/kg, respectively) highlight the current clinical 
problem and the resulting variability in dexamethasone exposure in preterms (Figure 
3.5). Interindividual differences in dexamethasone PK and variations in clinical practice 
mean that some infants may be at greater risk of adverse effects. A population based PK 
study to evaluate dexamethasone pharmacokinetics and explore potential covariate 
relationships in neonates treated for CLD is urgently needed. The simplicity and ethical 
advantages of DBS analysis to facilitate such studies are clear, but further investigations 
will be important to understand plasma to whole blood differences in dexamethasone 










Chapter 4  






4.1.1 Caffeine quantification in biological fluids 
Various analytical techniques have been applied to the quantification of caffeine 
concentrations in biological fluids including RIA, gas chromatography and LC with UV 
or MS detection (Table 4.1). A relatively large proportion of published methods have 
used LC-UV methodologies due to the simplicity of the technique and the relatively 
good quantification limits (80 ng/ml) achieved from micro volume samples (25 µl 
plasma) (Dorrbecker et al., 1984). To overcome the possibilities of co-eluting 
endogenous interferences and improve the selectivity of caffeine quantification both 
LC-MS and LC-MS/MS based techniques have been utilised (Hieda et al., 1995, 
Ptolemy et al., 2010). Selectivity gained with MS/MS detection has enabled the 
separation of multiple caffeine metabolites in some cases without the need for full 
chromatographic separation (Ptolemy et al., 2010). In addition to the selectivity 
afforded by MS, good detection limits have been achieved (Zhang et al., 2008, Li et al., 
2010). Caffeine has been quantified in plasma, whole blood and urine. It has also 
successfully been measured in saliva where it is present at appreciable concentrations 
following dosing (Emory et al., 1988). A DBS technique for the simultaneous 
quantification of caffeine and theophylline was reported as early as 1981 by Brazier et 
al for the purposes of TDM in newborns with AOP (Brazier et al., 1981). The 
methodology was based on the collection of a 30 µl whole blood sample onto S&S 2992 
paper using a direct approach. Once dried the entire blood spot was cut out using a 10 
mm punching device and transferred to a clean glass tube for solvent extraction with 
chloroform:isopropanol (95:5, v/v). Methylxanthine derivatisation was subsequently 
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performed prior to GC analysis. The validation results indicated linearity (r
2
 = 0.998) 
over a calibration range of 500 to 20000 ng/ml. Good accuracy (RE% < 5%) and 
precision (CV% < 9%) was reported at the concentration levels assessed (2000, 5000, 
10000 and 15000 ng/ml). The use of a direct blood sampling approach with extraction 
of the entire spot does however, raise questions on the accuracy of the DBS method for 
concentration measurements in patient samples. The sensitivity of the method (LOD, 
500 ng/ml) is not as high as other caffeine methods however, it was sufficient for its 
intended purpose. The investigators reported that the developed DBS method had been 
successfully used in PK studies and TDM in preterms in the clinical setting. Results 
were not published and therefore a comparison with plasma data was not possible. More 
recently a caffeine DBS method using LC-MS/MS detection has been established at 
GlaxoSmithKline (GSK) laboratories, UK (Lad, 2010). A LLOQ of 250 ng/ml was 
achieved from a 15 µl DBS sample on FTA Elute paper. Without the need for several 
work-up steps and compound derivatisation the developed method is simple, sensitive 
and practical.    
4.1.2 Dried blood spot method for caffeine quantification 
The bioanalysis arm of the caffeine PK study in neonates was supported through 
collaboration with the analytical team at GSK (Hertfordshire, Ware). All DBS samples 
collected from neonates were analysed at GSK laboratories using the caffeine DBS 
method developed by Lad, 2010. The methodology was validated in accordance to FDA 
regulatory criteria (Guidance for Industry; bioanalytical method development, 2001). A 




Table 4.1 A comparison of selected analytical techniques previously used for the 
quantification of caffeine in biological fluids 
 
4.1.3 Study aim  
An assessment of method transferability is an important component of method 
validation and becomes necessary when methods are transferred to different analysts 
and different instruments. The aim of this part of the thesis was to determine the 
transferability of the caffeine DBS method developed at GSK to a simple LC-MS 
Reference  Analytical technique LLOQ LOD Volume & type of 
biological fluid  
     
(Emory et al., 1988) RIA  250 ng/ml 0.3 to 0.5 ml saliva 
(Dorrbecker et al., 1984) LC-UV 80 ng/ml  25 µl plasma 
(Schreiber-Deturmeny 
and Bruguerolle, 1996) 
LC-UV 100 ng/ml  50 µl plasma 
 
     




LC-UV 100 ng/ml  0.2 ml plasma 
 
     
(Hieda et al., 1995) LC-MS  10 ng/ml 0.2 to 1 ml plasma 
or urine 
(Zhang et al., 2008) LC-MS/MS 49 ng/ml  50 µl plasma 
 
(Ptolemy et al., 2010) LC-MS/MS 485 ng/ml  0.5 ml plasma, 
saliva or urine 
 
(Li et al., 2010) LC-MS/MS 10 ng/ml  0.1 ml plasma 
 
(Lad, 2010) LC-MS/MS 250 ng/ml  15 µl dried blood 
spot 
(Jafari et al., 2011) ES-ion mobility MS 200 ng/ml  1.0 ml serum 
(Teeuwen et al., 1991)  GC  50 ng/ml 1.0 ml plasma 




instrument. For this purpose a working LC-MS method for the quantification of caffeine 
was initially established and validated. A series of validation tests were subsequently 
performed to determine the transferability and thus the robustness of DBS analysis. This 
included an assessment of accuracy, precision, selectivity, sensitivity and matrix effect 
(section 4.3). A clinical validation of the developed LC-MS DBS method was 
performed in two healthy adult volunteers following the administration of a single oral 
caffeine dose.  
4.2 GSK Dried blood spot method and validation results 
The caffeine DBS LC-MS/MS method used to support the PK study in preterm neonates 
(Chapter 5) is described here. All method development and validation work presented in 
this section was carried out by GSK analysts.  
4.2.1 Chemicals and materials 
Caffeine (1,3,7-trimethylxanthine) and caffeine-trimethyl-
13
C3 (IS) of analytical grade 
were obtained from Sigma-Aldrich (Poole, UK). The chemical structures of caffeine 
and IS are given in Figure 4.1. HPLC grade acetonitrile, methanol and water were 
obtained from Fisher Scientific (Loughborough, UK). Analytical grade formic acid, 
ammonium acetate, ammonia solution, dimethylformamide and isopropanol were 
supplied by VWR International Limited (Poole, UK). Sample tubes were obtained from 
Micronics (Platinastraat, The Netherlands). FTA Elute cards, drying racks and Harris 
punch and cutting matt were obtained from Whatman (part of GE Healthcare). 
Desiccant sachets were supplied by Sud-Chemie (Northwich, UK) and plastic bags for 
storage of samples were obtained from Fisher Scientific (Loughborough, UK). EDTA 
coated capillary tubes were obtained from Sarstedt (Leicester, UK). Blood (EDTA) for 
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method development and patient sample analysis was supplied by GSK volunteers in 
accordance with GSK ethical procedures (Lad, 2010). Blood donors were asked to 
adhere to caffeine free diets for at least two weeks beforehand. 
4.2.2 Preparation of caffeine stock and spiking solutions 
Stock solutions of caffeine were prepared by dissolving in dimethylformamide to 
produce a 10 mg/ml concentration. An aliquot of stock solution was used to produce a 
spiking solution of concentration 1000 µg/ml in acetonitrile:water (50:50, v/v). This was 
then used to make spiking solutions of concentration 100 and 10 µg/ml via serial 
dilution.    
                                        
Figure 4.1 Chemical structures of caffeine (left) and caffeine-trimethyl-
13
C3 (right) 
4.2.3 Preparation of extraction solution and mobile phase 
Stock solutions of IS were prepared by dissolving in dimethylformamide to give a 100 
µg/ml concentration. A 250 µl aliquot of this solution was added to 50 ml of methanol 
to give an extraction solution containing 500 ng/ml of IS. 
Mobile phase A was made by diluting 10 ml of 1 M ammonium acetate solution with 
water to give a final volume of 1000 ml and adjusted to pH 8 with ammonia solution. 




































4.2.4 Preparation of calibration and validation dried blood spots 
Calibration and validation standards were prepared by diluting an aliquot of (10, 100 or 
1000 µg/ml) working solution to 1000 µl with blank human blood. The volume of 
solvent used to produce calibration standards varied between 8 to 50 μl and therefore 
did not exceed 5% of the final volume. The final concentration of calibration standards 
were 250, 500, 1000, 5000, 8000, 15000, 20000, and 25000 ng/ml. Replicate 15 µl 
aliquots of standards were spotted onto FTA Elute paper using a volumetric pipette and 
allowed to dry at room temperature for at least 2 hours. Dried samples were stored at 
room temperature with desiccant.  
4.2.5 Dried blood spot extraction 
A 3 mm disc was punched out from the centre of DBS samples and transferred to a tube 
to which 100 µl of methanol containing 500 ng/ml of IS was added. The tubes were 
mixed using a vortex and extraction was facilitated by gentle shaking for 60 minutes. 
Extracts were transferred to a clean tube and vortexed briefly prior to LC-MS/MS 
analysis. 
4.2.6 Liquid chromatography triple quadrupole mass spectrometry conditions 
The LC system consisted of a HTS PAL autosampler (Presearch, Hitchin, UK) and an 
Agilent 1100 binary pump with a column oven. Separation was achieved on a Synergi 
Fusion C18 Column (50 x 3.0 mm i.d., 4 µm) (Phenomenex, Macclesfield, UK) within 
1.5 minutes under isocratic conditions with 10 mM ammonium acetate (pH 
8):acetonitrile (84:16, v/v). An oven column temperature of 60°C was maintained 




MS/MS detection was performed with a Sciex API-4000 (Applied Biosystems/MDS 
Sciex, Canada) with a TurboIonSpray
®
 ion source in positive ion mode. The ionisation 
temperature was set at 650°C. Nitrogen was used for gas 1 and 2 at a setting of 40 and 
50 psi, respectively. The curtain gas (nitrogen) was set to 25 psi and collision gas 
(nitrogen) to 6 psi. The declustering potential and collision energy value was set to 30 
and 27, respectively. Quantification was carried out under SRM using the precursor ion 
[M+H]
+
 to product ion transition 195 to 138 m/z for caffeine and 198 to 140 m/z for the 







, respectively. A dwell time of 200 msec and 150 
msec was used for caffeine and IS, respectively. All data was processed using Analyst 
software (version 1.4.1 Applied Biosystems/MDS Sciex). Concentrations in DBS 
samples were determined from peak area ratios using a GSK laboratory information 
management system SMS2000 (version 2.0, GSK, UK). 
4.2.7 Validation results  
4.2.7.1 Linearity, selectivity and sensitivity 
A weighted (1/x2) linear regression was fitted to calibration plots of caffeine 
concentration against analyte/IS peak area ratio in triplicate. Linearity (r
2 
> 0.99) was 
observed within the tested concentration range of 250 to 25000 ng/ml (Figure 4.2). 
Under the chromatographic conditions caffeine and IS co-eluted at a retention time of 
1.0 minute. Method selectivity was assessed by analysing control DBS samples from six 
individual volunteers. No unacceptable (> 20% LLOQ) interferences were observed in 
any of the chromatograms at the retention time of caffeine or IS (Figure 4.3). A LLOQ 
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of 250 ng/ml was achieved whilst maintaining a precision (CV%) of less than 15% and 
an accuracy (RE%) within 15% of the nominal concentration (Figure 4.4).  
 
 
Figure 4.2 A representative calibration plot of nominal caffeine DBS concentration 
against mean caffeine to IS peak area ratio n=2 
 
4.2.7.2 Accuracy and precision 
Assay accuracy (RE%) and precision (CV%) was assessed using samples at five 
concentrations (250, 1000, 8000, 20000 and 25000 ng/ml, n=6) in triplicate. 
Concentrations of caffeine within DBS samples were determined from a calibration line 
(250 - 25000 ng/ml) prepared using a separate stock solution. A RE% and CV% value 
of less than 20% at the LLOQ and ≤ 15% at all other concentrations was considered 
acceptable. Values determined were all within these limits (Table 4.2). 
  
y = 6E-05x + 0.0031 





























Figure 4.3 Representative LC-MS/MS chromatograms of a blank DBS sample 
extracted with IS where (A) is the SRM chromatogram for caffeine and (B) is the 







                                    
Figure 4.4 Representative LC-MS/MS chromatogram of a caffeine DBS extract at the 
LLOQ of 250 ng/ml  
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Table 4.2 Intraday and interday accuracy (RE%) and precision (CV%) results for the 
caffeine LC-MS/MS DBS method n=6 
  Intraday 
 Nominal conc. (ng/ml) 250 1000 8000 20000 25000 


























































































  Interday 
 Mean conc.  
(ng/ml) 
SD 






























4.2.7.3 Spot size and haematocrit 
The effect of varying the blood volume spotted was investigated between 10 and 20 μl 
at concentrations of 1000 and 20000 ng/ml in replicate (n=6). Spiked blood was used to 
produce 10, 15 and 20 µl spots on FTA Elute paper. The concentration of caffeine in 
3mm samples was calculated from a calibration line produced with 15 µl DBS samples. 
Results indicated a trend towards an increased caffeine concentration with increasing 
spot volume (Table 4.3). However, differences from the 15 μl spot were less than 8% 
and all RE% and CV% values were < 15% indicating method robustness to small 
variations in blood volume spotted.  
Haematocrit effects with FTA Elute paper was assessed at concentrations of 1000 and 
20000 ng/ml at haematocrit levels of 20%, 25%, 30%, 35%, 40% and 45% in replicate 
(n=6) using 15 μl spots. Blood haematocrit was adjusted by either removing or adding 
plasma. Concentrations of caffeine in DBS samples were determined from the 
regression equation generated from a calibration performed using blood with a 
haematocrit value of 45%. In Table 4.4 the accuracy (RE%) observed in caffeine 
measurements is presented as the difference from the analyte/IS peak area ratio at a 
haematocrit value of 45%. At each tested concentration a trend towards an increasingly 
negative bias was observed with decreasing haematocrit. The most marked difference in 
RE% (-18.4 and -14.1) at both concentrations was observed at a haematocrit level of 
40%. Thereafter changing from a haematocrit of 40% to 20% only gave further 
differences in RE% of -15% and -9.6% at 1000 ng/ml and 20000 ng/ml levels, 
respectively. Overall, the effect of haematocrit on assay accuracy (RE%) was found to 
significantly deviate from the acceptable ± 15% limit. The relationship between assay 
bias and haematocrit over the haematocrit range studied is shown in Figure 4.5.  
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Table 4.3 Effect of spot volume on accuracy and precision of caffeine assay n=6 
Nominal conc. (ng/ml) 1000  20000 
Volume  10 µl 15 µl 20 µl  10 µl 15 µl 20 µl 
































Table 4.4 Influence of haematocrit on the accuracy (RE%) of caffeine measurements 
presented as the difference from the analyte/IS peak area ratio at the 45% 
haematocrit level. Precision (CV%) values for respective values are shown in brackets 
n=6. 
 Nominal conc. (ng/ml) 
Haematocrit 1000 20000 
20% -33.4 (9.6%) -23.7 (3.4%) 
25% -33.9 (12.7%) -31.6 (3.8%) 
30% -31.4 (9.5%) -20.5 (3.1%) 
35% -25.2 (8.8%) -17.2 (4.7%) 
40% -18.4 (12.2%) -14.1 (6.8%) 









Figure 4.5 Relationship between accuracy (RE%) of caffeine DBS measurement and 
haematocrit (%) at concentrations of (A) 1000 ng/ml and (B) 20000 ng/ml   





































































4.2.7.4 Petroleum jelly 
The effect of petroleum jelly on caffeine DBS quantification was assessed using blood 
spiked at concentrations of 1000 and 20000 ng/ml (n=6). 30 μl spots were applied onto 
a glass slide covered with a thin layer of petroleum jelly. Using a pipette 15 μl aliquots 
were spotted onto FTA Elute paper after a contact time of 1 minute. This was then 
repeated without petroleum jelly and for a longer exposure time of 10 minutes. 
Differences in analyte to IS peak area ratio between samples exposed to petroleum with 
those that had not were less than 15%. Precision values were also within 15% (CV%) 
and were comparable. Therefore the use of petroleum jelly was not considered to 
significantly affect caffeine quantification. 
4.2.7.5 Matrix dilution 
Caffeine plasma concentrations greater than 25000 ng/ml can be expected in some 
neonates during treatment for AOP (Lee et al., 1997). To accommodate any 
concentration measurements falling above the higher limit of quantification the use of a 
10 fold matrix dilution was investigated during method validation using 50000 ng/ml 
DBS samples. A 3 mm punch was taken and extracted as described in section 4.2.5. 5 
μls of the resulting extract was diluted with a 45 μl aliquot of matrix solution (prepared 
by extracting blank DBS samples with IS). Concentrations in diluted extract samples 
were determined from a calibration line and corrected for using the dilution factor. 
Accuracy and precision values were within 15% indicating a 10 fold dilution using 
blank DBS samples extracted with IS is suitable (Table 4.5).  
4.2.7.6 Stability 
Stability of caffeine stock solutions was tested in replicate (n=6) by comparing the  
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Table 4.5 Matrix dilution data for caffeine DBS extracts (10 fold dilution) n=6 
Nominal conc. (ng/ml) 50000 









analyte to IS peak area ratio obtained from the analysis of stored solutions with those 
which had been freshly prepared. Concentrations of caffeine at 500 ng/ml were prepared 
from stock solutions for stability testing. Caffeine was stable for at least 31 days at 4°C 
with differences between fresh and stored stocks of less than 5%.  
The stability of caffeine in EDTA whole blood was determined by comparing DBS 
samples prepared using blood stored at 37°C for 4 hours with those that had been 
immediately spotted, at concentrations of 1000 and 20000 ng/ml. Differences in the 
analyte to IS peak area ratio resulting from the analysis of 3 mm discs were less than 
2% indicating stability during blood sample collection and handling. 
Caffeine stability within DBS samples was determined by analysing 3 mm discs taken 
from 15 μl DBS samples at 1000 and 20000 ng/ml after storage at room temperature for 
6 days in sealed plastic bags containing desiccant. Compared with freshly prepared DBS 
samples, differences were less than 15% indicating analyte stability within DBS on FTA 
Elute paper (Table 4.6). Long term stability data has shown caffeine is stable within 
DBS samples for at least 5 months stored with desiccant at room temperature.  
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In-process stability was assessed at five concentrations after storage of extracts for 120 
hours at room temperature by comparison against a freshly prepared calibration line. 
Accuracy and precision values were all within 15% indicating sample extract stability 
(Table 4.7).  
Table 4.6 Stability data for caffeine in DBS samples collected on FTA Elute paper 
stored at room temperature with desiccant for 6 days n=6 
Nominal conc. (ng/ml) 1000 20000 
 Fresh Stored Fresh Stored 
Mean conc. (ng/ml) 955 1034 18377 20054 
SD 99 95 819 1057 
CV% 10.3 9.2 4.5 5.3 
% Difference +8.3 +9.1 
 
 
Table 4.7 In-process caffeine stability at room temperature for 120 hours n=6 
 Nominal conc. (ng/ml) 
 250 1000 8000 20000 25000 
Mean conc. (ng/ml) 251 1057 8498 20644 24734 
SD 15 38 535 1022 2146 
CV% 6.0 3.6 6.3 5.0 8.7 




4.3 Method development and validation on a liquid chromatography single 
quadrupole mass spectrometer 
The methodology and validation results from investigations of caffeine DBS 
quantification by LC-MS are presented in this section. 
4.3.1 Chemicals and materials 
Caffeine (1,3,7-trimethylxanthine) ≥ 99.0% (HPLC) and caffeine-trimethyl-
13
C3 (IS) 1 
mg/ml 99% were obtained from Sigma-Aldrich (Poole, UK). FTA Elute paper and 
Harris punch and cutting mat were purchased from Whatman, UK (Part of GE 
Healthcare). Blood collection tubes (containing EDTA) and EDTA coated capillary 
tubes were obtained from Sarstedt (Leicester, UK). All other chemicals and materials 
used are given in Chapter 2 (section 2.3.1). Blank blood (EDTA) for method validation 
and patient sample analysis was obtained from healthy adult volunteers asked to abstain 
from dietary sources of caffeine for at least two weeks.  
4.3.2 Preparation of caffeine stock, working and spiking solutions 
A stock solution of caffeine was prepared by dissolving 0.05 g in 5 ml of 
methanol:water (80:20, v/v) to produce a 10 mg/ml concentration. This was diluted with 
methanol:water (50:50, v/v) to produce a 1000 µg/ml working solution which was then 
used to make a spiking solution for each calibration level. The final concentrations of 
spiking solutions were 5.25, 10.5, 21, 105, 168, 315, 420 and 525 µg/ml.      
4.3.3 Preparation of extraction solution and mobile phases 
An aliquot of the 1 mg/ml IS solution was diluted with methanol to produce a final 
concentration of 500 ng/ml. Mobile phase A was made by adding 650 µl of formic acid 
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to 500 ml of water to produce a 0.13% formic acid aqueous solution. Mobile phase B 
consisted of 100% acetonitrile.  
 4.3.4 Preparation and extraction of dried blood spots 
Calibration and validation standards were prepared by diluting 25 µl of each spiking 
solution with 500 µl of blank human whole blood. 15 µl volumes of spiked blood were 
applied onto FTA Elute paper and left to dry at room temperature overnight. The final 
concentration of calibration standards were 250, 500, 1000, 5000, 8000, 15000, 20000 
and 25000 ng/ml. Once dried, samples were stored at room temperature in plastic bags 
with desiccant. The extraction procedure used to recover caffeine is outlined in section 
4.2.5. Punched 3 mm discs were extracted in eppendorfs with methanol containing 500 
ng/ml of IS and analysed via LC-MS.   
4.3.5 Single quadrupole mass spectrometry  
4.3.5.1 Selection of ions for monitoring 
The behaviour of caffeine and IS in the ESI source was investigated in positive polarity 
mode. Figure 4.6 represents the mass spectrum obtained following the qualitative 
analysis of each compound using a 1000 ng/ml solution over a scan range of 100 to 300 
m/z. Major ions at m/z 195 [M+H]
+
 and m/z 198 [M+H]
+
 were identified corresponding 
to the protonated molecular ions of caffeine and IS, respectively. These ions were 









Figure 4.6 Full scan mass spectra under optimised MS conditions for (A) caffeine 















































































































4.3.5.2 Optimisation of ion transmission 
ESI parameter optimisation was based on transmission of the analyte ion at m/z 195 in 
SIM mode. The settings investigated were capillary voltage, fragmentor voltage, 
nebuliser gas pressure, gas flow rate and drying gas temperature. Fragmentor voltage 
had the greatest effect on the resulting detection sensitivity of caffeine. The effect of 
fragmentor voltage on analyte peak intensity between 5 V and 125 V in 15 V 
increments is shown in Figure 4.7. A maximum response was achieved at 95 V and 
therefore selected for optimal ion transmission. 
 
Figure 4.7 Effects of fragmentor voltage on caffeine signal intensity using a 100 
ng/ml solution in SIM mode 
4.3.5.3 Final conditions and instrumentation 
MS detection was performed with an Agilent 1200 mass spectrometer with a positive 
ESI source. The system was calibrated on a daily basis using a tuning mixture supplied 
by Agilent Technologies. The ionisation source settings optimised to give maximum 





















Fragmentor voltage (V) 
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capillary voltage, 3000 V; nebuliser pressure, 25 psig; nitrogen gas flow, 7 L/min. The 
protonated molecular ion [M+H]
+
 of caffeine at m/z 195 and IS at m/z 198 were 
monitored using SIM mode. A dwell time of 289 msec was used for each ion. The 
software programme Chemstation (series B.1.3, Agilent Technologies) was used to 
operate the system and aquire all data. Microsoft Excel 2007 (Microsoft Corporation, 
USA) and Chemstation were used to analyse the data.  
4.3.6 Liquid chromatography 
The chromatographic system consisted of an Agilent 1100 series quaternary solvent 
delivery pump, autosampler and vacuum degasser. Caffeine was analysed on a Zorbax 
Eclipse Plus C18 column (150 mm x 2.1 mm i.d., 3.5 m) attached with a C18 guard 
column (Phenomenex, Macclesfield UK, 3.0 x 4.0 mm) under isocratic conditions. 
Mobile phase A (water with 0.13% formic acid) and B (100% acetonitrile) were held at 
18% and 82%, respectively over a run time of 5 minutes. The column oven temperature 
was set to 40°C and the flow rate was 200 µl/min. The injection volume was 10 µl.  
4.3.7 Validation results and discussion 
4.3.7.1 Recovery of caffeine from DBS samples 
The overall efficiency of the extraction method utilising 100% methanol was 
investigated at DBS concentrations of 500, 8000 and 25000 ng/ml. At each 
concentration level replicate (n=5) 15 µl spots were made and allowed to dry. The entire 
DBS was subsequently cut out and extracted with 100% methanol. Recovery was 
determined by comparing the peak area obtained with DBS extracts to those obtained 
from caffeine in solvent containing an amount which assumes 100% recovery. 
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Recoveries were calculated from the equation:  
          
                      
                        
       
The overall recovery was relatively low (44 to 47%) but consistent and reproducible 
across the calibration range of the assay (Table 4.8).   





4.3.7.2 Matrix effects 
Matrix effects following plasma protein precipitation with organic solvents have been 
documented and therefore such concerns are not limited to DBS analysis. Phospholipids 
have been identified as an important endogenous source of matrix effects and are 
present in different amounts in various biological fluids including blood, plasma and 
urine (Lahaie et al., 2010, Guo and Lankmayr, 2011). Other factors which may affect 
ionisation efficiency of a compound are sub-optimal chromatography, the ionisation 
method and exogenous compounds e.g. anticoagulant.  
The effect of matrix on the resulting caffeine LC-MS signal intensity was investigated 
at concentrations of 500 and 25000 ng/ml in replicate (n=5). An assessment was made 
by comparing the peak area of caffeine spiked into blank DBS extracts with that of 
 Nominal conc. (ng/ml) 















caffeine in solvent. A 90 µl volume of blank DBS extract or 100% pure methanol was 
added to 10 µl of caffeine spiking solution. The matrix effect was calculated using peak 
area by the equation: 
               
                   
                        
       
Initial results indicated substantial ion suppression (≥ 15%) at both concentrations 
tested. To identify which components of the DBS sample where giving rise to the 
observed matrix effect the influence of FTA Elute paper was studied. FTA Elute paper 
extracts spiked with caffeine were prepared and compared to standards of the same 
concentration spiked into 100% methanol. The magnitude of the matrix effect was also 
studied using a different filter paper (S&S 903) and following the inclusion of IS. For 
the experiment including an IS the matrix effect % was calculated using the analyte/IS 
peak area ratio. Figure 4.8 shows the extent of the matrix effect observed under each of 
the experimental conditions. Components within extracts of blank DBS samples on 
FTA Elute paper resulted in 32 and 40% ionisation suppression of the caffeine signal 
under ESI at 500 and 25000 ng/ml, respectively. Results from the FTA Elute paper 
showed a similar matrix effect on the caffeine signal suggesting that chemical 
components within FTA Elute paper rather than endogenous components in blood are 
responsible for the ion suppression. Under identical chromatographic conditions using 
paper S&S 903 no significant matrix effects were observed. This provided further 
evidence of matrix effects arising from the impregnated chemicals in FTA Elute paper. 
These results are in agreement with the findings of a study where three different paper 
types (FTA Elute, FTA and Ahlstrom 226) were studied for potential matrix effects 
(Clark et al., 2010). Using 10 different compounds the investigators showed that FTA 
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Elute paper produced the most marked matrix effects. Signal suppression varied 
considerably from not significant to greater than 80% depending on the compound 
tested. Paper 226 which is not chemically treated was not associated with any 
significant matrix effects. Despite the severity of the matrix effect observed for some 
compounds, FTA Elute was found to be the only paper that enabled an acceptable 
degree of accuracy and precision for greater than 80% of test compounds (which was 
one of three core assessment criteria during the investigations). On that basis the authors 
concluded that FTA Elute was the preferred choice of paper substrate for method 
development.  
Several approaches have been used to remove matrix effects including improved sample 
clean-up (Guo et al., 2005, Van Hoof et al., 2005) and liquid chromatography parameter 
changes to separate the co-eluting interference from analyte (Chambers et al., 2007). 
Alternatively, labelled IS can be very useful in this situation by compensating for the 
matrix effect. As it co-elutes with analyte its response is expected to be affected to the 
same extent (Van Eeckhaut et al., 2009). After the inclusion of IS the matrix effect 
observed was within the accepted limit of 15% at both concentrations and therefore IS 
corrected for the effect observed. Although a correction was possible with the use of a 
labelled IS there is still the problem of a loss in sensitivity. This will be of particular 
importance in DBS analysis where detection is already limited by small sample volumes 
and for drugs which are less well ionised. The size of the matrix effect would account 
for the relatively low recoveries of caffeine calculated using methanol extraction 
(section 4.3.7.1). A matrix effect was not apparent at this stage since comparisons of 
DBS extracts were undertaken with standards made in 100% methanol. For the purposes 
of the current research objective the loss in sensitivity was not considered to be a 
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problem and therefore efforts were not made to remove the matrix effect. The benefits 
of sample clean-up procedures on matrix effects and sensitivity when using FTA Elute 
paper have been reported (Liu et al., 2010). 
 
Figure 4.8 Matrix effect observed for caffeine at two concentrations in FTA Elute 
DBS extract, FTA Elute paper extract, 903 paper DBS extract and FTA Elute DBS 
extract containing IS. Results are presented as a percentage of the peak area observed 
in pure solvent n=5. 
4.3.7.3 Linearity, selectivity and sensitivity 
A calibration plot of caffeine concentration against analyte/IS peak area ratio was 
constructed and a weighted 1/x
2
 linear regression was applied. The response was linear 
(r
2
 ≥ 0.99) over the calibration concentration range of 500 to 25000 ng/ml (Figure 4.9). 
Under the chromatographic conditions a run time of 5 minutes was achieved with co-
elution of caffeine and IS at a retention time of 3.3 minutes. Method selectivity was 
demonstrated following the analysis of DBS samples (n=1) collected from five 
individual human subjects. There were no significant (≥ 20% of LLOQ peak area) 
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and IS. The selectivity of the method is shown in the representative chromatogram in 
Figure 4.10. Signal-to-noise ratios were calculated by dividing peak height by the 
baseline noise (where noise is given as six times the standard deviation of the linear 
regression). The LLOQ with a signal-to-noise ratio of  ≥ 10 and CV% and RE% less 
than 20% was determined to be 500 ng/ml (Figure 4.11).  
 
 
Figure 4.9 Representative calibration plot of nominal caffeine concentration against 
mean analyte to IS peak area ratio (n=5) 
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Figure 4.10 A representative LC-MS chromatogram of a blank DBS sample extracted 
with IS where (A) is the total ion chromatogram (TIC), (B) is the extracted ion 




Figure 4.11 A representative LC-MS chromatogram of a spiked DBS at 500 ng/ml 
extracted with IS where (A) is the TIC, (B) is the EIC for m/z 195 and (C) is the EIC 
for m/z 198 
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4.3.7.4 Accuracy and precision 
The assay accuracy and precision was assessed by analysing calibration standards at 7 
concentration levels (n=5) within the calibration range of 500 - 25000 ng/ml on three 
separate days. Intraday CV% and RE% was within the acceptable 20% limit at the 
LLOQ and within 15% for all other concentrations. In addition, the interday CV% and 
RE% was within 15% (Table 4.9).  
4.3.7.5 Carryover and injector precision 
Sample carryover was assessed by analysing blank DBS extracts following the analysis 
of the highest DBS concentration (25000 ng/ml) in the calibration range. No significant 
peak (> 20% of LLOQ peak area) was observed in blank DBS chromatograms. 
Similarly, potential contamination resulting from the punch was assessed by analysing 
two blank DBS discs cut from the same punching device previously used to cut out 10 
discs of blood from 25000 ng/ml DBS samples. In the absence of a significant peak 
attributable to caffeine in resulting chromatograms the punching device was also 
excluded as a major factor affecting assay accuracy and precision. Injector precision 





Table 4.9 Intraday and interday accuracy (RE%) and precision (CV%) results for the 
LC-MS caffeine DBS method n=5 
  Intraday  
 Nominal conc. 
(ng/ml) 
500 1000 5000 8000 15000 20000 25000 

























































































































  Interday  
 Mean conc.  
(ng/ml) 
SD 







































Table 4.10 Injector precision and retention time variability results for caffeine and IS 
Injection 
number 
Peak area ratio Caffeine retention 
time (min)  
IS retention time 
(min) 
1 0.028 3.327 3.321 
2 0.029 3.312 3.315 
3 0.025 3.287 3.307 




Mean  0.027 3.301 3.314 
SD 0.002 0.018 0.005 
Precision 
(CV%) 
6.4 0.5 0.2 
 
4.3.7.6 Stability 
Bench top stability of caffeine solutions was tested using the lowest spiking standard 
concentration in replicate (n=5). The peak area obtained from the analysis of freshly 
prepared spiking standard was compared to those stored at room temperature for a 
period of 48 hours. The difference in peak area between stored and fresh solutions was 
2.8% (CV, 1.3%) indicating caffeine stability at 22°C for at least 48 hours.  
The stability of caffeine within DBS samples and extracts (in-process stability) has been 
demonstrated at room temperature (section 4.2.7.6). An important, additional 
consideration is the effect of drying and storage temperature on the stability of caffeine 
in DBS samples. To investigate the effect of temperature 15 µl blood spots were applied 
in replicate (n=5) to FTA Elute paper using blood spiked with caffeine at concentrations 
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of 500 and 25000 ng/ml. Samples were immediately transferred to an oven set to 30°C 
or left to dry at 22°C. Following a period of 48 hours under these storage conditions, 3 
mm discs from DBS samples were extracted and resulting peaks area ratios were 
compared. The difference in peak area ratio at concentrations of 500 and 25000 ng/ml 
was -1.1% and 9.5%, respectively (Table 4.11). This provides assurance of analyte 
stability at warmer temperatures likely to be experienced where sample collection and 
drying will take place.     
Table 4.11 Stability of caffeine in DBS following drying and storage at 30°C for 48 
hours n=5  
Nominal conc. (ng/ml) 500 20000 
 22°C 30°C 22°C 30°C 
Peak area ratio (mean) 0.04 0.04 1.17 1.28 
SD 0.007 0.002 0.151 0.068 
CV% 18.9 6.1 12.9 5.3 
% Difference -1.1 +9.5 
 
4.3.7.7 Caffeine red blood cell association 
Caffeine exhibits relatively low plasma protein binding, mainly to albumin (Blanchard, 
1982). In-vitro investigations have shown a constant unbound concentration with 
increasing caffeine concentration indicating the suitability of plasma for PK studies 
(Blanchard, 1982). The drug enters RBCs but does not bind to cellular constituents 
there, freely moves between RBCs and plasma and has a blood-to-plasma ratio equal to 
1 (Poulin and Theil, 2009, Rowland and Emmons, 2010). The factors that can affect PK 
interpretation when using whole blood (e.g. RBC partitioning) would therefore not be 
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expected to affect caffeine. Based on these drug distribution kinetics either plasma or 
blood should be a suitable matrix for performing PK studies. As the blood-to-plasma 
ratio is 1 a comparison between plasma and DBS caffeine PK data is possible without a 
prior need to convert drug concentration values.   
4.3.8 Clinical validation 
4.3.8.1 Patients and method 
The validated caffeine DBS LC-MS method was applied to samples collected from two 
healthy non-smoking (NS) adult volunteers (1 male, 1 female) following the ingestion 
of a single 100 mg oral caffeine dose. Prior to caffeine administration individuals were 
asked to abstain from dietary sources of caffeine for at least two weeks. Replicate (n=2) 
15 µl capillary blood samples were collected following a finger-prick before caffeine 
administration and thereafter at intervals of 0.5, 1, 2, 4, 6, 12 and 24 hours post dose. 
Each 15 μl blood sample was collected into separate EDTA coated capillary tubes and 
immediately spotted onto FTA Elute paper. Samples were left to dry at room 
temperature for at least 2 hours prior to storage.  
Patient samples were analysed alongside a freshly prepared caffeine DBS calibration 
line. Measured concentrations for each patient were fitted individually to a one 
compartment PK model within NONMEM (version 7.0) with a GNU Fortran Compiler 
95. Post processing of NONMEM data was undertaken with PDx-POP (version 4.0, 
ICON Development Solutions, USA) and Microsoft Excel 2007 (Microsoft 
Corporation, USA).     
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4.3.8.2 Pharmacokinetic profile in adults 
The DBS concentration-time profiles for patient 1 and 2 along with the model 
predictions are shown in Figures 4.12 and 4.13, respectively. A one compartment model 
with first order oral absorption and elimination fit the data well. First order absorption 
with lag time was required to capture the absorption phase for patient 2. The absorption 
rate constant (Ka) was fixed to 12 h
-1 
(Shi et al., 1993). No detectable caffeine levels 
were present in DBS samples collected prior to caffeine administration. Results from 
previous studies demonstrate caffeine exhibits rapid and complete absorption when 
administered orally with peak plasma levels achieved within 30 to 90 minutes for most 
individuals (Newton et al., 1981). Similarly, peak DBS levels were reached within 30 to 
60 minutes in both patients. The PK parameter estimates for CL and V for patients 1 
(male) and 2 (female) are presented in Table 4.12. They are in agreement with Joeres et 
al who reported a mean plasma CL and V of 1.43 ml/min/kg and 0.51 l/kg, respectively, 
in adults (Joeres et al., 1988). The CL and V estimates obtained were also comparable 
to other previous PK reports for caffeine in plasma (Table 4.13). A higher CL estimate 
was obtained for patient 1 compared to patient 2 (2.02 versus 1.31 ml/min/kg) which 
may in part be explained by gender related differences since there is evidence to suggest 
increased activity of the key enzyme responsible for caffeine metabolism, cytochrome 
P450 1A2 (CYP1A2), in males (Ou-Yang et al., 2000). A relatively small caffeine dose 
of 100 mg was used in the current study, however, a comparison of PK parameters with 
reported studies was possible as caffeine is known to obey first order kinetics, at least 
up to a dose of 750 mg (Newton et al., 1981). The similarity of the DBS concentration-
time profiles and PK estimates to those obtained in plasma demonstrate the suitability of 
the DBS method for application to PK studies.  
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Figure 4.12 DBS concentration-time profile for patient 1 following the ingestion of 
100mg of caffeine. The solid line represents the model predicted PK profile. 
 
 
Figure 4.13 DBS concentration-time profile for patient 2 following the ingestion of 








































































Table 4.12 DBS estimates of caffeine clearance, volume of distribution and half life 













   
V (l/kg) 0.74 0.58 
   
a
t1/2 (h) 4.2 5.1 
 
a.                    .   
 
Table 4.13 A comparison of plasma caffeine PK estimates reported in the literature 














t1/2                    
(h) 
 





Dose 50 mg 
 
 
1.12 ± 0.30 
 
0.35 ± 0.1 
 
5.7 
     
(Joeres et al., 1988) 7 NS adults 
Dose 366 mg 
 
1.43 ± 0.54 0.51 ± 0.13 4.8 
     
(Kaplan et al., 1997) 12 adults 
(10 NS) 
Dose 250 mg 
2.07 ± 0.40 0.58 ± 0.03 3.9 
     
 
(Seng et al., 2009) 
 
14 NS adults 
Dose 3mg/kg 
 
1.81 ± 0.67 
 




a. NS = non smoker 
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4.3.8.3 Incurred sample reanalysis 
There are differences between liquid plasma and DBS samples which may be of 
importance for incurred sample reanalysis (ISR). Plasma represents a homogenous 
sample from which serial analyses are possible. In DBS analysis, the sample is usually 
only used once and therefore necessitates the collection of replicate spots at each time 
point. These could be viewed as separate samples and raises questions on the 
reproducibility and quality of capillary blood sampling for PK determinations. 
To assess the accuracy of caffeine measurements in DBS samples collected from 
patients 1 and 2 a repeat analysis was performed. This involved the analysis of a second 
spot alongside a fresh calibration line (for 9 out of 14 samples) 3 weeks after the 
original analysis. Differences from the original results were within the ± 20% limit of 
the original concentration measurement providing confidence in the reliability and 
reproducibility of the developed method (Fast et al., 2009). However, higher 
concentrations were measured in all repeat DBS samples giving a positive bias (Figure 
4.14). Investigations into analytical errors due to incorrect preparation of stock solution 
and calibration standards were made but could not account for the positive bias 
observed. A possible explanation may be the blood collection method used to obtain 
samples from patients. The initial droplet of blood was not wiped away prior to the 
collection of DBS samples. Therefore it is possible that the first spot collected was 
diluted by the presence of tissue fluid resulting in lower caffeine concentration 
measurements. The reanalysis of a larger number of samples would enable a more 




Figure 4.14 Results from the reanalysis of DBS samples from patient 1 and 2. 
Differences calculated as: (repeat – original / mean)   100.  
4.4 Comparison of analytical techniques for caffeine DBS quantification  
The accuracy (RE%) and precision (CV%) results for LC-MS and LC-MS/MS methods 
(Table 4.14) were within the accepted validation criteria of less than 20% at the LLOQ 
and below 15% at all other tested concentrations. Linearity was observed with a 
weighted 1/x
2
 regression up to a DBS concentration of 25000 ng/ml for both methods 
(mean r
2 
= 0.9960 and 0.9970 with method 1 and 2, respectively). A better detection 
sensitivity was however achieved with LC-MS/MS (250 ng/ml vs. 500 ng/ml) despite 
the comparatively smaller amount of caffeine analysed on column (injection volume 3 
µl vs. 10 µl). TurboIonSpray
®
 (a form of electrospray) enables the use of higher flow 
rates whilst maintaining detection sensitivity. In addition, depending on the compound 
under study, improved sensitivity due to more efficient ionisation has been noted with 































Measured caffeine concentration (ng/ml) 
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observed could therefore be attributable to better ionisation of caffeine in the 
TurboIonSpray
®
 source. A more efficient detection system in the newer GSK 
instrument is also likely to have contributed to this difference. Both formic acid and 
ammonium acetate are recommended for the improvement of ionisation when using MS 
based techniques (Maurer, 1998). A simple isocratic elution method with water 
containing formic acid (mobile phase A) and acetonitrile (mobile phase B) was chosen 
for the LC-MS analysis of caffeine. An alternative mobile phase additive such as 
ammonium acetate may have improved the detection sensitivity by improving 
molecular ion formation but was not investigated.  
The dosing protocol at the Leicester NICU for AOP is 10 mg/kg of caffeine base as the 
loading dose followed by a 2.5 mg/kg once daily maintenance dose. Previously reported 
population PK studies in neonates which incorporated a similar dosing strategy would 
suggest that the LLOQ achieved with LC-MS/MS and LC-MS detection are 
approximately 10 and 5 fold, respectively greater than the lowest caffeine concentration 
(~ 2500 ng/ml) expected during the treatment period (Lee et al., 1997, Lee et al., 2002). 
Therefore a sufficient degree of sensitivity is afforded by either quantification method 
for application to caffeine PK studies or TDM in neonates.  
There were no significant interferences at the retention time of caffeine and IS in any of 
the control DBS chromatograms for either method indicating the selectivity of the 
developed analytical techniques. LC-MS/MS techniques are often preferred due to their 
inherent selectivity. The results obtained here indicate the potential of SIM and SRM in 
providing a selective method for the quantification of caffeine within DBS samples 
under the sample preparation conditions used. Results from the matrix effect experiment 
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suggested significant ion suppression from the FTA Elute paper itself and demonstrate 
the importance of understanding the source and extent of matrix effects. Matrix effects 
have been shown to be dependent on the ionisation source design (Mei et al., 2003) but 
a comparison between LC-MS (Agilent) and LC-MS/MS (Sciex) instruments was not 
possible as a matrix effect evaluation was not carried out during LC-MS/MS method 
development. 
Table 4.14 Chromatographic and mass spectrometer settings for in-house (method 1) 
and GSK laboratories (method 2) caffeine DBS methods 
 Method 1 (LC-MS) Method 2 (LC-MS/MS) 




Zorbax Eclipse Plus C18 150 
mm x 2.1 mm i.d., 3.5 m  
 
Synergi Fusion C18 50 x 3.0 
mm i.d., 4 µm 
 






Mobile phase A 
 
0.13% formic acid in water 
 
10 mM ammonium acetate 
(pH 8) in water 














Elution and run time 
 
Isocratic (82% A: 18% B) 
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195 m/z (caffeine) 
198 m/z (IS) 
 
SRM precursor ion [M+H]
+
 to 
product ion transitions: 
 195 to 138 m/z (caffeine)  





Method transferability is an important issue when transferring methods across 
laboratories and to other analysts. Although it is expected that a cross-validation should 
be performed in these circumstances there is currently no specific criteria on how this 
should be performed or which experiments should be included (Viswanathan et al., 
2007). The extent of validation required will depend on the differences likely to be 
encountered as well as whether there will be a change in the analytical technique 
altogether. At least in situations where a method is transferred to a different analytical 
instrument (or mode of detection) it is clear a complete validation would be necessary. 
To determine the transferability of the caffeine DBS method developed at GSK to an 
LC-MS instrument validation experiments were focused on linearity, selectivity, 
sensitivity, accuracy, precision and matrix effects. The validation results suggest assay 
performance to regulatory validation criteria, highlighting the robustness of DBS 
analysis and transferability of the technique to simpler MS detection methods and 
different laboratories. Further assessment of method transferability would involve the 
simultaneous analysis of patient samples on the LC-MS and LC-MS/MS instrument. 
Although this was not done, application of the developed LC-MS method to samples 
collected from two adult volunteers demonstrated the successful application of the DBS 
technique.  
A simple and sensitive DBS LC-MS/MS method for caffeine quantification has been 
developed at GSK laboratories. Requiring only a 15 µl blood sample for quantification 
the method is compatible with the blood sampling restrictions which apply to neonates. 
The flexibility in blood volume spotted (10 to 20 µl) helps to maintain simplicity in the 
blood collection procedure. Long term stability under simplified room temperature 
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conditions has been demonstrated. In addition, caffeine is stable within DBS samples at 
elevated temperatures likely to be encountered during the drying process. Results from 
the validation of the DBS method, however, suggest variability in haematocrit to be a 











Chapter 5  





5.1 Introduction  
Caffeine is a highly water soluble compound (Log P = -0.091), displays limited plasma 
protein binding and does not accumulate or bind to constituents of RBCs (blood-to-
plasma ratio = 1) (Blanchard, 1982, Poulin and Theil, 2009, Rowland and Emmons, 
2010). As previously discussed, additional factors such as haematocrit and blood cell 
partitioning that need to be considered when interpreting whole blood derived PK data 
therefore should not be a concern here. In the absence of PK related issues, caffeine is a 
suitable test drug for performing a clinical validation of DBS analysis for drug 
quantification in PK studies involving neonates. Furthermore, caffeine has been 
extensively studied in neonates thereby enabling a DBS versus plasma comparison to be 
made (Aldridge et al., 1979, Aranda et al., 1979b, Gorodischer and Karplus, 1982, 
Thomson et al., 1996, Falcão et al., 1997, Lee et al., 1997, Lee et al., 2002, Charles et 
al., 2008).  
5.2 Study aim 
The aim of this study was to clinically evaluate the reliability of DBS analysis as a 
method for generating PK data in neonates, and to identify any practical issues 
associated with developing a population model based on DBS samples in a busy clinical 
unit. For this purpose DBS samples were prospectively collected from preterm neonates 
receiving caffeine therapy for AOP. Concentrations of caffeine within samples were 
determined using the LC-MS/MS quantification method in Chapter 4 (section 4.2). A 
non-linear mixed effects approach was used to develop a population PK model based on 
DBS caffeine measurements and estimate PK parameters and their variability. Model 
evaluation techniques were used to determine the robustness of the final DBS model 
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and the accuracy and precision of population mean parameter estimates. At this stage a 
comparison was made between DBS derived PK parameter estimates and reported 
plasma PK data in neonates.  
5.3 Patients and study protocol 
5.3.1 Patients       
Patients were recruited from within the University Hospitals of Leicester NHS Trust 
NICUs. All infants on the NICUs treated with caffeine for AOP were eligible for study 
inclusion on the provision of informed written consent from their parents or guardians 
(Appendix IV). Exclusion criteria included congenital or chromosomal abnormalities, 
cardiac arrhythmia, hypoxic ischaemic encephalopathy, sepsis, grade 3 or 4 cerebral 
haemorrhage, evidence of renal or hepatic damage or if the clinical team for any reason 
considered inclusion unsuitable. The study was approved by the Trent NHS Research 
Ethics Committee, the Research and Development Department at University Hospitals 
of Leicester NHS Trust and De Montfort University Research Ethics Committee. 
5.3.2 Study design 
Infants recruited onto the study received oral or IV caffeine base as directed by the 
clinical team and unit protocol. A caffeine loading dose of 10 mg/kg followed by a 2.5 
mg/kg once daily maintenance dose was administered to patients. The maintenance dose 
was increased at the discretion of the clinical team in the event of increased apnoeic 
episodes. The length of caffeine therapy is variable and in some infants can continue for 
several weeks. The sampling design was unstructured and DBS samples were collected 
opportunistically at random time intervals post caffeine administration. Between 1 and 
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10 (replicate 15 μl, n=3) DBS samples were planned for collection from each neonate 
during caffeine treatment. In order to define the terminal phase of caffeine elimination 
DBS samples where possible were also collected after the discontinuation of treatment. 
The total volume of blood removed from each infant for the entire study period did not 
exceed 0.45 ml (10 x 45 µl) and records of the volume of blood removed were kept on a 
daily basis for each patient for the duration of the study. The sampling process involved 
the collection of blood (either capillary, venous or arterial) into an EDTA coated 
capillary tube with a suction bulb attached at one end. A separate capillary tube was 
used to collect each 15 μl blood sample. Capillary blood collection was performed as 
outlined in Chapter 3 (section 3.3.3). On occasions of blood collection from arterial or 
venous sampling sites, blood was initially drawn into a syringe without anticoagulant by 
clinical staff. Blood samples for the study were collected into capillary tubes directly 
from the syringe. Samples were immediately spotted within the designated area onto 
FTA Elute paper. An example of a typical DBS card collected from study patients is 
shown in Figure 5.1. It was estimated that approximately 250 DBS samples from 50 
patients (average of 5 samples per patient) would be required to develop a robust 
population model of caffeine PK. Accurate caffeine administration and DBS sampling 
information was recorded for each patient on a case report form (Appendix V). 
Demographic data was collected for each infant from medical notes. Clinical data (if 
available from tests ordered by the clinician) were recorded for days on which DBS 
samples were collected.  
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5.3.3 Sample storage and analysis 
Samples collected were left to dry on an elevated drying rack for a minimum of 2 hours 
in a dedicated room on the NICU. Once dried samples were placed in sealable plastic 
bags containing desiccant and transferred to the Child Health Laboratories at the 
University of Leicester for storage at room temperature until analysis. All DBS samples 
were transported via courier delivery to GSK laboratories (Ware, UK) where caffeine 
bioanalysis was performed as described in Chapter 4 (section 4.2). Concentrations of 
caffeine were determined from a single spot per card using the equation generated from 
a DBS calibration line analysed alongside the patient samples.  
 
Figure 5.1 An example of a DBS card collected from a patient during the study. 
Replicate (n=3) 15 μl blood samples collected for a single time point. 
5.4 Pharmacokinetic and statistical analysis 
5.4.1 Non-linear mixed effects modeling 
Non-linear mixed effects modeling was performed within NONMEM (version 7.0) 
using the First Order Conditional Estimation method with a GNU Fortran Compiler 95. 
Data generated by NONMEM was processed using PDx-POP (version 4.0, ICON 




Austria) and Microsoft Excel 2007 (Microsoft Corporation, USA). Using this approach 
it is possible to estimate population mean PK parameters, the interindividual variability 
(IIV) in these parameters as well as the interoccasion variability (IOV). NONMEM also 
enables the estimation of the residual error which is the difference between the observed 
and model predicted concentrations. In the initial stages of the model building process 
one and two compartment models were fitted to all data. The most suitable structural 
model was identified using statistical criteria (OFV, i.e. -2 log likelihood difference) 
and examination of graphical goodness of fit and residual error plots. Initial estimates of 
PK parameters were obtained from a reported population PK model in neonates 
(Charles et al., 2008). Caffeine is known to be rapidly and completely absorbed when 
given orally and thus for oral doses bioavailability was assumed to be 100% (Giacoia et 
al., 1989, Charles et al., 2008). Sufficient post dose samples were not available to 
support the estimation of the rate of caffeine absorption and therefore Ka was fixed to 
4.0 h
-1
 on the basis of previous PK reports (Falcão et al., 1997). Varying the value of Ka 
did not affect the goodness of fit of the concentration data at early time intervals 
following oral dosing and thus the chosen value was considered to be suitable. IV doses 
of caffeine (administered over 5 minutes) were duration modelled using a fixed value of 
0.08 h. An initial analysis was conducted by permitting NONMEM to estimate the base 
model parameters. Clinical and demographic covariates were subsequently tested within 
the base model to identify patient characteristics which improved the goodness of fit of 




5.4.2 Interindividual and interoccasion variability 
The IIV in CL and V was modelled using an exponential error model in which 
differences between an individual and the population (ηi) are assumed to be log 
normally distributed. Exponential error models are advantageous as they avoid negative 
parameter estimation which can occur with additive error models. Deviations of caffeine 
CL and V for the ith individual from the population mean values were estimated as 
follows: 
CLi = TVCL.e
(ηi,CL + Κj,CL) 
Vi = TVV.e
(ηi,V + Κj,V) 
CLi and Vi = Estimated parameters in the i
th
 individual on the j
th
 occasion. 
TVCL and TVV = Population mean values for CL and V predicted by the 
regression model, respectively.  
ηi,CL and ηi,V = Random variables, which are normally distributed with 
variance, ω
2
, mean 0 and represent the difference between an individual and the 
population in CL and V, respectively. , Falcão et al., 1997 
 
Ignoring IOV in population models can result in biased parameter estimates (Karlsson 
and Sheiner, 1993). As samples were collected over several dosing occasions the 
inclusion of an error model to account for variability in PK parameters on different 
occasions (i.e. from one day to the next) was investigated. IOV in PK parameters was 
modelled exponentially as suggested by Karlsson and Sheiner, where Κj,CL and Κj,V 
are random variables which represent the variability in CLi and Vi estimates on j 
occasions for an individual, respectively (Karlsson and Sheiner, 1993). An occasion was 
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defined as a dose or sequential doses followed by at least one observation. There were a 
median of 4 (range 1 to 10) occasions. Κj,CL and Κj,V were assumed to be normally 




V, respectively. The IOV 




V) was assumed to be sampled from the same 
sampling distribution.  
5.4.3 Intraindividual variability 
The residual variability was evaluated using additive, proportional and combined error 
models.  
Additive model:    Cij = Ĉij + ε1,ij 
Proportional model:                    Cij = Ĉij . (1 + ε1,ij) 
Proportional and additive model: Cij = Ĉij . (1+ ε1,ij) + ε2,ij 
Cij = The jth observed concentration in the ith individual 
Ĉij = The jth model predicted concentration in the ith individual.  






5.4.4 Covariate analysis 
The regression model was developed within NONMEM using a forward inclusion 
backward elimination method (Wählby et al., 2002). The OFV (-2LL) was used to test 
for statistical significance. The difference in OFV value between two models (one 
nested in another) approximates a chi squared distribution, with the degrees in freedom 
being the difference in the number of parameters. During the forward inclusion step for 
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models which differed by one parameter a drop in the OFV of greater than 3.84 which 
corresponds to a p value 0.05 was considered as statistically significant. All biologically 
plausible continuous and categorical covariates were tested one at a time in the base 
model and the change in OFV noted. Other criteria used to discriminate between two 
models included the interindividual variance (ω
2
), residual variance (σ
2
), precision in 
parameter estimation, precision in estimates of coefficients (95% confidence intervals 
for estimates do not contain 0) and improvement in goodness of fit plots. All significant 
covariates identified were incorporated into the base model to produce a full model. The 
backward elimination step was performed by removing each covariate one at a time to 
determine its influence within the model. Covariates which failed to show statistical 
significance were deleted from the model. A change in the OFV of 7.81 corresponding 
to a p value of 0.005 was required at this stage for covariates to be kept in the final 
model.     
5.4.5 Model validation 
Model validation is an important component of the model development process. Since 
there is no right or wrong model the subjectivity associated with model development 
also extends to the validation process. As such there is no single test or series of tests 
for determining the validity of a model and in practice a range of methods have been 
used (Guidance for Industry: Population Pharmacokinetics 1999). Although there is 
currently no consensus on the statistical approach that constitutes a validated model the 
method and extent of validation should be based on the purpose for which the model 
was developed and its intended use (Guidance for Industry: Population 
Pharmacokinetics 1999). Internal validation techniques involve resampling from the 
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original data set used to build the model and are particularly useful for paediatric studies 
where patient numbers are limited and there is no test data set available. External 
validation techniques require an additional data set but provide the most stringent 
method for evaluating the predictive performance of a model (Sun et al., 1999). The 
purpose of the current model was to estimate PK parameters and describe the variability 
in caffeine disposition. The model was not intended for predictive applications or dose 
adjustment recommendations and thus an internal validation technique with 
bootstrapping was used to test the developed final model. With bootstrapping it is 
possible to calculate the precision, bias and confidence intervals of parameter estimates 
(Parke et al., 1999). The method entails the generation of a series of new datasets of 
equal size to the original dataset by sampling individuals with replacement from the 
original dataset. The final model is then fitted to each dataset and the distribution of 
parameter estimates examined for bias and precision. Validation was performed using 
500 datasets within PDx-POP (version 4.0, ICON Development Solutions, USA).  
5.5 Results 
5.5.1 Demographics of study patients 
A total of 67 patients over a 10 month period were recruited onto the study from which 
384 DBS samples were collected. The demographic characteristics of the study 
population are presented in Table 5.1. The study group consisted of preterm infants all 
born at less than 33 weeks gestation (24.6 - 32.7 weeks) with equal numbers of males 
and females. The PNA on the day of study enrolment varied significantly (range, 1 - 
69), but the majority of patients were recruited within the neonatal period (Figure 5.2). 
Patient weight was recorded at each sampling time point and whenever infants were 
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weighed on the unit between sample collection times. Figure 5.3 shows the distribution 
of weights recorded for patients on the day of study enrolment. Except for a single 
patient, all preterms were of low weight (< 2 kg), approximately 20% of which were 
very low weight (< 1 kg). The only maternal covariate collected was smoking status 
during pregnancy and was obtained from medical notes. Clinical covariate data is 
presented in section 5.5.3.  
Table 5.1 Characteristics of 67 preterm neonates 
  
Patient characteristics Mean (± SD, CV%) and range 
Sex 33 Males          34 Females 
Gestational age (weeks) 29.0 (± 1.9, 6.7%)                                 
24.6 - 32.7 
Postnatal age on day of study inclusion (days) 9.7 (± 12.2, 125.1%)                                 
1 - 69  
Postmenstrual age on day of study inclusion 
(weeks) 
30.4 (± 2.1, 7.1%)                                        
25.4 - 37.1 
Postnatal age at end of study (days) 31.3 (± 18.2, 58.1%)                                       
7 – 79 
Birth weight (kg) 1.25 (± 0.34, 27.2%)                               
0.6 - 2.01 
Weight on day of study inclusion (kg)  1.26 (± 0.34, 27.3%)                               
0.65 - 2.5  
 Number of patients 
Ethnicity                                                                    
White                                                                       
Indian                                                                    
African-Caribbean                                                 
Other 
                                                                       
50                                                            
10                                                                    
2                                                                        
5                                                                            




















































5.5.2 Dried blood spot sampling and caffeine measurements 
Recruited patients received a mean caffeine loading dose of 10.1 mg/kg (range 9 - 12.5 
mg/kg) followed by a once daily mean maintenance dose of 2.8 mg/kg (range 1.4 - 7 
mg/kg) orally or intravenously (Table 5.2). Of the 384 DBS samples collected by 
researchers and clinical staff trained in the DBS technique, approximately 10% (40 DBS 
samples) did not meet the minimum standard of quality required for drug quantification 
and were not analysed. A further 6 DBS samples all collected several days after caffeine 
had been discontinued were determined to be BLOQ and were omitted from the data 
set. Therefore a total of 338 DBS caffeine concentration measurements from 67 patients 
were available for the PK analysis. Between 1 and 10 (mean, 5.6; mode, 5) DBS 
samples were collected from each patient over a mean study period of 21.6 days (Figure 
5.4). DBS samples were collected following 245 enteral and 93 IV doses of caffeine. 
The times of DBS collection post caffeine administration are shown in Figure 5.5. 
Samples were collected at a range of post dose intervals which is necessary for the 
estimation of PK parameters, CL and V. For most patients a DBS sample was collected 
after the discontinuation of caffeine, but none were collected prior to the start of 
treatment. Most blood samples (297) were collected following a capillary heelstick 
procedure. A small number of blood samples were collected from venous (27) and 
arterial (13) sites for patients with catheters in situ. Caffeine DBS concentrations 
determined via LC-MS/MS analysis (Chapter 4, section 4.2) ranged between 2780 to 
43045 ng/ml in patients during treatment (Figure 5.6) (Appendix VI).   
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Table 5.2 Caffeine dosing and DBS sampling information 
Dosing and sampling information Mean (range) 
Caffeine dose Loading: 10.1 mg/kg (9 - 12.5 mg/kg) 
Maintenance: 2.8 mg/kg (1.4 - 7 mg/kg) 
Total length of caffeine treatment (days) 28.2 (6 - 65)  
Day of caffeine therapy on study 
enrolment 
8.4 (1 - 47) 
Study participation (days) 21.6 (1 - 61) 
Number of samples per infant 5 (1 - 10) 
a
Concentrations measured in DBS 
samples (ng/ml)                                            
16124 (665 - 43045) 
Concentrations measured in DBS 
samples during treatment (ng/ml)                                           
 
16475 (2780 - 43045) 
                   

































Figure 5.6 Caffeine concentrations measured in DBS samples collected from patients 















































































DBS caffeine concentration (mg/l) 
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5.5.3 Clinical covariate data 
Clinical covariate data recorded with each DBS sample included haematocrit, albumin, 
creatinine, feeding regimen and co-medications. Caffeine disposition has been shown to 
be affected by the feeding method used and therefore information was collected on the 
type of enteral feeding received (formula, breast milk or a combination) and parenteral 
nutrition status (Falcão et al., 1997, Blake et al., 2006). During the study 106 (33%) 
samples were collected from patients receiving parenteral nutrition. The types of enteral 
feeds received by patients are shown in Figure 5.7. The majority of samples (n=195, 
58%) were collected from infants who were receiving breast milk. A smaller number 
were collected from patients on formula feeds or a combination of formula and breast 
milk. Significant variability in haematocrit (mean, 34%; range, 21 - 58%) was observed 
in the study population (Figure 5.8). As expected, the highest values were observed in 
the youngest neonates and a general decrease in haematocrit was observed with 
increasing PNA. A wide range of albumin concentrations were recorded for patients 
(mean, 30.9 g/l, range, 20 - 41 g/l) but correlations with age (GA, PNA or PMA) could 
not be detected (Figure 5.9). Patients received between 1 and 12 (mean 4) co-
medications. A single patient was prescribed phenobarbitone, but no other known 
inhibitors or inducers of caffeine metabolism were identified. Medications most 
frequently prescribed to the study population (> 15%) were benzylpenicillin, 


















































Figure 5.9 Albumin concentrations (g/l) measured in each patient 
 
5.5.4 Pharmacokinetic analysis  
5.5.4.1 Base model 
All caffeine DBS concentration measurements (n=338) were allocated to the 
development of the PK model. Residual analysis and the OFV were used to assess 
goodness of fit in the structural model selection process and discriminate between 
different error models. A one compartment model resulted in a better fit of the data 
(OFV, 6135 units) compared with a two compartment model (OFV, 8822 units) and was 
therefore chosen to fit the DBS concentration-time data. An oral absorption model 
(Figure 5.10) with direct input of IV doses into the central compartment was used to 
enable the simultaneous analysis of DBS concentration data collected following oral 


























            
     
                        
         
 
Figure 5.10 Structural model of the PK of caffeine: an oral absorption model with 
direct dose input into central compartment for IV doses.  
 
The model assumes first order oral absorption for oral doses, zero order infusion for IV 
doses and first order elimination from the central compartment. Bioavailability (F) and 
Ka were fixed with CL and V parameters to be estimated. Both additive and combined 
error models were found to be suitable for modeling the residual error. In the selected 
base model residual variability was modelled using an additive residual error model and 
IIV and IOV were modelled using exponential error models. The inclusion of IOV in 
CL significantly reduced the OFV (from 6135 to 6020 units) and reduced the residual 
variance, but an IOV on V could not be estimated. The base model converged 
successfully to give initial population mean estimates of 9.1 ml/h (CV%, 4.6) and 767 
ml (CV%, 7.9) for CL and V, respectively. 
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5.5.4.2 Covariate model 
Scatter plots of covariates versus individual Bayesian parameter estimates were 
examined to aid in the identification of factors which may have an influence in the 
model. These plots were also used to identify the likely nature of the covariate-
parameter relationship (linear or non-linear) and derive initial numerical estimates of 
coefficients and exponents. A correlation between CL and weight (r
2 
= 0.28) as well as 
PNA (r
2 
= 0.21) was evident (Figure 5.11). A positive correlation between weight and V 
was also observed.  
Covariate-PK parameter correlations are not always evident from the visual examination 
of scatter plots and thus all biologically plausible covariates were tested in the base 
model. During the forward selection process the effect of the continuous covariates 
weight, age in various forms (GA, PNA and PMA) and albumin were tested in the V 
model. Continuous and categorical covariates screened for influence on CL estimation 
included weight, age, albumin, creatinine, urea, haematocrit, feeding regimen, sex, 
ethnicity and maternal smoking status. Current weight resulted in the largest drop in 
OFV (14 units) in the V model followed by PMA and albumin. In the CL model, weight 
(58 units) and age (PNA, 74 units; PMA, 56 units) resulted in the largest drop in OFV. 
Haematocrit, parenteral nutrition and albumin were also identified as significant 
covariates for CL. After the inclusion of weight on CL and V, PMA was no longer 
statistically significant on either PK parameter. However, PNA was still a significant 
covariate for CL. At this stage GA was formally tested as a dichotomised variable in the 
CL model with patients divided into two groups; those born at less than 28 weeks (very 
premature infants) and greater than 28 weeks gestation. No improvement in the fit of the 
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data resulted from the inclusion of GA. The full model which consists of the base model 
with all statistically significant covariates incorporated is shown in Table 5.3.  
During the backward elimination process only weight and PNA were found to be 
significant covariates in the CL model, whereas weight alone was the only covariate 
influential in the V model which was demonstrated by an increase in OFV of > 7.84 
units when either of these covariates was removed from the model. Figure 5.12 shows 
the distribution of weighted residuals before and after the inclusion of weight as a 
covariate in the CL model. Before the inclusion of weight a systematic deviation in the 
residuals could be seen with an under prediction at low weights and over prediction at 
high weights. Following the inclusion of weight an improvement was observed with 
residuals more evenly distributed around the zero ordinate. Similarly the systematic 
deviation in the differences between the population mean and individual CL estimates 
(ETAs) were no longer apparent after modeling the effect of weight on CL (Figure 
5.13).  
Other covariates which were significant in the base model during the initial (forward 
selection) screening process did not show significance even at a p value of 0.05 (change 
in OFV of 3.84) after the inclusion of weight and PNA. As a final check each covariate 
in the final model was removed one at a time and the reduced model was tested for 















































Figure 5.11 Scatter plots of individual Bayesian estimates of CL versus weight (A), 





































Table 5.3 Covariate model development; the effect of covariates in the determination 










6020.391   Base model (no 
covariate influence)  
CL = f(WT, PNA, HAEM, ALB, PN) 
V = f(WT, ALB) 
5904.203  p < 0.005 Full model 
 
CL = f(WT, PNA, HAEM, ALB) 
V = f(WT, ALB) 
5905.093 ↑ 0.890 p < 0.005 PN does not affect 
CL 
CL = f(WT, PNA, HAEM) 
V = f(WT, ALB) 
5905.874 ↑ 0.781 p < 0.005 ALB does not affect 
CL 
CL = f(WT, PNA) 
V = f(WT, ALB) 
5908.920 ↑ 3.046 p < 0.005 HAEM does not 
affect CL 
CL = f(WT) 
V = f(WT, ALB) 
5923.642 ↑ 14.722 p < 0.005 PNA does affect CL 
CL = f(PNA) 
V = f(WT, ALB) 
5946.290 ↑ 37.371 p < 0.005 WT does affect CL 
CL = f(WT, PNA) 
V = f(WT) 
5909.877 ↑ 0.957 p < 0.005 ALB does not affect 
V 
CL = f(WT, PNA) 
V  
5934.938 ↑ 25.061 p < 0.005 No covariate 
influence on V 
WT does affect V 
a. Change in objective function (-2 log likelihood) resulting from the removal of individual 
covariates from the model. Assuming a chi squared distribution, a change in OFV of 7.84 units 
(p < 0.005) was accepted as statistically significant. 









Figure 5.12 Scatter plot of weight versus conditional weighted residuals before (A) 









































































Figure 5.13 Scatter plots of weight versus ETA (η,CL), the difference between an 
individual and the population mean in CL before including weight as a covariate (A) 



































5.5.4.3 Final model 
The final PK model is shown below where CL (theta 1, θ1) is modelled as a function of 
weight and PNA, and V (θ2) is modelled simply as a function of weight alone. θ5 to θ7 
are exponents and coefficients for the covariate influences on PK parameters. Covariate 
effects centred on median weight and age resulted in the most numerically stable 
covariate models in NONMEM. It was possible to model the influence of weight on 
parameters linearly and non-linearly using a power equation with little difference in the 
resulting drop in OFV. A power model was chosen due to their purported biological 
basis for relating physiological processes such as CL and V to size (weight) (Mordenti 
et al., 1991). The relationship between PNA on CL could be modelled linearly and 
exponentially. A larger drop in the OFV with better precision in estimating covariate 
influence was possible using a linear equation and was therefore used in the final model.  
The final PK model: 
                 
  
    
 
  
                    
              
  




                  
                               





V) in the OMEGA matrix of the NONMEM output and 
expressing the value as a percentage: 
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The IOV in CL was similarly calculated by taking the square root of the variance 
component (π
2
CL) in the OMEGA matrix. Residual variability was calculated by taking 
the square root of the residual variance estimate (σ
2
) in the SIGMA matrix of the 
NONMEM output to give the SD. Table 5.4 summarises the influence of each covariate 
addition on the population variability in CL and V. The addition of weight as a 
covariate into the base model resulted in a decrease in the IIV in CL and V from 30.1% 
to 26.1% and 50.5% to 43.4%, respectively. The incorporation of PNA in the CL model 
did not reduce the interindividual variance and therefore explain any of the population 
variability in CL but was kept in the final model as it provided an improvement in the 
OFV. Although CL was influenced by body weight the covariate only described 25% of 
the interpatient variability. Weight as a covariate accounted for 20% of the IIV in V. A 
reduction in the IOV from 41.1% to 34.1% and 31.4% was observed following the 
inclusion of weight and PNA, respectively on CL. 
The final structural and random error model parameter estimates along with their 
associated precision (CV%) are presented in Table 5.5. The precision (CV%) of 
parameter estimates was calculated by dividing the standard error of the parameter 
estimate by its value and expressing the ratio as a percentage as shown below (Grasela 
and Sheiner, 1991): 
                         
                              
                  




Table 5.4 Effect of covariates on objective function value and random effect variables 
(IIV, IOV and residual error).  
















CL = θ1 


















     
CL (ml/h) = θ1   (WT/1.28)
θ5 
V = θ2 
 
 
26.1 _ 34.1 1863  5962.291 
CL (ml/h) = (1+θ7   (PNA-15)) 
V = θ2 
 
 





     
V (ml) = θ2   (WT/1.28)
θ6
  
CL = θ1 
 
 





     
CL (ml/h) = θ1   (WT/1.28)
θ5
   
(1+θ7   (PNA-15)) 






24.7 45.7 31.2 1764  5909.877 
a. Objective function value (-2 log likelihood). 
The population mean PK estimates for CL and V were 8.6 ml/h (range 2.4 - 30.1 ml/h) 
and 774 ml (range 214 - 1654 ml), respectively. Both CL (CV%, 4.0) and V (CV%, 7.9) 
were estimated within the acceptable precision limit of less than 20 - 25% which has 
been suggested for fixed effect parameters (Ette et al., 1993, Ette et al., 1998). The 
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estimated exponents for weight on CL (0.79) and V (1.03) were very close to the 
physiologically based values of 0.75 and 1 which have been used to relate weight to PK 
parameters (Mordenti et al., 1991, Anderson et al., 2000). Fixing the exponents in the 
final model to these theoretical values did not affect parameter estimation or improve 
the precision of estimates or the fit of the data. As the estimate of the exponent for 
weight on V was essentially 1, the correlation between weight and V is effectively 
reduced to a simple linear relationship (V = θ2  (WT/1.28)). The exponents for weight 
on CL (CV%, 17.7) and V (CV%, 24.9) were estimated with reasonable precision. 
Estimation of the coefficient for PNA on CL was associated with the highest 
imprecision (CV%, 32.9). This may have been due to the relatively small number of 
patients studied in relation to the large variability in PNA (1 - 69 days) amongst study 
participants. The population IIV in CL and V and IOV on CL was estimated with a 
precision (CV%) of 25.0%, 44.2% and 22.5%, respectively. The additive residual error 
was estimated with a precision (CV%) of 23.7%. The error (SD, 1.76 mg/l) associated 
with prediction of caffeine concentrations expressed as a percentage of the mean 
caffeine concentration (16.5 mg/l) measured during treatment was 10.7%. Despite the 
relatively high imprecision in estimating IIV in V all random effects parameters were 
estimated within the accepted 50% limit (Ette et al., 1993). 
Scatter plots of conditional weighted residuals (CWR) against final model predicted 
concentration (A), time after last dose (B) and patient ID (C) are shown in Figure 5.14. 
CWR were randomly and symmetrically distributed around the mean (zero ordinate, 
line of unity) with no systematic deviations in predicted concentration indicating the 
suitability of the error model chosen. Similar CWR were observed according to time of 
sampling indicating suitability of the structural model. Most residuals were within ± 2 
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SD of the mean and thus the model enabled an adequate description of caffeine PK. The 
histogram presented in Figure 5.15 also shows weighted residuals were randomly and 
evenly distributed with a mean of 0 in the final model. The relationship between the 
population and individual model predicted and observed DBS concentrations are shown 
in Figure 5.16. Simulations using individual parameter estimates for selected patients 
presented in Figure 5.17 demonstrate the goodness of fit between model predicted and 
observed concentrations. Goodness of fit plots between model predicted and observed 
concentrations for all patients are presented in Appendix VII. 
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Fixed effect parameters (structural model                                                                           
& covariate model)  
θ1 CL 8.6 ml/h  4.0 
θ2 V 774 ml 7.9 
θ3 Ka 4.0 h
-1 
Not estimated 
θ4 Duration (IV bolus) 0.08 h Not estimated 
θ5 Exponent for WT on CL 0.786 17.7 
θ6 Exponent for WT on V 1.030 24.9 
θ7 Coefficient for PNA on CL 0.013 32.9 
c
Random effects parameters                                                                                      
(Variance model) 
 IIV ωCL  24.7 %  25.0 
 IIV ωV  45.7 % 44.2 
 IOV ΚCL  31.2 % 22.5 
Random effects parameter                                                                                         
(Residual error model) 
 σ, additive (SD)  1.76 mg/l  23.7 
 
a. Final model: CL (ml/h) = 8.6   (WT/1.28)0.786   (1 + 0.013   (PNA-15)) 
V (ml) = 774   (WT/1.28)1.03.  
b. Standard error / parameter estimate   100 = CV%. 
c. (Variance)
0.5
   100 = % variability in population. 













































































Figure 5.14 Diagnostic goodness of fit plots of conditional weighted residuals versus 
(A) model predicted concentration, (B) time after dose and (C) patient number. For 
each plot the dotted line represents perfect agreement (line of unity).    
 
                          


























































Figure 5.16 Goodness of fit plots for observed versus population model predicted 












































































Figure 5.17 Predicted DBS caffeine concentration-time profiles (―) and observed 





























































5.5.4.4 Model validation 
During the bootstrap validation 94% of (500 replicate) NONMEM runs minimised 
successfully indicating stability of the final population model. The bootstrap parameter 
estimates and 95% confidence intervals generated by fitting the final model to 500 
datasets randomly constructed with replacement are shown alongside the final model 
parameters estimated from the original dataset in Table 5.6. The bootstrapped structural 
model parameters (CL, V and coefficients) and random effects parameters closely 
agreed with respective values from the final model (differences < 6%) indicating the 
robustness of the final model. Furthermore all parameter estimates were within the 
bootstrap generated 95% confidence interval. The precision associated with estimation 
of the residual error was higher in the bootstrap results (23.7% vs. 39.8%) but still 
acceptable. For all other parameters the precision was comparable between the bootstrap 
and final model results. These results indicate that the developed model is robust and 
has good stability. 
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Table 5.6 A comparison of nonparametric bootstrap estimates with original estimates 
Parameter NONMEM                      
(original)          







 Estimate CV% Estimate CV%   
Fixed effects          
CL ml/h 8.6  4.0 8.6 4.1 0.07 7.9 - 9.3 







Ne - - 
Duration (IV bolus) h 0.08  Ne 0.08  Ne - - 
Exponent for WT on 
CL 
0.786 17.7 0.784 18.9 0.17 0.504 - 1.090 
Exponent for WT on 
V 
1.030 24.9 1.031 29.0 -0.15 0.524 - 1.700 
Coefficient for PNA 
on CL 
0.013 32.9 0.014 36.3 -5.29 0.005 - 0.025 
       
b
Random effects        
IIV ωCL  24.7 % 25.0 24.5 % 30.9 0.58 15.7 - 31.6 
IIV ωV  45.7 % 44.2 43.9 % 45.5 3.88 22.0 - 62.1 
IOV ΚCL  31.2 % 22.5 30.1 % 28.4 3.30 18.5 - 37.7 
       
Random effects 
Residual error σ, 












1.36 - 2.78 
 
Ne = Not estimated 
a. % bias = (final model estimate - bootstrap estimate) / final model estimate  100. 
b. Estimates given as CV%. 
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5.6 Comparison of pharmacokinetic model with plasma data 
Several traditional (Aranda et al., 1979b, Gorodischer and Karplus, 1982, Le Guennec 
et al., 1985) and population studies (Thomson et al., 1996, Falcão et al., 1997, Lee et 
al., 1997, Lee et al., 2002, Charles et al., 2008) have been conducted to investigate the 
plasma PK of caffeine in neonates. As such caffeine PK has been well characterised in 
this age group and a selection of reported studies are shown in Table 5.7. For 
comparative purposes three large prospective population studies were chosen (Table 
5.8) (Thomson et al., 1996, Lee et al., 1997, Charles et al., 2008). There were 
differences in the maturity (GA and PNA) of patients in each study, the treatment dose 
and methods of sample collection and bioanalysis. The comparison was possible as 
linear disposition kinetics have been observed in neonates for caffeine doses up to at 
least 30 mg/kg (Lee et al., 1997). In each of these reported studies a one compartment 
model was also found to be the most suitable for modeling caffeine disposition in 
neonates. The plasma PK estimates are compared alongside estimates obtained in the 
current study in Table 5.9. The population mean CL value of 7.3 ml/h/kg determined in 
the current study is very close to the average estimates of 7.9 ml/h/kg and 7.0 ml/h/kg 
reported by Thomson et al and Charles et al, respectively. The lower CL (4.9 ml/h/kg) 
reported by Lee et al may be due to the lower PNA (4 days, range 2 - 15) of the patients 
studied since age has been shown to be positively correlated with caffeine CL both in 
the current and previous studies. The mean V determined in the current study of 593 
ml/kg was lower than the values of 970 ml/kg, 640 ml/kg and 851 ml/kg previously 
reported. The lower V may be due to the changes which occur in the extracellular fluid 
(ECF) compartment with age. Neonates have an increased volume of ECF relative to 
total body water compared with infants and adults which can lead to higher distribution 
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volumes for drugs such as caffeine which readily distribute throughout the body. The 
ECF gradually decreases with PNA and can fluctuate with the relative humidity of the 
environment (Kearns et al., 2003). Although the mean PNA of the study group was only 
9.7 days on study entry, by study exit this had increased to 31.3 days. It is noteworthy 
that the lowest literature V estimates (of 640 ml/kg and 781 ml/kg) were reported in 
studies involving relatively more mature neonates (Gorodischer and Karplus, 1982, 
Thomson et al., 1996). Thus, differences in population demographics as well as patient 
care may account for the lower V in this study compared to published data. A smaller V 
would also account for the comparatively lower mean caffeine half life (57 h) estimated 
in the current study.  
On comparison of the random effects variables, the IIV in CL (24.5%) was similar to 
that reported by Lee et al (25.0%), Thomson et al (20.0%) and Charles et al (18.8%). 
The IIV in V (45.7%) however, was significantly higher than previous reports of 11%, 
24.3% and 18.8%. This may have been a consequence of the limited (< 1%) DBS 
samples collected following the loading dose (and hence the distribution phase) in the 
present study. This contrasts to comparative studies where samples were collected at 
random time intervals following the loading dose for each patient. The precision 
associated with the estimation of IIV in V (44.2%) in the current study was similar to 
that reported by Lee et al (47.4%). The precision associated with parameter estimates 
were not reported in the other two studies. The IOV in CL was similar to that 
determined in the study by Charles et al (31.2 vs. 35.1%). Although the IOV was greater 
than the IIV in CL in the present study, this was not as pronounced as previously 
observed where an almost two fold difference was noted. The additive residual 
variability (SD, 1.8 mg/l) was slightly higher than that reported in the study by Charles 
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et al where the residual variance was modelled using a combined additive and 
proportional error model (σ1, 0.9 mg/l; σ2, 6.0 CV%). The absence of an error model to 
account for IOV in structural parameters as well as differences in bioanalytical methods 
may have contributed to the larger residual error reported by Lee et al and Thomson et 
al (3.9 mg/l and 2.5 mg/l, respectively).
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Table 5.7 Reported plasma PK studies for caffeine in neonates 
 
CL, V and t1/2 estimates are expressed as mean values unless otherwise indicated; ― = not reported. 
a. Median value reported. b. Estimates were normalised to weight using the mean study group weight. 
C = capillary; V = venous; PNA = postnatal age; GA = gestational age.  
Reference Sample size Sampling site PNA          
(days) 
GA           
(weeks) 
CL              
(ml/h/kg) 
V       
(ml/kg) 
t1/2        
(h) 




11.5 28.5 8.9 916 103 
(Charles et al., 2008) n=110 
 







(Gorodischer and Karplus, 1982) n=13 
 
C 6.5 30.6 8.5 781 65 
(Lee et al., 1997) n=89 C 4.0 28.2 4.9 970 144 
(Lee et al., 2002) n=18 
 









23 31.0 7.9 640 ― 
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Table 5.8 A comparison of the current study design with three selected population PK studies 
Study information Current study                                                 Study I                       
Lee et al., 1997  
Study II           
Thomson et al., 1996 
Study III                    




9.7 (1 - 69)  
29.0 (24.6 - 32.7)  
1.26 (0.65 - 2.50) 
4.0 (2 - 15)  
28.2 (24 - 31)  
1.17 (0.57 - 2.31) 
a
23 (1 - 100) 
― 
a
1.3 (0.6 - 2.9) 
12 (1 - 45) 
27.5 (24 - 29) 
0.99 (0.66 - 1.86) 
Study duration  1 - 61 days ≤ 7 days  ― ≤ 7 days  
Dose & sampling 10 mg/kg (L), 2.5 mg/kg (M)  
Opportunistic, random 
sampling design                 
338 DBS samples             
Mean 5 (range 1 - 10) time 
points per patient 
30, 15 or 3 mg/kg (L), 15, 7.5 
or 1.5 mg/kg (M)               
Pre-randomized sampling 
times                                  
430 capillary blood samples 
Mean 5 (range 3 - 6) time 
points per patient 
10 mg/kg (L), 2.5 mg/kg 
(M)                              
Once weekly sampling      
186 blood samples          
a
3 (range 1 - 13) time 
points per patient 
40 or 10 mg/kg (L), 10 or 2.5 
mg/kg (M)                         
Pre-randomized sampling 
times                                     
431 venous blood samples 
Mean 4 (range 1 - 8) time 
points per patient 
Bioanalysis 15 µl DBS sample              
LC-MS/MS                   
LLOQ, 0.25 mg/l  
Serum (250 µl blood)          
LC-UV                          
LLOQ 0.2 mg/l 
Serum (―)                     
Enzyme immunoassay 
LLOQ, 1 mg/l  
Plasma (2 ml blood)      
Enzyme immunoassay 
LLOQ, 0.1 mg/l  
 
Values given as mean and range unless otherwise indicated; ― = Not reported; L = loading dose; M = maintenance dose.                                                                                                                                          
a. Median value reported. b. Postmenstrual age of study group was 31 weeks (median), range 25 - 41 weeks.            
206 
 
       Table 5.9 A comparison of the final model parameter estimates with reported 1 compartment PK models for caffeine in plasma 
Parameter Current study, n=67 Study I, n=89 
Lee et al., 1997 
Study II, n=60 
Thomson et al., 1996 
Study III, n=110 













7.3 (2.3 - 16.9) 
 
593 (174 - 1005) 
 





4.9 (2.3 - 9.0) 
 
970 (740 - 1400) 
 

















7.0 (1.6 - 22.56) 
 
a
851 (365 - 1761) 
 
a
101 (24.5 - 371) 
Interindividual variability (IIV) 
  
CL (CV%) ωCL 
 































Interoccasion variability (IOV) 
 
CL (CV%) ΚCL 
 



























Residual error  
 
σ1, additive (mg/l) 
 
























Estimates of CL, V and t1/2 are given as the mean and range unless otherwise indicated; ― = Not reported.                                                                        
a. Median value reported.  
b. Standard deviation reported.
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5.7 Influence of haematocrit on final model 
Patient haematocrit varied significantly amongst the study group (n=253, 21 - 58%). 
The majority of these values (92%) were within the experimentally investigated 
haematocrit range of 20 to 45% for which a negative bias of approximately 30% was 
determined for caffeine measurements using DBS analysis (Chapter 4, section 4.2.7.3). 
In order to determine the potential impact of this systematic assay bias on PK estimation 
a sensitivity analysis was conducted by normalising caffeine measurements according to 
haematocrit. On the assumption patient samples were analysed alongside a calibration 
line of haematocrit 45%, using the equation generated from the regression of assay bias 
(at the 1000 ng/ml level) against haematocrit the likely bias incurred and thus the 
correction factor required was calculated (Chapter 4, section 4.2.7.3). Of the 253 
haematocrit measurements available only 138 were recorded on days for which a DBS 
sample was collected. Therefore it was only possible to adjust 138 out of 338 DBS 
caffeine concentrations according to haematocrit level. It was assumed that the 
remaining 200 caffeine concentration measurements were unaffected by assay bias. The 
final model with haematocrit normalised caffeine concentrations was re-run within 
NONMEM. The PK parameter estimates obtained are presented in Table 5.10 along 
with the original estimates from the final model. The results from this analysis indicated 
a decrease in CL (8.6 vs. 7.9 ml/h) and V (774 vs. 722 ml). A decrease in the 
unexplained interindividual variability in V was observed and the residual error 
increased from 1.76 mg/l to 2.82 mg/l. All other PK parameters were comparable and a 




Table 5.10 Influence of patient haematocrit on final population PK model  
Parameter Final model Model incorporating 
normalised caffeine 
concentrations (n=138/338) 
Fixed effects Estimate CV% Estimate CV% 
θ1 CL 8.6 ml/h  4.0 7.9 ml/h 4.1 
θ2 V 774 ml 7.9 722 ml 6.0 





θ4 Duration (IV bolus) 0.08 h Ne 0.08 h Ne 
θ5 Exponent for WT on CL 0.786 17.7 0.745 18.4 
θ6 Exponent for WT on V 1.030 24.9 0.917 29.1 
θ7 Coefficient for PNA on 
CL 
0.013 32.9 0.010 60.0 
a
Random effects parameters                                                                                      
(Variance model) 
  
 IIV ωCL  24.7 %  25.0 25.4 % 24.7 
 IIV ωV  45.7 % 44.2 34.8 % 44.1 
 IOV ΚCL  31.2 % 22.5 26.6 % 30.6 
Random effects parameter                                                                                         
(Residual error model) 
 σ, additive (SD) 1.76 mg/l  23.7 2.82 mg/l 24.5 
 
Ne = Not estimated 





The primary aim of this study was to clinically evaluate the use of DBS analysis for PK 
parameter estimation and to identify potential problems associated with developing a 
population model based on DBS samples in a neonatal population. A total of 338 DBS 
samples were available from 67 preterms neonates for the development of the 
population model. The whole blood caffeine concentrations measured varied widely 
(2780 to 43045 ng/ml) despite study infants being on relatively similar maintenance 
doses of caffeine (1.4 - 7 mg/kg). A wide range in plasma caffeine concentration (2500 
to 49900 ng/ml) has also been reported by Lee et al following the administration of 
maintenance doses of 1.5 and 7.5 mg/kg (Lee et al., 1997). The DBS concentration data 
is therefore comparable to caffeine plasma levels which have been measured in patients 
which received similar maintenance doses to those in the current study. The modeling 
analysis showed a one compartment model adequately described the DBS 
concentration-time course of caffeine and enables the estimation of primary PK 
parameters CL (CV%, 4.0) and V (CV%, 7.9) with relatively good precision. The DBS 
dataset supported the precise estimation of the population variability in PK parameters 
and the residual variability. It was also possible to model the interoccasion variance in 
CL for the population.  
A relatively large amount of clinical and demographic data was collected during the 
study to enable a thorough investigation into potential covariate effects which may be 
important in explaining the variability in caffeine CL that exists in neonates. Smoking 
status and ethnicity are significant covariates in adults, but were not found to be 
determinants of caffeine CL in neonates (Parsons and Neims, 1978, Landi et al., 1999). 
Genetic factors alone determine around 72.5% of the variability in activity of CYP1A2, 
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the key enzyme involved in caffeine metabolism in adults (Rasmussen et al., 2002). 
Bimodal and trimodal polymorphic distributions in CYP1A2 activity have been 
identified in adult populations (Butler et al., 1992). These types of covariate-parameter 
relationships may be difficult to detect in neonates due to the slow maturation of the 
CYP1A2 enzyme and the presence of developmental changes in renal function which 
predominate. Very low to absent CYP1A2 expression has been found in the foetal and 
neonatal liver (Cazeneuve et al., 1994). Postnatally, around 4 - 5% of adult levels of 
CYP1A2 activity have been observed in neonates with progressive increases to 10 - 
15% of adult levels by the age of 1 to 3 months (Sonnier and Cresteil, 1998). Adult 
levels of enzyme activity are not reached until beyond one year of age. Three major 
metabolites theobromine, paraxanthine and theophylline have been measured in the 
urine of adults following a caffeine dose with less than 2% of the dose recovered 
unchanged (Burg, 1975). In contrast, as much 85% of an administered caffeine dose has 
been measured in the urine of neonates in its unchanged form (Aldridge et al., 1979). 
The predominance of a renal clearance pathway in neonates, which is less efficient 
compared with hepatic metabolism, would provide some explanation of their markedly 
increased caffeine half life compared to adults (Blanchard and Sawers, 1983). 
Significant changes in renal development occur during the postnatal period in term and 
preterm neonates. The GFR in the full term neonate is 35% of the adult value (Rhodin et 
al., 2009). A large increase in the GFR occurs in the first two postnatal weeks in term 
and preterm neonates, thereafter it continues to increase until about one year of age to 
adult capacity (Rhodin et al., 2009). In preterms, the maturation of renal function also 
depends on GA and therefore PMA (GA and PNA) is considered to be the best 
parameter of renal immaturity in neonates and infants (Rhodin et al., 2009). In the 
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current study PMA provided no improvement in the fit of the data or a reduction in the 
interindividual variance term after the inclusion of weight. This is surprising given the 
range in GA (24.6 to 32.9 weeks) and PNA (1 to 69 days) of the study group. The 
addition of PNA age however, significantly improved the fit of the data. This is in 
agreement with other population models where weight and PNA were also found to be 
the two most influential covariates for estimating CL (Lee et al., 1997, Charles et al., 
2008). Although a large variability in haematocrit and albumin was noted amongst 
study patients, these covariates were not determined to have an influential effect on the 
final model. However, this may not be true for other drugs. 
The form of nutrition received by infants has previously been linked to the rate of 
CYP1A2 maturation. Blake et al reported accelerated CYP1A2 expression in infants 
receiving formula feeds compared with breast milk evidenced by higher levels of 
urinary CYP1A2 caffeine metabolites (Blake et al., 2006). Significantly higher caffeine 
CL values have also been reported in neonates receiving parenteral feeds in a previous 
population PK study (Falcão et al., 1997). A structural parameter–covariate relationship 
has similarly been demonstrated for theophylline indicating that parenteral nutrition 
may interfere with the elimination or metabolism of methylxanthine drugs (Moore et 
al., 1989). Other PK studies which have looked for an influence of feeding regimen on 
CL including the present could not identify any correlation. Caffeine is known to be 
present in appreciable amounts in breast milk, but unfortunately DBS samples were not 
collected prior to starting caffeine treatment and therefore it was not possible to assess 
pre-dose caffeine concentrations. In a previous large population study 80% of neonates 
had detectable pre-dose caffeine concentrations which ranged between 0.2 to 5.1 mg/l 
(mean, 1.2 mg/l) (Lee et al., 1997). No maternal covariate data on timing and amount of 
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caffeine consumption were collected in the present study but given the large number of 
DBS samples obtained from infants receiving breast milk it is likely that this will have 
contributed to the residual error of 1.8 mg/l.  
On comparison with literature data, the PK parameter estimates derived from DBS 
measurements were found to be in good agreement with plasma values reported in 
previous population studies in neonates. These findings would suggest that the blood-to-
plasma ratio for caffeine is 1, which is indeed the case, and, importantly, implies that 
interpretation of PK data from DBS and plasma samples is interchangeable. To assess 
the potential impact of the observed systematic assay bias from haematocrit effects on 
the final PK model, a sensitivity analysis was performed. Given the negative assay bias 
observed when changing from 45 to 20% haematocrit a decrease in primary PK 
estimates is predictable, and this was observed with an 8.9% and 7.2% decrease in 
estimates of CL and V, respectively (Table 5.10). A decrease in the IIV in V of 23.9% 
was also observed suggesting differences in haematocrit between patients also has the 
potential to significantly inflate the estimated between subject variability. The poorer 
predictive capability of the adjusted model (residual error, 1.76 vs. 2.82 mg/l) is likely 
to have arisen due to the partial normalisation of the dataset. A disadvantage of the 
modeling approach used is that only a fraction of the data set was normalised (138 of 
338 data points) and therefore differences in PK estimates from the final model are 
likely to be an under prediction of the true impact of bias arising from variability in 
haematocrit. Despite this limitation, these results demonstrate the potential for 
haematocrit to significantly affect PK parameter estimation and will be important for 
analysts to consider during method development and certainly before reporting DBS 
concentration measurements for PK analyses.  
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During the bioanalysis of patient samples, whole blood for the preparation of calibration 
standards was ethically obtained from healthy adult female volunteers. Although a 
haematocrit measurement of the donated blood was not taken at the time, considering 
the normal haematocrit range for females, it would have been reasonable to assume an 
average level of 40%. Under these circumstances, based on the relationship observed 
between haematocrit and assay bias, a less pronounced negative systematic bias on PK 
parameter estimates would be expected. The sensitivity analysis was however, 
performed on the assumption of a 45% haematocrit level. This was done to test the 
robustness of the final model to the effects of haematocrit and to account for the 
possibility of a higher adult blood haematocrit. Based on the assumption patient samples 
were analysed alongside a 45% haematocrit calibration line, and taking into account the 
results of the sensitivity analysis as well as the average haematocrit for the study group 
(34%), it is likely for systematic assay bias to have affected the estimation of CL and V 
parameters by 10 to 20%. Factoring this bias into the DBS derived caffeine PK 
estimates, the results from this study are still comparable to reported plasma data. 
The data generated here has little impact on clinical practice as the caffeine dose has 
been well established and clinicians in the UK generally treat infants according to 
therapeutic response and not therapeutic drug levels. In the treatment of AOP, caffeine 
levels between 5000 and 20000 ng/ml are generally considered therapeutic with some 
infants requiring higher levels of up to 40000 ng/ml to effectively treat apnoeic episodes 
(Natarajan et al., 2007). Therefore for the majority of patients, concentrations of 
caffeine were attained within therapeutic levels (Figure 5.6). Considering the IOV in CL 
determined in this study and elsewhere, dose adjustment recommendations used on the 
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basis of plasma caffeine levels by some units may be of limited value (Charles et al., 
2008).  (Wieling and Tump, 2004) 
The results of this study provide important data on the practicality of DBS analysis and 
the problems likely to occur during the sample collection process in a clinical 
environment such as the NICU. The feasibility of the method was reflected by the 
number of DBS samples collected, the high sample accrual rate and the large percentage 
of these which met the standard of quality required for drug quantification (90%). The 
high success rate would suggest that this technique is relatively simple and can be 
performed with minimal training in a busy clinical unit. A 10% loss of data may 
however, be significant in situations where there are limited patient and sample 
numbers. Reasons for poor quality samples included visually apparent coagulation, 
decentred spots (which includes the printed circle on FTA Elute paper), application of 
spots too close to each other resulting in merged samples, insufficient sample and 
capillary tube indentation marks on the sample surface from an incorrect blood spotting 
technique. The provision of adequate practical training in the DBS technique will thus 
be crucial in minimising the percentage of samples collected below the standard of 
quality required. There is a greater risk of blood coagulation as the duration of capillary 
blood collection increases. Therefore it is possible for the use of an opportunistic blood 
sampling method to have contributed to the collection of coagulated DBS samples.  
DBS analysis provides a potential solution to the blood sampling difficulties 
encountered in PK studies. However, the methodology will only be useful if it is well 
accepted by parents and clinical staff. A qualitative study aimed at determining parental 
and healthcare professional acceptability of the DBS method was carried out alongside 
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the caffeine PK study. Although this was not the focus of this thesis the outcomes from 
the study will provide important information on the design and conduct of how best to 
perform PK or PK-PD studies in neonates in the future. Preliminary data based on the 
percentage of parents approached who consented to the study (~93%) and sample 
accrual rate during the PK study would suggest DBS to be an acceptable method of 
blood collection in neonates. Similarly, a high percentage (6 out of 7, ~85%) of parents 
approached during the dexamethasone PK study consented to study participation. 
5.9 Conclusion 
The results from this study indicate that DBS analysis is a technique with significant 
potential as a robust method for drug quantification in neonatal PK studies. The PK 
interpretation of DBS data and comparison with reported plasma estimates were 
simplified by the distribution kinetics of caffeine in whole blood. Therefore the use of 
DBS would need to be considered in the context of the behaviour of a candidate drug 
with respect to RBC association and protein binding. The results from this study also 
demonstrate that DBS sampling within the context of an opportunistic sampling design 
is an accepted and feasible approach for performing PK studies in neonates, and 
potentially older age groups. There is clearly a greater potential for problems with assay 
bias when using DBS analysis. To minimise any adverse effects on PK parameter 
estimation, analytical issues such as filter paper related haematocrit effects will need to 

















6.1 General discussion 
The ability to accurately and precisely measure drug levels from micro blood volumes is 
an important stepping stone to understanding drug pharmacology and deriving 
scientifically based dosing regimens in neonates and children. However, there are a 
number of factors associated with DBS that have potential to affect the accuracy of drug 
measurements. For the developed dexamethasone and caffeine DBS quantification 
methods results from in-vitro validations demonstrate an accuracy, precision and 
selectivity in accordance with the requirements of current regulatory FDA guidelines. 
On testing for the robustness of the DBS assays to haematocrit effects, both drugs were 
found to be sensitive to changes in haematocrit. This was most noticeable for caffeine 
where a relatively small change in haematocrit (5%) resulted in a significant bias (RE%, 
18.4% at 1000 ng/ml level). This suggests that for some drugs, even small fluctuations 
in blood haematocrit of ± 5% which are generally considered to be normal in healthy 
adults would need to be considered when developing DBS based methods (Hillman et 
al., 2005). A regression of the relationship between haematocrit and bias (RE%) to a 
polynomial function provided a good fit indicating potential for modeling the effect of 
haematocrit on caffeine assay bias. The equation generated formed the basis of 
investigations undertaken to assess the effect of systematic measurement noise on PK 
parameter estimation. This may be a useful method of normalising caffeine 
concentration data prior to PK data analysis. A disadvantage is that it introduces an 
additional variable and a validation would be necessary to determine whether a 
correction within acceptable accuracy is possible across the calibration range of the 
assay. The accuracy of blood haematocrit readings can vary significantly between 
different instruments and therefore this would need to be considered during 
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investigations (Al-Odeh et al., 1994). Furthermore, correction for the influence of 
haematocrit this way would be difficult to achieve in neonates since haematocrit tests 
are not carried out on a daily basis on the NICU and would thus necessitate additional 
blood collection. The difficulty in correlating haematocrit effect to assay bias has 
previously been highlighted and therefore the use of a correction factor to account for 
varying haematocrit amongst study patients will not be a universal approach (Denniff 
and Spooner, 2010a). 
For compounds which show an unacceptable bias within the haematocrit range expected 
in a study population, a more practical solution may be through modification of the 
sampling method so that an accurate blood volume is spotted onto filter paper with a 
subsequent extraction of the entire spot. The approach has been reported in TDM for 
drugs including chloroquine and lumefantrine with adequate precision and accuracy 
(Blessborn et al., 2007, Lejeune et al., 2007). Drug quantification now becomes 
independent of changes in distribution of blood or drug on filter paper. However, the 
flexibility around the blood volume collection afforded by the current approach is no 
longer possible and the degree of skill with which samples must be collected and 
spotted is increased. This may be less feasible in a clinically orientated environment. An 
additional concern is that it may not be possible to collect the full volume required on 
each sampling occasion which would impact on the sampling success rate. An 
alternative approach may be to investigate different filter paper types as haematocrit 
effects have been shown to be compound and paper dependent (Denniff and Spooner, 
2010a). Recently, a non-cellulose based blood collection paper has been reported with 
consistent spot homogeneity and minimal changes in spot size (11%) with haematocrit 
changes from 20 to 80% (Ritu et al., 2011). This may provide a practical way of 
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overcoming haematocrit effects for some drugs whilst maintaining flexibility in the 
blood collection process.   
The degree to which the DBS calibration line reflects concentrations measured in the 
patient is also important, particularly in patient groups where the average haematocrit 
level may be significantly different to the haematocrit of healthy adult blood used to 
produce the calibration line. For dexamethasone, an adjustment of the calibration line to 
35% haematocrit was incorporated into the methodology to reflect the average 
haematocrit value expected in patients as well as to limit assay bias arising from 
interindividual variability in haematocrit. For caffeine an adjustment of the calibration 
line to the average haematocrit (34%) measured for the patient group would not have 
been more suitable due to the large interindividual variability in haematocrit (Chapter 5, 
section 5.5.3). When the assay bias is outside the recommended ± 15% limit there is an 
increased potential to affect PK parameter estimation as demonstrated with caffeine 
(Wieling and Tump, 2004). Analytical issues related to DBS such as haematocrit can be 
overcome, but will need to be carefully considered.  
A limiting factor in the use of DBS analysis for some compounds such as 
dexamethasone may be sensitivity. For drugs such as caffeine that are dosed on a mg/kg 
basis and have a relatively long half life, quantifying therapeutic drug levels will 
evidently be easier. For dexamethasone, alternate methods of sample preparation and 
detection will be necessary to adequately capture the PK profile in neonates. A problem 
with liquid extraction techniques are the large solvent volumes used compared with the 
volume of sample available. Some investigators have minimised losses in sensitivity 
through sample concentrator techniques which involve drying extracts to a residue 
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followed by reconstitution in a smaller volume of solvent before analysis (Christianson 
et al., 2010). Results from the investigation of sample drying and reconstitution 
methods for dexamethasone gave unacceptable precision values (CV% > 20) and further 
work is necessary to identify the reason for inconsistent drug recovery. Solid phase 
micro extraction has been suggested as a sample preparation method with potential to 
facilitate the quantification of drugs in micro volume fluids such as those handled in 
DBS (Millership, 2011). The technique involves the adsorption of analyte from either 
an aqueous or gaseous phase onto a fibre coating immobilised onto silica (Pawliszyn, 
2001). For thermally labile or non-volatile compounds, analyte concentrated on the 
fibred coating can be detected using LC-UV following desorption with a solvent 
volume which is very small compared with the sample volume (Kumar et al., 2008). 
The feasibility of this sample preparation methodology for the types of volumes in DBS 
sampling which are significantly lower compared with previous applications (1.5 ml 
blood) would need to be investigated (Szultka et al., 2010). Direct DBS surface 
sampling techniques such as the thin-layer chromatography mass spectrometer interface 
(TLC-MS) have been reported with the benefit of significantly higher detection 
capability (Abu-Rabie and Spooner, 2009, Loppacher et al., 2011). The TLC-MS 
interface is designed to elute DBS samples on-line into the LC-MS system with or 
without LC separation. Direct sampling techniques are associated with issues such as 
carryover, matrix effects and process efficiency which mean that they may not be a 
practical solution at present. However, considerable effort is being made on the 
development and improvement of automated methods which should facilitate the 
analysis of micro samples and encourage future widespread usage of DBS analysis. The 
use of an alternate MS detection system is a potential option for improving the current 
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dexamethasone sensitivity. An LC-MS/MS method has been reported in the literature 
which has enabled dexamethasone to be quantified in plasma to levels as low as 0.5 
ng/ml from a 50 μl plasma sample (Zhang et al., 2011). In this report separation was 
achieved using a shorter column (50 mm, flow rate 0.3 ml/min) and detection performed 
in SRM mode using an API 4000 triple quadrupole mass spectrometer with a 
TurboIonSpray
®
 source. A TurboIonSpray
®
 source due to a better dexamethasone 
ionisation efficiency has also been preferred by other analysts and combined with 
further investigations on a pre-column sample concentrator method may be very useful 
for improving detection capability (Samtani and Jusko, 2007).  
There are other important analytical aspects of DBS analysis that need to be addressed 
such as the stage of incorporation of the IS. The IS is used to account for variability 
during the extraction, chromatography and ionisation of an analyte. Like many previous 
reported DBS methods for practical reasons the IS in the present study was added to the 
extraction solvent used to reconstitute the DBS sample. Therefore the variability in the 
extraction method is not accounted for. A two stage approach has been suggested to 
overcome this problem (Liu et al., 2010). The first stage involves a reconstitution of the 
DBS sample in an aqueous liquid containing IS. In the second stage a liquid-liquid 
extraction is performed to recover the drug and IS using a water immiscible organic 
solvent, similar to the procedure used in plasma analysis. Alternate ways of introducing 
the IS at an earlier stage of the extraction process have been suggested and include 
impregnating the filter paper with IS and spraying the DBS specimen with IS 
(Christianson et al., 2010, Manicke et al., 2011, Zimmer et al., 2011). These methods 
would be very useful provided they are validated to show reproducibility and are 
sufficiently standardised to avoid operator dependent variability. Drying conditions, in 
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particular the effects of humidity have been identified as a factor with potential to affect 
the integrity of the DBS sample (Denniff and Spooner, 2010b). Denniff and Spooner 
reported on the effects of high humidity (81%) on FTA Elute, FTA and S&S 903 paper. 
On visual examination only the FTA Elute paper was found to be sensitive to the effects 
of high humidity with noticeable deterioration of both the DBS and paper. Although 
such an extreme in humidity would not have occurred on the NICU in the current study 
this may be an important variable in neonatal studies. The NICU environment is 
generally well controlled, but temperatures can be warmer (23 to 25°C) due to 
incubators, and fluctuations in room humidity (20 to 50%) have been reported with 
seasonal changes (Thomas et al., 2010). Both caffeine and dexamethasone were found 
to be stable under an elevated drying and storage temperature (30°C), but the stability of 
these compounds were not tested with respect to fluctuations in humidity. All FTA 
paper DBS samples were however, stored with desiccant after drying to protect samples 
from the effects of humidity. On visual examination, DBS samples collected during the 
study did not appear to be affected by humidity. Given the susceptibility of FTA Elute 
to humidity, this blood specimen collection paper may be the least preferred for use in 
future neonatal PK studies. Further work will be necessary to determine the effects of 
drying and storage humidity on analyte quantification within clinical environments such 
as the NICU. 
A great deal of work has been undertaken to evaluate and improve the DBS method for 
drug quantification but a major concern is the current variability in extent of validation 
performed in reported DBS methods and lack of consensus on what constitutes a 
validated DBS method. The development of guidelines specifically on the validation of 
DBS assays will be important so that analysts, pharmacokineticists and regulatory 
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agencies have confidence in DBS derived PK data. This has been acknowledged and 
progress to a more standardised DBS validation practice is now of interest to many 
analysts developing DBS methods (Abbott et al., 2010, Evans et al., 2010, Timmerman 
et al., 2011). 
During the caffeine study replicate (n=3)15 μl blood spots were requested for collection 
at each sampling opportunity to ensure sample availability in the event of bioanalytical 
problems which may necessitate a repeat sample analysis. This was possible on 77% of 
sampling occasions which indicates the feasibility of repeat sampling during 
opportunistic blood collection. The low blood volume (15 μl) required per spot was an 
important factor governing the success of replicate sample collection and therefore this 
volume should be kept as low as possible. A larger blood volume of 30 μl was collected 
for dexamethasone analysis to maximise detection sensitivity. This sampling 
methodology will need to be modified to increase the feasibility of replicate sampling. 
Using an accurate spotting method with a smaller blood volume of 15 μl with 
subsequent extraction of the entire spot will be helpful in minimising the loss in 
dexamethasone sensitivity. With changes in regulatory guidelines on the bioanalysis of 
drugs, ISR is now mandatory (Savoie et al., 2010). This involves the reanalysis of a 
percentage (5 to 10%) of the original study samples and therefore the collection of 
replicate DBS samples will need to be a standard practice. It is an important component 
of bioanalysis as it provides assurance on the precision and accuracy of the developed 
assay and can be used to test the robustness of repeat capillary DBS sample collection. 
A PK model can only be as good as the quality of drug concentration information 
provided and therefore it will be important to assess the reproducibility or quality of 
data obtained from capillary blood sampling. The experiences of ISR at GSK from 42 
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analyses would suggest DBS sampling and analysis is a robust method for drug 
quantification in PK studies (Barfield et al., 2011). ISR may be a concern where 
excessive squeezing is used to obtain a capillary blood sample or when the initial 
droplet of blood formed is not wiped away. On the repeat analysis of caffeine 
concentrations in DBS samples collected from adult volunteers, whilst all measurement 
were within ± 20% of the origin result a positive bias was observed which may have 
been due to contamination from interstitial fluids. This is less of a concern where an 
opportunistic blood sampling approach is used as the initial drop of blood thought to 
contain high levels of tissue fluids has been removed. Poor capillary blood flow can 
necessitate squeezing and in this situation there is therefore potential for contamination 
of the blood sample collected. There is at present a lack of data on the reproducibility of 
capillary blood sampling in neonates. The blood sampling method is as important as the 
method of bioanalysis and therefore further work including the reanalysis neonatal 
patient samples from the caffeine PK study will be important for providing assurance on 
the robustness of capillary blood collection in this age group. A potential problem that is 
specific to capillary DBS sampling in neonates is the use of petroleum jelly which could 
contaminate the sample collected. However, in-vitro experiments suggest that exposure 
to petroleum jelly did not affect dexamethasone or caffeine quantification by DBS 
analysis.  
There are alternative methods of blood collection and spotting that may be adopted to 
ensure a homogenous sample. For example, capillary blood may initially be collected 
into a blood collection tube containing anticoagulant, mixed and subsequently spotted 
onto filter paper using either a capillary tube or pipette. Alternatively a single large 
blood spot may be collected which allows ISR through repeat sub-sampling from 
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different areas of the DBS surface. This method is based on the assumption of an even 
distribution of drug across the entire DBS sample. However, differences in analyte 
distribution have been observed between peripheral and central locations and therefore 
sample homogeneity would need to be evaluated beforehand (Ren et al., 2010). A 








Haematocrit effect on filter paper  Normalise measured concentration using patient 
haematocrit 
 Alternative cellulose filter paper 
 Investigate non-cellulose paper 
 Accurate blood spotting with extraction of entire 
DBS sample 
 
Suitability of matrix used to 
prepare calibration standards 
 Adjustment of blood haematocrit (through 
addition or removal of plasma) to reflect average 
haematocrit of study population 
 Limit blood matrix dilution through addition of 
minimal drug spiking solution (<5%)  
 
Sensitivity  Optimise analyte recovery  
 Optimisation of sample clean-up procedure to 
remove matrix effects 
 Pre-column sample concentration 
 Investigate micro sample preparation techniques 
e.g. solid-phase micro extraction 
 Use an alternative instrument or detection system 
for quantitative analysis 
 Direct DBS surface sampling techniques e.g. 
TLC-MS 
 
Stage of IS incorporation  Impregnate filter paper with IS prior to blood spot 
collection 
 Spray IS on the surface of DBS sample prior to 
extraction 
 Two stage approach incorporating liquid-liquid 
extraction with an immiscible organic solvent 
 
Humidity and drying temperature  Perform in-vitro investigations under expected 
study conditions to assess appearance of sample 
and recovery of analyte 
 Storage of DBS samples in sealed plastic bags 
with desiccant 
 Drying and storage of samples in a well controlled 
environment 
 
Incurred sample reanalysis  Collect replicate DBS sample per time point 
 Use a single large DBS sample to allow replicate 
sub-sampling 
 Collect blood into a blood collection tube prior to 
blood spotting 
 
Use of creams or petroleum jelly 
during blood collection 
 Perform in-vitro validation to ensure chemical 




Considerations also need to be given to the implications of using DBS as an alternative 
matrix to plasma in PK studies (Table 6.2). Problems in PK interpretation could arise 
when the total blood (DBS) concentration does not reflect the unbound drug 
concentration due to changes in either haematocrit, blood-to-plasma ratio or protein 
binding (Emmons and Rowland, 2010). An example of a drug affected by haematocrit is 
tacrolimus, a hepatically cleared immunosuppressant. Tacrolimus exhibits a high 
affinity for RBC binding resulting in a whole blood-to-plasma ratio of greater than 50 in 
humans (Jusko et al., 1995). Alterations in albumin concentrations have negligible 
effects on the unbound to bound drug ratio, whereas high haematocrit levels are 
strongly correlated to low plasma concentrations due to increased RBC partitioning 
(Jusko et al., 1995, Chow et al., 1997). The total blood concentration does not change 
but the amount of (unbound) drug which is able to exert a pharmacological effect has 
changed. Under these circumstances a mechanistic approach to modeling PK data can 
result in assigning high blood concentrations to a low hepatic CL of tacrolimus when in 
fact the drug has accumulated in RBCs due to a high haematocrit and the intrinsic 
metabolic capacity of the liver has not changed. It may be argued that plasma levels 
should provide a better indicator of pharmacological events, but despite the problems 
with using whole blood it has been the preferred matrix for the TDM of tacrolimus in 
clinical practice (Hoogtanders et al., 2007b). This is largely due to the difficulty in 
measuring tacrolimus concentrations in plasma which are much lower than in whole 
blood and the temperature dependence of RBC binding which needs to be considered 
during the separation (centrifugation) process (Machida et al., 1991). Another reason 
whole blood is preferred is that sample haemolysis can significantly increase plasma 
concentrations thereby introducing assay bias.  
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Tacrolimus is an extreme example of the complications associated with using whole 
blood concentrations over plasma. It does however, highlight the potential for 
misinterpreting data if a drugs distribution kinetics are not adequately understood. This 
type of concentration dependent partitioning is most likely to be observed for 
compounds with a blood-to-plasma ratio > 2 (Rowland and Emmons, 2010, Phadnis et 
al., 2011). At the other end of the spectrum, for hydrophilic drugs (blood-to-plasma 
ratio = 0.55) that do not associate with RBCs, variability in partitioning is not a concern 
and the only additional variable to consider when using DBS is haematocrit.  
Neonates are amongst patient groups which display significant variability in 
haematocrit and albumin. Albumin concentrations are initially lower in neonates and 
show lower drug binding affinities compared with adults (Notarianni, 1990). Increases 
in albumin concentration from 20 g/l in 28 weeks gestation babies to approximately 30 
g/l in term babies have been shown. During the first 8 postnatal weeks the increase in 
albumin concentration continues at a similar rate (Cartlidge and Rutter, 1986, Reading 
et al., 1990). In addition, high levels of the foetal protein alpha-fetoprotein are observed 
in the neonates which is almost entirely replaced with albumin by the late neonatal 
period (Notarianni, 1990, Bader et al., 2004). Studies suggest the binding affinity of 
alpha-fetoprotein to drugs is lower than for albumin (Hirano et al., 1985). The changes 
which occur in protein composition and drug binding affinity continue in infants until 
about 1 year of age when levels of albumin and binding capacity are similar to adults 
(McNamara and Alcorn, 2002). Hyperbilirubinemia during the neonatal period adds to 
the variability in drug protein binding. The changes in haematocrit which occur during 
the first few months of life are also well known (Christensen et al., 2009, Jopling et al., 
2009). , Lugo et al., 1996) 
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Therefore the effect of protein binding and haematocrit on PK parameter estimation 
may need to be investigated; just as it has been important to show linear protein binding 
kinetics as a function of drug concentration for the measurement of drug in plasma. This 
is not necessarily an inhibitory factor for the use of DBS concentration measurements in 
neonates. Drug distribution kinetics in blood such as the blood-to-plasma ratio, red 
blood cell partitioning concentration dependency and protein binding at therapeutic 
concentrations can be studied in-vitro prior to the conduct of PK studies. Once the 
important variables have been identified and the magnitude of the effect characterised it 
may be possible to account for their influence on PK estimation by incorporation into 
the PK model. The use of patient haematocrit for example has been used to guide the 
therapeutic dosing of tacrolimus in paediatric renal transplant patients (Zhao et al., 
2009).  
To determine the factor most likely to influence changes in the total unbound to bound 
drug ratio of dexamethasone, investigations were focused on RBC association and the 
underlying concentration dependency of the blood-to-plasma ratio. Results indicated a 
constant ratio at all tested dexamethasone concentrations. On the basis of a blood-to-
plasma ratio of 1 for dexamethasone and caffeine, a comparison between DBS derived 
and literature plasma PK data was made. This method of comparison may be easier to 
perform but a clinical validation involving direct DBS to plasma comparisons would be 
more informative and may be necessary in some cases. Despite the limitations of the 




In a recent publication, Suyagh et al reported on the application of an LC-UV DBS 
quantification method for the determination of the population PK of metronidazole in 
preterm neonates (Suyagh et al., 2010a, Suyagh et al., 2011). Blood samples (30 μl) 
were collected directly onto S&S 903 paper at times on most occasions when blood was 
collected for clinical reasons. A total of 203 DBS samples from 32 preterm neonates 
were collected and dedicated to the model building process. Structural and random 
effects parameters were estimated with precision and bootstrapping confirmed the 
accuracy of the estimates with differences between the original data set and bootstrap 
estimates of less than 5%. These results strengthen the evidence for DBS quantification 
as a robust methodology for PK studies. Furthermore, the population model was used to 
generate dose recommendations in the treatment of necrotizing enterocolitis for which 
age specific guidelines have been lacking. Metronidazole displays limited protein 
binding and has a high affinity for RBCs, therefore there is potential for haematocrit to 
affect PK estimation (Ralph et al., 1974). However, the investigators could not identify 
a significant relationship between haematocrit and PK parameters. Direct DBS versus 
plasma data comparisons were not carried out, but DBS PK estimates of CL and V were 
found to be similar to estimates reported in plasma studies.  
The ethical constraints associated with neonatal PK studies warrant careful 
consideration of the blood volume collected at each sampling point as well as the total 
volume collected over a given time period. With these in mind there is a degree of 
flexibility to allow for direct comparisons between plasma and DBS measurements. 
This could be achieved through the incorporation of a sparse sampling methodology 
based on the requirement of micro DBS and DPS samples. This may be particularly 
important to consider in light of the variability in physiological parameters expected in 
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neonates and the underlying disease mechanisms with potential to further complicate 
PK interpretation. Further clinical work involving the study of a limited number of drug 
candidates, encompassing a range of chemical properties, may be useful in facilitating a 
better understanding of the impact of using DBS measurements on PK estimation in 
neonates.      
In adults, DBS to plasma concentration correlations have been investigated but for a 
limited number of drug candidates. Youhnovski et al reported on the plasma and DBS 
naproxen PK profiles following the administration of a single 440 mg dose to four 
subjects (Youhnovski et al., 2010). Plasma concentrations were approximately twice 
that measured in DBS samples in all subjects indicating limited RBC association, but 
the data showed a strong correlation between plasma and DBS at all time points of the 
PK profile. For compounds like naproxen which largely reside in the plasma 
compartment RBCs can effectively be considered as a diluent. As there was very little 
difference in the haematocrit of studied patients and data from only 4 patients were 
available it was difficult to evaluate the influence of haematocrit on the plasma-DBS 
correlation. Differences in drug concentration between DBS and plasma have also been 
reported for theophylline, etravirine and darunavir, but similar to the findings of 
Youhnovski et al, a correlation was observed between the two matrices at all time 
points (Hibberd et al., 1986, ter Heine et al., 2009, ter Heine et al., 2011). Comparisons 
between plasma and DBS will be necessary to provide assurance that whole blood data 
can be used to determine drug exposure. Ideally, as has been observed for some reported 
compounds the concentration ratio between the two matrices should be constant at all 
sampling time points. It is likely that drug regulatory agencies will initially want to see 
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comparisons between plasma and DBS in clinical trial and marketing authorisation 
applications (Beharry, 2010).    
A combination of DBS samples from capillary, arterial and venous sampling sites were 
used in the PK analysis of caffeine. However, the interchangeability of DBS sampling 
this way may not be appropriate as sampling site dependencies in concentration 
measurements have been noted for a number of drugs in animals and humans (Chiou, 
1989). In a clinical study which involved the administration of paracetamol to healthy 
adult volunteers significant differences in drug concentration were observed between 
capillary and venous DBS samples at 15, 30 and 60 minutes post dose (Mohammed et 
al., 2010). The highest difference was observed at 15 minutes when the DBS finger-
prick paracetamol median concentration (22.9 μg/ml) was approximately 4 times greater 
than the venous DBS concentration (5.1 μg/ml). By 60 minutes the concentration 
difference between the two sites was 9.3%. These results suggest a site concentration 
dependency during the early distribution phase for paracetamol. Spooner et al reported 
similar sampling site differences for the same drug with the greatest differences in 
paracetamol concentration at the earliest time points post dose (Spooner et al., 2010). 
Differences in drug measurement during the early phase have been assigned to the 
diffusion of drug into the extravascular space through the capillary membrane giving 
higher arterial concentrations (Chiou, 1989). Since capillary blood is actually a 
combination of arterial, venous and capillary blood this would help to explain the higher 
concentrations at early sampling times. A constant concentration ratio between 
sampling sites at all time points post dose has been reported for AZD2019 (an 
AstraZeneca Pharmaceuticals compound) (Smith et al., 2011). For this compound 
assuming an instant equilibrium would be suitable. Similarly tacrolimus and everolimus 
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capillary DBS concentrations have not been found to significantly vary from venous 
blood concentrations (Hoogtanders et al., 2007a, van der Heijden et al., 2009). Since 
differences in peripheral (capillary) DBS and venous DBS concentration appear to be 
compound dependent, to ensure correct use of DBS sampling clinical validation will be 
necessary where different blood sampling sites are to be incorporated into the study 
protocol. During the caffeine PK study only 3 venous and 0 arterial blood samples were 
collected within the first 2 hours post dose. Therefore potential differences in sampling 
site caffeine concentrations are unlikely to have had a significant effect on the final 
caffeine PK parameter estimates. A number of studies have reported higher haematocrit 
levels in capillary blood compared with venous blood and this difference is most 
marked in neonates (Linderkamp et al., 1977, Rivera  and Rudolph, 1982, Daae et al., 
1988). For drugs that are sensitive to haematocrit related effects on filter paper a bias 
may be introduced when making DBS capillary to DBS venous comparisons. To avoid 
confounding bias associated with the filter paper a DBS technique which involves the 
extraction of an accurate blood volume may be most appropriate for investigating 
sampling site drug concentration dependencies. 
Table 6.2 Factors considered influential in pharmacokinetic interpretation when 
using DBS concentration measurements 
 
 
 Red blood cell association (blood-to-plasma ratio) 
 
 Concentration dependency in red blood cell partitioning 
 
 Plasma protein binding 
 
 Sampling site (capillary, venous, arterial) 
 




The ability to measure therapeutic drug concentrations well within the blood sampling 
limits considered to be acceptable in preterm and term neonates is a major advantage. 
The micro samples collected in DBS analysis also means that the feasibility of 
opportunistic blood sampling in population PK studies is increased. The results from 
this thesis have shown that DBS analysis with MS detection has significant potential as 
a robust method for use in clinical PK studies in neonates. The investigations described 
in this thesis are limited to two test drugs and therefore further in-vitro and in-vivo 
studies will be important in understanding the impact of using DBS as an alternative 




6.2 Final conclusion 
 In-vitro investigations have shown developed DBS based drug quantification 
methods to be accurate and precise, in accordance with regulatory acceptance criteria 
on the validation of bioanalytical methods. 
 
 The transferability of the DBS technique to different analytical instruments and 
laboratories was demonstrated thereby highlighting the robustness of the 
methodology for bioanalysis. 
 
 Assay performance was not significantly affected by factors specific to the DBS 
process including small variations in blood volume spotted, spotting device, presence 
of petroleum jelly or an elevated drying and storage temperature (30°C). Variability 
in haematocrit level was the most influential factor affecting the accuracy of drug 
concentration measurements during in-vitro investigations. 
 
 DBS sampling coupled with LC-MS/MS analysis enabled the precise and accurate 
estimation of caffeine population PK parameters in preterm neonates. Furthermore, 
DBS generated PK estimates were in agreement with reported plasma values in this 
age group. 
 
 A sensitivity analysis performed using the population caffeine model highlighted the 
potential for systematic assay bias arising from paper related haematocrit effects to 
significantly affect PK parameter estimation.  
 
 Dexamethasone DBS PK estimates were comparable to reported estimates of plasma 
CL and V, however, further investigations will be necessary to understand the impact 
of protein drug binding changes on the PK of dexamethasone. 
 
 The results from this study indicate that DBS analysis is a technique with significant 
potential as a robust method for drug quantification, and within the context of an 
opportunistic sampling design is an accepted and feasible approach for performing 
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Study Number: UHLPFL001 
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Title of Project: New microanalytical method to assess the effect of varying doses of 
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Please read this form and sign it once the above named or their designated representative, has 
explained fully the aims and procedures of the study to you 
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th 
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 I have been given the opportunity to ask questions and discuss the study with one of the 
above investigators or their deputies on all aspects of the study and have understood the 
advice and information given as a result.  
 




 I understand that I am free to withdraw my baby from the study at any time, without having 
to give a reason for withdrawing. 
 
 I voluntarily agree to enable my baby to take part in this study 
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Compartmental models used in NONMEM to fit DBS concentration data 
1a. One compartment PK model, IV bolus, first order elimination 
 
      
 
 
C(t) = Dose   1/V e-K10*t 
Where C(t) = concentration in blood at time, t 
    V = distribution volume 








1b. One compartment PK model, first order oral absorption, first order elimination 






























C(t) = Dose   1/V (A.e-α*t + B.e-β*t) 
 
Where A = (k21 – α) / (β – α) 
            B = (k21 – β) / (α – β) 












  V1 = 1 / (A +B) 
  V2 = V1   k12 / k21 
CL1 = V1   K10 
CL2 = V2   K21 
 
 
2b. Two compartment model, first order oral absorption, first order elimination  
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Caffeine pharmacokinetic study consent form 
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I understand that my baby’s participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my baby’s medical care or 
my legal rights being affected. 
 
I understand that relevant sections of my baby’s care record, and data collected 
during the study, may be looked at by responsible individuals from the research 
team, individuals from regulatory authorities or from the NHS Trust where it is 
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 Name of person taking consent  Date    
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Caffeine drug concentrations measured in neonatal DBS samples n=338 
TAD = Time after last caffeine dose 
Caffeine concentrations given as ng/ml 
         
Patient TAD Level Patient TAD Level Patient TAD Level 
1 5.08 10320 6 6.78 19946 11 167.67 1249 
1 7.92 11966 6 5.48 30375 11 2.50 39638 
1 4.30 10481 6 20.40 17537    
1 30.61 8484 6 5.28 26325 12 27.58 6831 
   6 1.08 35150 12 10.42 22302 
2 21.85 18625 6 6.08 32339 12 3.25 24239 
2 14.83 31767    12 6.00 22322 
2 17.50 28009 7 2.58 9021    
2 1.84 36948 7 1.97 12750 13 6.08 8571 
2 21.19 27527 7 1.85 13949 13 2.34 16635 
2 22.00 30892 7 1.25 11396 13 5.90 8158 
2 46.75 16994 7 5.67 18610 13 1.50 14548 
2 23.68 27627    13 0.42 14461 
2 23.22 35873 8 14.92 30287 13 4.17 16696 
   8 11.67 36113 13 2.57 23056 
3 0.62 8710 8 11.41 38385 13 22.08 16505 
3 263.67 1198 8 213.97 5056    
3 98.78 3826 8 21.03 35532 14 55.00 3344 
   8 15.50 21488 14 10.34 11178 
4 6.62 7841 8 21.99 36489 14 7.54 12361 
4 5.09 7807 8 5.40 43045 14 14.21 14374 
      14 18.50 11420 
5 20.00 14453 9 2.92 15771 14 22.78 13948 
5 1.91 21444 9 6.14 23305 14 15.18 17791 
5 7.00 27968 9 22.58 15731 14 3.77 17051 
5 10.34 21907 9 1.75 20159 14 18.39 18659 
5 9.42 21597 9 5.35 26146 14 22.99 17397 
5 9.92 21367 9 16.50 26030    
5 10.95 24457    15 3.92 9845 
5 4.66 28296 10 22.33 21288 15 2.17 12098 
5 7.66 32197 10 11.12 27674    
   10 2.40 23378 16 3.90 28753 
6 2.32 14628 10 10.08 25342 16 3.58 28486 
6 6.00 25763 10 59.25 18882 16 4.17 39422 
6 10.67 19968 10 8.67 29588 16 14.89 21346 
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16 3.29 39296 23 18.67 13478 29 15.67 11482 
   23 11.38 20940 29 18.17 11866 
17 15.58 11518 23 22.50 14297    
17 225.83 2788 23 16.42 12926 30 2.84 15297 
17 222.92 2780 23 4.67 17222 30 1.83 16051 
17 144.25 6517 23 10.65 19753 30 23.50 30453 
17 22.00 20949 23 0.33 18902    
17 51.17 10711 23 3.92 16190 31 2.50 16829 
17 15.46 14484 23 10.80 22107 31 21.25 13593 
17 0.80 15800    31 23.42 18106 
17 73.50 8247 24 123.37 8881    
17 58.12 9666 24 23.87 22917 32 21.33 14991 
   24 5.67 32205 32 44.83 11240 
18 1.50 19502    32 3.32 25561 
18 23.58 12283 25 99.70 4758    
18 20.25 21244 25 2.17 27750 33 288.07 1526 
18 16.53 17040 25 6.17 31989 33 2.15 13618 
18 35.71 14427       
18 28.11 10390 26 174.53 1716 34 168.82 3108 
18 21.33 18245 26 22.25 17127 34 21.05 19048 
18 9.58 23449 26 11.07 17576 34 1.22 28239 
   26 2.50 21049    
19 179.09 5699 26 12.60 19082 35 46.80 9924 
19 188.84 4337 26 14.15 18922    
19 16.11 31593 26 18.17 19519 36 3.22 7198 
   26 12.67 21119    
20 2.92 14039 26 5.70 19793 37 2.67 19270 
20 2.35 15441 26 13.63 19362 37 122.63 7586 
20 1.17 17681    37 7.12 19486 
20 16.50 14036 27 0.83 17085    
20 18.08 19430    38 191.36 1553 
20 2.42 30135 28 4.20 7080 38 21.93 14790 
20 5.17 24082 28 193.50 665 38 21.83 15491 
20 18.17 24191 28 2.16 10155    
   28 11.50 10155 39 20.98 13114 
21 3.83 26608    39 21.67 14895 
   29 0.33 4363 39 19.93 16265 
22 6.93 11031 29 17.00 4901    
22 6.36 13716 29 3.54 6096 40 2.33 16757 
22 8.93 18554 29 51.47 4031 40 169.00 3574 
22 8.50 15070 29 15.26 6717    
22 6.09 19789 29 20.00 8647 41 7.83 16317 
22 8.20 23083 29 8.84 10947 41 3.05 18048 
   29 11.45 13290 41 7.75 17711 
280 
 
41 19.05 13462 47 23.33 4448 54 25.73 8588 
41 17.15 14816 47 147.58 3067 54 24.00 7443 
41 19.58 15699 47 4.95 15839 54 3.71 15066 
41 24.08 15966 47 2.00 16762 54 25.42 11429 
41 21.08 16145    54 1.33 17577 
41 19.50 16047 48 3.22 7940    
   48 21.50 11322 55 50.83 2929 
42 14.83 13923 48 0.02 12604 55 2.53 9537 
42 7.88 15765 48 4.33 17164 55 3.50 13961 
42 0.03 15758       
42 13.22 18191 49 22.00 12423 56 0.50 15110 
   49 12.06 17606    
43 5.12 15626 49 20.23 16872 57 2.67 15686 
43 6.88 17866 49 20.80 18306 57 2.75 10759 
43 4.83 15783 49 1.42 23617 57 19.47 7702 
43 6.16 16293    57 204.13 2656 
43 5.24 15750 50 6.00 9534 57 27.43 10609 
   50 15.50 11390 57 17.66 13060 
44 18.90 16999 50 16.75 12116 57 17.73 14830 
44 23.59 15662 50 18.00 10460 57 4.10 30691 
44 18.50 15558 50 25.28 9381    
44 10.84 14207 50 6.42 12011 58 7.45 12741 
44 18.59 13504 50 16.91 11392 58 4.14 22757 
44 18.25 14063 50 17.83 12280 58 17.25 20899 
44 7.58 17714 50 18.50 10441 58 3.92 27113 
44 9.58 17521    58 17.75 23205 
   51 13.75 10490 58 4.75 21756 
45 4.00 12128 51 16.58 10975    
45 89.25 6458 51 11.67 11586 59 71.47 8756 
45 61.25 9005 51 14.42 11031    
45 56.42 7951 51 3.98 15842 60 51.49 10378 
45 64.58 6790 51 17.83 13296    
45 48.25 8265 51 20.83 11412 61 3.08 10928 
45 43.25 7815 51 11.42 14604    
45 1.36 24925 51 16.67 14619 62 50.90 4713 
   51 24.21 12851 62 3.06 12880 
46 2.55 5592    62 5.97 14999 
46 5.04 7321 52 16.10 10175 62 14.73 9677 
46 20.10 8133 52 10.50 10306 62 1.63 12049 
46 6.34 9135 52 21.83 14190 62 3.88 10113 
46 6.05 11203    62 15.50 16801 
46 4.67 12857 53 8.52 15729    
46 1.25 14928 53 8.28 11376 63 0.75 11192 





64 2.30 7546       
64 75.22 2377       
64 4.78 11070       
64 1.84 15011       
         
65 17.24 6958       
65 18.50 8145       
65 0.49 10768       
65 7.25 8935       
65 21.12 10226       
65 24.75 9070       
65 22.75 11289       
65 19.00 15034       
65 21.30 12337       
65 21.25 16204       
         
66 4.33 18298       
66 0.47 18860       
66 24.23 14352       
66 2.75 25718       
66 24.28 15433       
66 7.25 28852       
         
67 3.52 23608       
67 3.00 23167       
67 20.00 17167       
67 12.00 19050       
67 3.46 30743       
67 19.34 19886       
67 2.01 21365       
67 7.41 36765       
         
         
         
         
         
         





The population  predicted (PRED), individual predicted (IPRED) and observed 
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